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Introduction
The Biological and Toxin Weapons Convention (BWC) will hold its Eighth Review Conference 
late in 2016 which will consider ‘new scientific and technological developments relevant to  
the Convention’. This review will draw upon work undertaken in a standing agenda item in  
the BWC’s 2012 – 2015 work programme.
Each year, States Parties have reviewed developments 
in science and technology relevant to the BWC, 
focusing on advances that could have benefits for, 
or which could possibly be used in contravention to 
this international instrument. During the course of 
their work, States Parties supported by international 
organizations, scientific bodies, companies and 
individual experts, have reviewed developments in: 
enabling technologies; for dealing with disease; in the 
understanding of pathogenicity, virulence, toxicology, 
immunology and related issues; as well as production, 




In September 2015, a Trends Symposium to review 
relevant developments in the science and technology 
was organised by the Royal Society, the US National 
Academies of Sciences and the IAP: Global Network 
of Science Academies, represented by the current 
Chair of the IAP Biosecurity Working Group, the Polish 
Academy of Sciences. The Symposium was attended 
by 72 participants from 30 countries. 
A series of background documentsi were commissioned 
to inform the discussions at the Trends Symposium, 
which were then reviewed in light of the presentations 
and discussions to produce this technical document 
and accompanying summary documents.ii
The Biological and Toxin Weapons Convention   7
Executive summary 
The Trends Symposium and background documents noted many issues of relevance to the 
Review Conference and reached several overarching conclusions which are outlined below.
The Trends Symposium concluded that:
•	 Technological barriers to acquiring and  
using a biological weapon have been significantly 
eroded since the Seventh Review Conference,  
there had been no further novel developments  
that could enable activities inconsistent with the  
aims and objectives of the BWC. 
•	 Likewise, there were no developments that 
would not be covered by the treaty or additional 
supplementary understandings, but 
•	 The speed at which the life sciences and 
technology are advancing, and the rate of 
convergence of disciplines, is still accelerating. 
This increases the likelihood of such 
developments in the foreseeable future. 
•	 Such potential problems, as well as any 
appropriate responses could be discussed  
prior to the 9th Review Conference.
•	 Biotechnology is increasingly important around 
the world as a manufacturing technology and has 
therefore become a potential target for biological 
weapons itself. It should be explored whether 
there are any risks not already captured by existing 
treaties and laws of weapons that cause damage to 
equipment supplies, or material associated with the 
bio-economy. 
•	 There was an increased need for education and 
outreach to promote the aims and objectives of the 
BWC amongst the scientific community. 
There were four themes that arose from the 
background papers and during the Trends 
Symposium around which this report is structured: 
•	 Biosciences are developing at an unprecedented 
rate.
•	 The BWC should continue to monitor these 
developments.
•	 Global ability to detect and treat disease has  
been enhanced.
•	 Recent advances could facilitate the development 
of biological weapons.
Summaries of these sections are provided below  
and each is considered in detail in each chapter in 
the reminder of this report, including a synopsis of the 
research papers which lie behind the developments 
provided in the annotated references. 
The biosciences are developing at an 
unprecedented rate 
The rate and scale of progress in the life sciences  
and biotechnology continues to grow rapidly. There 
is an increasing diffusion of knowledge around the 
world and more interconnection between knowledge 
hubs, many of them ‘virtual’. Laboratories operate in 
more diverse geographic locations and across different 
sectors of our societies. 
The character of life sciences and biotechnology 
is evolving with greater focus on rational design, 
biological engineering, and more flexible production. 
Moving from ‘concept’ to ‘application’ is becoming 
ever simpler, unlocking further potential for progress. 
The adoption of engineering paradigms has 
contributed to progress.
All these factors have both positive and negative 
implications for the BWC.
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The BWC should continue to monitor these 
developments. 
For this reason, the BWC should continue to ensure 
that such developments are not used in prohibited 
activities, whilst facilitating their use for peaceful 
purposes. It could achieve this by devising an effective, 
on-going, and suitably resourced mechanism to: 
•	 Develop specific questions that can be answered 
through an on-going review of developments in 
science and technology; 
•	 Identify current scientific and technical capabilities 
applicable to these questions; 
•	 Consider the implications of those developments in 
the context of the BWC; and 
•	 Formulating informed decisions about any further 
actions that may be required.
The conference observed that the development of a 
technique for systematically assessing the risk of new 
scientific developments to the BWC would greatly 
assist in this process.
The global ability to detect and treat disease has  
been enhanced. 
The meeting noted that one positive outcome of 
developments since the Seventh Review Conference 
is that our collective capacity to combat disease has 
markedly improved, regardless of whether the outbreak 
is naturally occurring or the result of a malevolent act. 
Whilst it would require remaining logistic, economic and 
technical barriers to be surmounted, the conference 
noted that it should now be possible to assemble 
patchwork capabilities into a diffuse but integrated 
system for countering global or local outbreaks. 
Such a system could scale from local needs through 
to international responses. A structure that enabled 
data such as pathogen sequences to be shared more 
effectively and efficiently would facilitate a rapid an 
effective response. As expertise and ‘know-how’ 
matures, opportunities for technological leapfrogging 
appear, as was the case with mobile communication 
systems. Developing countries can then access 
opportunities and capabilities in the field that match, if 
not surpass, those found in developed countries.
 
Increasing ‘digitization’ of pathogen data enables 
the identification and characterisation by centralised 
facilities of the infectious agent facilitating development 
of countermeasures and the use of ‘distributed 
diagnostics’ at the site of the outbreak. This concept has 
already been partially implemented in both developed 
and developing countries. The conference noted a 
pressing need for more comprehensive sets of baseline 
and reference pathogen data. ‘Microbial forensics’ can 
be used to help establish attribution if a malevolent 
deployment is suspected.
Vaccines and drugs can now be developed more 
rapidly than ever before. Lead times can be reduced 
through rapid detection and characterisation of 
outbreaks. The design, testing and optimisation of 
vaccines and drugs have been streamlined using 
better computational technologies, modelling tools 
and platform technologies although provision of 
bioinformatics capabilities remain challenging.
Outsourcing of key production steps has reduced  
the need for dedicated vaccine production 
infrastructure. It is increasingly simpler, faster and 
cheaper to industrialize production processes. 
Single-use equipment and modular production 
technologies shorten turn-around times. A more 
distributed production base in industry reduces the 
distance a product has to travel to its point of use. 
However, regulatory and liability issues associated with 
diagnostics, drugs and vaccines in health emergencies 
continue to limit potential for progress and this is an 
issue that should be addressed.
Recent advances have also facilitated the 
development of biological weapons. 
The scientific advances reported at the conference 
could also facilitate almost every step of a biological 
weapons programme and technological barriers to 
acquiring and using a biological weapon have been 
conspicuously eroded since the Seventh Review 
Conference. 
Both novel and traditional approaches continue to 
offer opportunities for acquiring an agent from nature. 
The sometimes-formidable challenges associated with 
the synthesis of existing agents and the development 
of novel agents have been overcome by using gene 
transfer and other biosynthetic engineering approaches. 
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Modification of biological agents enables them to 
be more easily optimised for use in a biological 
weapon. Developments in scale-up and production 
technologies have changed production signatures. 
Less space and time are needed, narrowing windows 
for interdiction. 
Although these trends diminish the need for 
stockpiling, the proliferation of such capabilities, 
such as freeze-drying capacity, has actually reduced 
the space required to store biological weapons. 
It is also now easier to deliver a biological agent 
given advances in areas such as nanoparticles and 
sophisticated modelling of dispersal patterns using the 
techniques of aerobiology.
Many of these advances are at the leading edge 
of current capabilities. They are expensive and 
complicated to acquire and to deploy successfully. 
Making use of them for prohibited purposes would 
probably currently require the resources of a state 
but this situation may change in the future, reinforcing 
the need for on-going efforts to review relevant 
developments in science and technology.
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Scope of the BWC
The upcoming Review Conference will consider whether there had been any novel 
developments since the Seventh Review Conference that could either enable activities 
inconsistent with the aims and objectives of the treaty, or which would not be covered by  
the BWC or additional understandings reached at subsequent review conferences. No 
concrete examples of such developments were identified either through the literature 
reviews or in workshop discussions. 
However, a number of potential future scenarios were 
identified that do give cause for concern. Situations 
where, for example, the mechanisms of action of 
weapons are not clearly ‘chemical’ or ‘biological’, where 
components are significantly different from existing 
biological systems, or where inorganic materials mimic 
biological function, thereby having a biological effect. 
It was easy to envisage how progress in areas such 
as the convergence of the sciences, nanotechnology 
and therapeutic design, might lead to such concerning 
developments. States Parties could proactively consider 
the implications of these scenarios before they can be 
realised, thereby providing a window of opportunity to 
develop appropriate responses and actions. 
Given the increasing pace of progress and the 
additional possibility of sudden ‘non-linear’ advances 
in research fields, it is difficult to estimate when such 
potential scenarios might become relevant to the BWC. 
Further consideration of progress in this area may be 
needed prior to the 9th Review Conference and this 
reinforces the importance of a flexible process for on-
going reviews (see Section 2). 
Biotechnology is an increasingly important global 
manufacturing technology. Degrading manufacturing 
infrastructure and capability has long been a tool of war, 
insurgency and armed conflict. The ‘bio-economy’ itself 
is therefore a potential target for biological weapons. 
The BWC currently prohibits weapons that cause 
harm to humans, animals and plantsand it should 
be explored wether they are any risks, not already 
captured by existing treaties and laws of weapons 
that cause damage to equipment supplies, or material 
associeted with bio-econommy.
The conference also noted an increased need 
for education and outreach to promote the aims 
and objectives of the BWC amongst the scientific 
community as well as the provision of responsible 
mentorship for early-stage researchers. There are 
already some examples of excellence in this area (see 
Box 1) but more effort is needed by States Parties and 
‘best practices’ disseminated.
1
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Box 1: Synbio LEAP – An example of excellence in socially responsible scientific mentorship
The Leadership Excellence Accelerator Program 
(LEAP) provides Fellows with mentorship, practical 
skills and a sustaining network to help them guide  
a socially responsible future for synthetic biology. 
It is an incubator for emerging leaders across 
disciplines and sectors to develop new strategies  
for biotechnology in the public interest. 
LEAP is an intensive year-long non-residential 
Fellowship program. Each round, twenty fellows 
participate in two in-residence workshops during 
which Fellows work together to develop strategies 
to address their top challenges for the practice of 
synthetic biology, under the guidance of world-class 
experts across disciplines and sectors.
Image 
Participants at a LEAP meeting at the Wilson Center, Washington DC. 
Photo courtesy of David Sun Kong Photography.
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Monitoring developments in science 
and technology 
It is clearly desirable for the BWC to ensure that new knowledge and techniques do not 
facilitate breaches of the treaty, whilst expediting their peaceful applications. This requires  
an understanding of how developments in the life sciences and biotechnology might  
impact the treaty. 
There is therefore a pressing need for effective, on-
going, and suitably resourced arrangements to:
•	 Formulate specific questions that can be answered 
by reviewing developments in science and 
technology; 
•	 Identify current scientific and technical capabilities 
pertinent to these questions; 
•	 Consider the implications of those developments in 
the context of the BWC; and 
•	 Take decisions or actions necessitated by those 
developments. 
Models used by other international bodies, including 
disarmament forums, environmental or health treaties 
could be adapted for this purpose. The advantages 
and disadvantages of these different formats should be 
explored in the context of the BWC’s remit.
Whatever processes is eventually implemented, it 
should be:
•	 Flexible: able to adjust to changing needs and 
priorities;
•	 Inclusive: able to take advantage of expertise, 
wherever it is to be found;
•	 Agile: able to adjust quickly to seize all available 
opportunities;
•	 Responsive: able to actually change when needed; 
•	 Able to foster greater engagement: actively 
encouraging and enabling contributions from the 
widest possible set of stakeholders; and 
•	 Transparent: ensuring the widest possible group  
of stakeholders benefit from its work.
The Trends Symposium observed that the 
development of a technique for systematically 
assessing the risk of new scientific developments 
would be of enormous help in assessing the threat 
of future trends. Such a process might also usefully 
consider criteria for identifying relevant or significant 
developments.
2
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The global ability to deal with disease
Since the Seventh Review Conference, developments in the understanding of disease  
have increased capacity to deal with disease, regardless of whether the outbreak is  
naturally occurring or the result of a malevolent act.
The following sections consider each of the following 
factors which have contributed to this:
•	 Understanding disease
•	 Detecting technology
•	 Diagnosis and surveillance
•	 Drugs (including vaccines and therapeutics)
•	 Responses
3.1 Understanding disease
Improved understanding of disease mechanisms 
has increased our capacity to detect, respond to 
and mitigate outbreaks, regardless of their source. 
Such developments strengthen capacities relevant to 
Articles VII and X of the BWC. 
Particularly noteworthy is our enhanced understanding 
of transmissibility and host range; pathogenicity and 
virulence; toxins; unusual disease agents (including 
prions and fungi); immunology and host-pathogen 
interactions; the role of the microbiome; and the 
significance of ‘biofilms’ for pathogen persistence. 
3.1.1 Transmissibility and host range
Since the Seventh Review Conference there have 
been incremental increases in our understanding of 
transmissibility and host range. This includes structural 
and genetic analysis, production or isolation of 
pathogens with increased transmissibility or host range 
and improved tools to investigate these.
Transmissibility 
Examples of genetic sequences or mutations that have 
been identified include: 
•	 mutations in H5N1,1, 2, 3, 4, 5 H7N1 influenza virus6, 7 
and H1N1 influenza viruses8, 9 which confers aerosol 
transmission in mammals;
•	 mutations in HA region of H5N1 influenza virus that 
improves affinity for humanlike airway receptors;5 
•	 a mutation in H7N9 influenza that confers an  
ability to bind to both human and avian receptors;10 
•	 the sequence of a H7N9 influenza virus adapted 
for efficient growth in human lung tissue;11 
•	 mutations in H7N9 influenza virus conferring antiviral 
resistance with no impact on transmissibility;12 and
•	 mutations associated with host range.13
Pathogens with increased transmissibility have been 
produced or isolated: 
•	 a H5N11 and H1N15 recombinant influenza viruses 
capable of aerosol transmission in ferrets;1, 5
•	 the use of site-directed mutagenesis and serial 
passaging in ferrets of the H5N1 and H7N1 influenza 
virus to confer airborne transmission;2, 6 
•	 a H7N9 influenza virus adapted for efficient growth 
in human lung tissue;11 
•	 a recombinant human and bat influenza virus;7 and 
•	 the use of serial passaging of an engineered re-
assorted H1N1 influenza virus in pigs.9
Host range 
Identification of key structural elements that affect host 
range, including how the structure of HA regions affect 
H5 influenza viruses ability to bind to avian and human 
receptors;14, 15 and the H7N9 influenza viruses.15, 10
Improved understanding of the interconnections 
between pathogenicity, transmissibility and drug 
resistance identification of mutations that can confer 
additional functional characteristics without degrading 
others.12
Pathogens with an altered host range have been 
produced, including:
•	 enteroviruses type 71;4 
•	 H1N1 influenza virus;4
•	 H5N1 influenza virus;4 and 
•	 Dengue fever virus.4
3
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Tools 
More sophisticated tools for identifying factors 
associated with transmissibility and host range and 
integrating them into agents have been developed, 
such as: 
•	 tools to study genetic evolution of viruses and 
search for mutations known to confer altered 
transmissibility;3 
•	 synthetic biology approaches;16 
•	 approaches for characterizing host shifts for rabies 
viruses in bats17 and Ebola virus between pigs and 
non-human primates; and 
•	 model systems that recapitulate in vivo viral life 
cycles.18
3.1.2 Pathogenicity and virulence
Since the Seventh Review Conference there have 
been incremental increases in our understanding of 
what causes pathogenicity and virulence. This includes 
structural and genetic analysis, investigation of other 
factors which effect virulence (infection location, 
acclimatisation) and improved tools to investigate these. 
Genetic and structural analysis 
Identification and characterization of genetic 
components conferring pathogenicity in the following 
organisms, such as:
•	 a particularly lethal Escherichia coi (O104:H4);19 
•	 SARS coronavirus;20 
•	 HIV;20 
•	 enteroviruses type 71;21 
•	 influenza A H1N1 virus;21 
•	 H5N1 influenza viruses; 21 
•	 Dengue fever virus; 21 
•	 methicillin-resistant Staphylococcus aureus;22 
•	 Mycobacterium tuberculosis;22 
•	 an unculturable bat virus;7 
•	 H7N9 influenza virus,23, 24 further work on 
indicated;25 
•	 Bacillus anthracis;26 and 
•	 wheat yellow rust.27 
Identification and characterization of transcription 
signatures connected to pathogenicity e.g. in H5N1  
and H1N1 influenza viruses.28 
 
Identification of key structural elements that affect 
pathogenicity including: 
•	 intercellular nanotubes used to exchange plasmids, 
including those containing pathogenicity factors;29 
•	 mapping and characterisation of infection-specific 
structures in rice blast;30 
•	 changes in the HA and NA regions of human and 
bat influenza viruses;7 
•	 type III secretion systems used by pathogens, such 
as Salmonella typhimurium, to manipulate host 
cells;31 
•	 how hydrophobic structures in the core of viral 
capsids can be crucial for infectivity;32 and
•	 partial characterization of the virus-host structural 
components in a particularly virulent strain of H7N9 
influenza virus.33 
Other factors  
Improved insights into other factors that impact 
pathogenicity, such as physical location in the host 
and the need to adapt to a new temperature. Some 
examples include:
•	 bacteraemia in inhalational anthrax infections – a 
novel model of which suggests that higher levels 
of mortality witnessed in inhalational anthrax is due 
to bacteria present in the lymph nodes, rather than 
presence in the lungs;34 and 
•	 a requirement for acclimatization to the host’s 
temperature for the production of virulence factors 
in Yersinia pestis infections.35
Interconnections between pathogenicity, 
transmissibility and drug resistance e.g. mutations that 
can confer additional functional characteristics without 
degrading others.12
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Tools 
More sophisticated tools for identifying factors 
associated with pathogenicity and integrating  
them into agents have been developed, including: 
•	 the use of sequencing technologies to identify  
new agents and pathogenicity factors;36, 37 
•	 improved understanding of how pathogenicity 
factors spread in the wild, such as’ horizontal gene 
transfer;38 
•	 computational approaches and software tools 
for the identification of pathogenicity islands and 
virulence factors;22, 39, 40 
•	 synthetic biology approaches;16, 20, 41
•	 bioinformatics tools for manipulating pathogenicity 
data;41 
•	 systems biology and understanding the impacts  
of systems modulation on disease;41 
•	 improved mechanisms for combining sequence 
data and structural analysis for detecting virulence 
factors;37 
•	 whole genome ‘directed evolution’;16 
•	 methodological approaches for testing the clinical 
and public health significance of microbe-disease 
associations;42 
•	 approaches for predicting the virulence of a 
pathogen from its sequence information;22 
•	 the recreation of a centralised repository for 
pathogenicity islands and resistance islands;43 and 
•	 model systems that recapitulate in vivo viral life 
cycles.18
Increased virulence 
Pathogens with increased virulence have been 
produced: 
•	 the use of serial passaging of Schmallenberg  
Virus in a mouse model;44 
•	 the use of serial passaging of H7N1 in ferrets;6 
•	 recombination of influenza viruses to create a  
novel virus that is functionally similar to the  
causative agent of the 1918 pandemic but with 
increased pathogenicity;8 
•	 the use of serial passaging of an engineered 
reassortant swine influenza virus in pigs;9 and 
•	 the use of serial passaging of Ebola virus in  
guinea pigs.13
 
There has been progress in identifying ways in which 
pathogens cause damage by manipulating their host, 
for example, modulating the damage caused by 
cytokine storms45, 46 or inflammatory responses.46, 47
3.1.3 Toxins
Since the Seventh Review Conference there have 
been incremental increases in our understanding 
of the production and action of toxins. This includes 
structural and genetic analysis, characterisation 
of the mechanisms of action and novel toxins and 
drugs to neutralise toxins, detection procedures and 
improved tools to investigate these. There has been 
increased interest in toxins for applications in medical 
treatment, life sciences research, pharmaceuticals, and 
agriculture.48
Genetic and structural analysis 
Identification and characterization of genetic 
components associated with toxins, including:
•	 genome-wide RNAi screens identifying 
genes required for intoxication from Ricin and 
Pseudomonas exotoxin;49 
•	 743 mutations in 12 human genes important for 
intoxication by four different cytolethal distending 
toxins;50 
•	 human genetic variation that determines sensitivity 
to the anthrax toxin;51 
•	 publication of sequence and transcription data for 
king cobra venom;52 and 
•	 genetic elements associated with Botulinum 
neurotoxins.53
 
Improved understanding of interactions between 
genetic elements also plays an important role in the 
production and action of toxins, for example, gene 
interaction mapping of Ricin toxin.54
Characterisation of mechanism of action
Characterization of the mechanisms of action 
associated with toxins: 
•	 increased understandings of the cellular mode  
of action of Ricin toxin;55
•	 characterization of the mechanism by which 
Botulinum neurotoxins are taken up at the pre-
synaptic nerve terminal;56 
•	 characterization of the metabolic pathway that 
produces Saxitoxin;57 
•	 modulation of binding immunoglobulin protein  
to increase cytotoxicity;58 
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•	 characterization of the mechanism of action of the 
monoclonal antibody which neutralises Abrin;59 
•	 characterization of the mechanism of action of 
monoclonal antibodies targeting both Ricin A and B 
chains;60 
•	 characterization of a novel Botulinum neurotoxin;61 
•	 characterization of the absorption, distribution and 
pathological injury in mice due to Ricin poisoning 
via the alimentary pathway;62 
•	 insights into the general circulation, 
neuronal binding, membrane translocation 
and neuroparalysis Botulinum neurotoxin 
administration;53 and
•	 details of structural interactions between Botulinum 
toxin and host cells.63 
Tools
More sophisticated tools for researching and 
manipulating toxins have been developed, such as: 
•	 synthetic biology approaches;41, 48 
•	 bioinformatics tools for manipulating environmental 
stability data;41 
•	 systems biology and understanding the impact of 
biological systems modulation on disease;41 
•	 metabolic pathway engineering;64 and 
•	 computational design tools leveraging advances 
in understanding in structural-functional 
relationships.65
Novel toxins and drugs
Novel toxins, or those with altered or enhanced 
characteristics have been identified or produced, 
including:
•	 an anthrax toxin with altered receptor specificity;66 
•	 a novel form of Botulinum toxin;67 
•	 a robust high-content screen developed to discover 
novel compounds that stabilize intracellular Ricin 
and limit Ricin intoxication;68 and 
•	 a recombinant Botulinum type A – Tetanus toxin.69
Novel drugs, drug targets and drugs that neutralise 
the effect of toxins have also been developed: 
•	 a compound to block the uptake of Botulinum 
neurotoxins at the pre-synaptic nerve terminal;56 
•	 a monoclonal antibody capable of neutralizing  
the Ricin toxin;70 
•	 sub-domains of Ricin’s B subunit now targeted by 
toxin neutralizing and non-neutralizing monoclonal 
antibodies;71 
•	 competitive active-site inhibitors of Ricin Toxin A;72 
•	 comparative analysis of monoclonal antibodies 
target the A and B chains of Ricin;73 
•	 demonstration that fragments of monoclonal 
antibodies function as effectively as full length 
compounds in neutralizing Ricin in a cell based 
assay;74 
•	 monomeric single-chain camelid antibodies  
capable of neutralizing Ricin in vitro;75 
•	 an engineered heterodimeric camelid antibody 
capable of neutralizing Ricin in vivo;75 and 
•	 the use of intact IgG from goat anti-ricin 
hyperimmune sera to provide immediate protection 
following Ricin exposure and to confer an active 
immunity against Ricin that subsequently results in 
long term protection.76, 77
Detection
Shortcomings at the national and laboratory level 
were identified in maintaining and ensuring standards, 
methodologies and reference materials for detecting 
toxins.78
3.1.4 Unusual disease agents (including prions 
and fungi)
Since the Seventh Review Conference there have been 
incremental increases in our understanding the role of 
disease causing agents other than bacteria and viruses. 
Fungi
High profile reviews focusing on human, animal and 
plant diseases caused by fungi, including significant 
historical epidemics.79 
Plasmodia
Continued interest in diseases caused by plasmodia, 
including the identification of genetic elements 
associated with malaria.80
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Prions
There has also been progress in understanding prions, 
how they cause disease and potential therapeutic 
interventions, including: 
•	 the identification of genetic elements that when 
overexpressed significantly reduce the incubation 
time of prion diseases;81 
•	 the role that the mis-folded proteins (usually 
associated with a diseased state) play in healthy 
neurological development;82 and 
•	 the development of a novel screening process to 
identify therapeutics.83
3.1.5 Immunology and host-pathogen interactions
Our understanding of host-pathogen interactions has 
also progressed since the Seventh Review Conference. 
These include modulating immune response to 
pathogens, characterisation of how pathogens evade 
the immune system and better understanding of the 
causes of side-effects produced following treatments 
with small molecule anti-infective drugs. 
Expanding range of pathogens
Host-pathogen relationships are also being studied  
in an expanding range of pathogens:
•	 Enterobacteriacea;38 
•	 influenza viruses;84, 85, 86, 87
•	 Yersinia pestis;35, 45, 47, 87, 88, 89
•	 Schmallenberg Virus;44 
•	 Mycobacterium tuberculosis;90 
•	 flaviviruses91; Dengue virus;87 
•	 SARs coronavirus;87 
•	 Salmonella enterica;87 
•	 Brucella sp.;87 
•	 E.coli;87 
•	 West Nile virus;87 
•	 Mycoplasma sp.;87 
•	 varicella zoster virus;87 




Developments in understanding host-pathogen 
relationships enabling the modulation of immune 
responses in the host: 
•	 reducing or removing cytokine storms93 and  
their impact on clinical outcomes;94 
•	 the inflammatory mechanisms of gut bacteria, 
including the horizontal gene transfer of key 
factors;38 
•	 novel functional characterization of B cells  
and autoantigens;95 
•	 the impact of human genetic variation on  
sensitivity to anthrax toxin;96 
•	 the identification of a novel neutrophil-based 
immune response to viruses;97 
•	 the use of non-structural proteins to interfere  
with a host’s epigenome and make cells more 
susceptible to viruses;84 
•	 modulation of host proteins which inhibit viral 
replication;85 
•	 infection kinetics and the impact of the physical 
location of pathogens in a host on the speed of 
infections;88 
•	 mechanisms through which pathogens can  
interpret extracellular stimuli;98 
•	 plant immune receptors and their interaction  
with plant pathogens and virulence proteins;99 
•	 the use of natural (e.g. polysaccharide) or  
manmade (e.g. polyelectrolyte based nano-thin 
polymer) coatings to isolate cells from the host’s 
immune system;87, 100 
•	 gene silencing in a virus to enable a dormant  
state in the host’s neuron’s, dramatically increasing 
the persistence and re-emergence of infections;22 
•	 degradation of the functional capacity of host 
macrophages, enabling pathogens to survive  
inside them; 87 
•	 characterization and comparison if the host  
immune response to H7N7, H5N1, and H1N1 
influenza viruses;28 and 
•	 a novel bacterial mediator of pulmonary 
inflammation in pneumonic plague.101
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Pathogen evasion of the immune system
There have been significant developments in 
understanding the mechanisms through which 
pathogens evade the host’s immune system: 
•	 proteins used by pathogens to suppress  
immunity in plants;102 
•	 mechanisms for negating innate immunity;22, 35, 47, 86, 
87, 89, 91 
•	 mechanism for negating vaccine-acquired  
adaptive immunity;22, 89 
•	 modulation of the production of viral proteins  
used to block interferon production in the host;44 
•	 a viral mechanism using RNA motifs to avoid a  
host immune response;103 
•	 chemical modification of the pathogen’s genetic 
material to void detection;87 
•	 the production of proteins by a pathogen to  
interfere with the host’s ability to trigger an  
immune response,87 including type III  
secretion processes; antigenic variation;87 
•	 the use of TAM receptors to inhibit innate  
immune response;87 
•	 interference with receptor proteins on host  
immune cells;87 and 
•	 broadly-reactive antibody-binding proteins  
used to block antibody-antigen binding.87
Drug side-effects
There have been new insights into hazardous 
side effects caused by drugs, for example, better 
characterization of the mechanisms responsible for 
hypersensitivities to small molecule drugs used for  
the treatment of infection.104
3.1.6 Improved tools to characterise disease
In general, there has been continued progress in 
enabling technologies offering ‘many benefits in faster, 
cheaper, and easier application of biological science 
and technology for both public health and security 
purposes, increased capacity and better understanding 
of disease and healthcare technologies by more people 
in more locations throughout the world’.105
In particular there have been advances in sequencing 
technologies, including linking sequencing and 
functional data, working with large datasets, complex 
disease models, structural analysis, neurobiological 
techniques, tracking infection in the host, agent 
identification and drug development. 
Tools developed since the Seventh Review 
Conference can characterise disease arising from 
infection with a range of agents of relevance to the 
BWC, including Yersinia pestis,88 HIV,32 foot-and-
mouth disease virus,106, 107 and toxins, such as  
cytolethal distending toxins,50 and Ricin.54
Sequencing
Advances in sequencing technology now provide: 
•	 improved identification of agents;36, 42, 108 
•	 enhanced epidemiology and near real-time 
surveillance;36 
•	 better tools for managing disease outbreaks;36 
•	 techniques for establishing the limits of the use  
of genetic elements to predict disease course;109 
•	 the use of genetic interaction mapping to identify 
functional relationships between genes;54 and 
•	 the use of transcriptomics to provide insights  
into plant pathogens that would otherwise be 
difficult to study.27
Developing superior tools to link sequence and 
functional data: 
•	 connecting deep sequencing data with global  
gene disruption to allocate genes to phenotypes;50 
•	 using genome wide association studies with non-
targeted metabolomics to establish linkages with 
metabolic phenotypes;110 and 
•	 the re-creation of databases to house details of 
pathogenicity islands and resistance islands.43 
Datasets and models
Improved tools and technologies to address the 
significant challenge of manipulating and analysing 
the massive amounts of data being generated by 
automated, high throughput technologies, for  
example, distributed computing technologies.111
Developing models to describe complex biological 
systems and to use them to further understandings of 
disease, for example a model of the capsid of foot-
and-mouth disease virus was used to explain physical 
characteristics of the virus106 as well as biological 
functions.107
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Structural analysis
Improved techniques for structural analysis: 
•	 techniques for stabilising receptors allowing 
previously uncharacterized structures to be 
determined using x-ray crystallography;112 
•	 combined use of cryo-electron microscopy and cryo-
electron tomography to identify the structure and 
molecular dynamics of a mature viral capsid;32 and 
•	 room-temperature macromolecular 
crystallography.113
Neurobiological techniques
There have been a broad range of advances in  
tools for studying neurobiology, including:
•	 in optogenetics where light is used to switch  
specific neurons, or classes of neurons on and off  
in a living host – helping to determine the role of 
those neurons in certain physiological states;114, 115, 116
•	 techniques for making biological material transparent 
to light, allowing neurological reactions to be 
studied in real time in a living host;117 stimulating the 
neurons identified;118 and for elucidating form-function 
relationships;116, 119 and 
•	 translation of such approaches and techniques for 
work in non-human primates.120
Nanotechnology
The continued integration of nanotechnology in 
relevant tools has led to new capacities for example 
to measure the cellular secretion of growth factors, 
cytokines, and other signalling molecules into 
extracellular spaces.121
Tracking infection in living hosts
Progress has been reported in being able to track 
infections in living hosts: 
•	 the use of bioluminescence to study the kinetics of 
infection and the physical movement of a pathogen 
during different stages of disease course;88 
•	 fabrication, characterization, and testing of a polymer 
‘microprojection array’ for the direct and selective 
capture of circulating biomarkers from the skin.122
Agent identification
Sequencing technologies,36 metagenomics 
technologies,108 and mass spectrometry123 are platforms 
that have all been used to identify agents more rapidly 
and reliably. 
Drug development
Better tools for drug development are available, 
including: 
•	 the use of 3D printed cells and tissues for the pre-
clinical modelling of drug impacts and side effects;124
•	 the identification of a protein useful for purifying, 
immobilizing, and detecting all types of human and 
nonhuman immunoglobulin G antibodies;125 
•	 biodegradable  silicon nanoneedles to deliver  
nucleic acids into cells;126 and 
•	 further humanized forms of mouse antibodies.127
3.1.7 The role of the microbiome in disease
There has been an improved understanding of how 
communities of commensal microbes contribute to 
healthy and diseased states:128
•	 The Human Microbiome Project Consortium 
published details of the structure, function and 
diversity of the health human microbiome, providing 
a useful normal data set against which disease 
states can be compared.129 
•	 Studies have also demonstrated that indigenous 
microbes are closely connected with the spread of 
antibiotic resistance to pathogens.130
3.1.8 The role of biofilms in pathogenesis
There has been increased understanding of the role  
of biofilms in pathogenesis, including: 
•	 how biofilms form, through characterization of 
secreted proteins131 and physical processes;132
•	 the role of biofilms in disease, for example by 
protecting microbes, including pathogens, from 
antibiotics, hydrodynamic shear and environmental 
challenges.133, 134
•	 the role biofilms play in horizontal gene transfer, 
including plasmid-borne antibiotic resistance.135
3.2 Detection of disease
Developments in technology have enabled faster, 
more accurate detection and characterisation of 
disease outbreaks facilitating more rapid and  
effective intervention. These will reduce the impact  
of an outbreak, regardless of its origin, thus supporting  
the aims of Articles VII and X of the BWC. 
In particular, there have been significant advances in 
biosensors, biomarkers, mass spectrometry, microscopy 
and imaging. More comprehensive baseline data is 
needed to assist in comparisons and establish a ‘norm’ 
against which to compare unusual events.
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We are increasingly able to differentiate between 
deliberate and natural outbreaks, using genomics, 
PCR and mass spectrometry and the emerging 
discipline of ‘microbial forensics’ can help establish 
attribution if a malevolent deployment is suspected 
(see below). Such a finding would entail obligations 
and commitments by other States Parties under 
Article VII, as well as additional agreements reached 
at successive review conferences. 
3.2.1 Differentiating between deliberate  
and natural outbreaks
There have been advances in using genomics 
to differentiate between deliberate and natural 
outbreaks,136 including:
•	 using genomics to differentiate between an  
agent of interest from background microbes, 
including differentiating a specific lineage of 
Bacillus anthacis from samples of same species 
and strain, offering opportunities to link an 
environmental sample to samples from possible 
production facilities;137 
•	 they ability to differentiate between different 
isolates indistinguishable using physical 
characteristics enabling forensic epidemiology  
and modelling of the transmission routes  
involved;138 
•	 insights into the geographic origins of agents by 
identifying sequence differences corresponding  
to geographically distant but phenotypically 
identical pathogens, or more broadly to the 
geographic distribution of genetic elements;138, 139 
•	 mutational bias and possible deviations from  
normal evolutionary development;138, 139 
•	 comparative analysis of the causative organism 
of an outbreak to detect anomalies in antibiotic 
resistance, transmission routes or in outbreak 
intensity and clinical dynamics which might  
indicate an unnatural origin.139
Other techniques and approaches have been used to 
differentiate between deliberate and natural disease 
outbreaks, including the analysis of agents impossible 
or difficult to culture,123 including PCR140 and mass 
spectrometry.123, 140 Some of these platforms, such as 
PCR approaches, have been adapted for in-field use.141
3.2.2 Biosensors
It may be possible to detect a disease outbreak by using 
biosensors. These have been improved by increased 
sensitivity and ability to detect a wider range of agents 
using a wider range of samples and to detect functional 
changes in the host. 
Improved biosensors
The capacity of biosensors to detect an outbreak  
has improved due to: 
•	 increased sensitivity of the technology;142, 143
•	 applicable to a wider set of samples, for  
example, whole serum142 and urine;144, 145 
•	 removal of the need for separate desalination and 
centrifugation steps in sample preparation;146 and 
•	 improved capacity for quantitative analysis as well  
as simple detection;147, 148
•	 in-field biosensors combined with mobile 
applications and connections to remote databases, 
increases their utility.149
•	 ability to detect a wider range of agents, including: 
 - heavy metals;150 
 - pathogens,150 such as Bacillus anthracis147 and  
the causative agents of meningitis;148
 - toxins;151, 152, 153 and 
 - genetic material, including oligonucleotides.143
Advances in biosensors have also facilitated both 
diagnosis and the selection of appropriate therapeutics 
by better detection of functional changes in a host: 
•	 changes in phagocytes enabling differentiation 
between infections caused by viruses and those 
caused by bacteria;154 and 
•	 an order of magnitude increase in the sensitivity of 
detection of biomakers for prostate cancer.142
Technological advances
These improvements in biosensors are drawn from  
a wide range of technological advances, including: 
•	 nanoparticles:145, 155, 156
 - by reducing the physical space needed  
for chemiluminescent studies;154
 - as novel signal generators;142
 - on chip sample preparation;146
 - as scaffolds to hold functional elements;157, 158
 - for measurements at submicron and subcellular 
length scales;121 and 
 - in transduction.158
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•	 the design, construction and use of engineered 
organisms;150, 159
•	 plasmon resonance sensors;145, 151, 153
•	 planar waveguide devices;152 
•	 DNA scaffolds;160 
•	 the production of graphene surfaces;161 
•	 quantum dots;153, 162 
•	 surface enhanced Raman scattering;148 
•	 amperometry and magnetic relaxation;145 and 
•	 synthetic biology to engineer bacteria to detect  
and record environmental signals in the gut163  
and probiotics for disease detection.144
3.2.3 Biomarkers 
Biological markers of disease (‘biomarkers’) 
can detect disease rapidly. This improves our 
understanding of disease progression, enables  
earlier detection of disease, differentiates between 
different infections, and facilitates triaging of  
patients and epidemiological investigations. 
Biomarkers have been identified in a range of  
tissues and locations, including bone marrow,164 lung 
cells,165 and human sera.166 A synthetic system has 
been developed to identify biomarkers in the body  
and release reporters that can be detected in the 
patient’s urine.167, 168, 169
Biomarkers have been used to characterize the 
following: 
•	 signalling behaviour of cells;164
•	 gene products,170 including pre-clinical indicators  
of infection,171, 172 for differential diagnosis of different 
pathogens,171 and interaction with drugs;173 
•	 improvements in proteomics;170 
•	 gene expression and protein changes caused 
by pathogens,174 such as influenza165 and 
Mycobacterium tuberculosis,175 and to differentiate 
between different influenza infections;176 
•	 cytokine concentrations associated with different 
clinical outcomes;94 and 
•	 previous viral infections from circulating antiviral 
antibodies.166
Biomarkers are identified and detected through a 
variety of different technologies, including:
•	 single-cell mass cytometry;164 
•	 four-dimensional separation systems;170
•	 RNA-seq;174
•	 polymer microprojection arrays for transdermal 
biomarker detection in live animals;122
•	 RT-PCR TaqMan low-density arrays;176 and 
•	 nanoparticles and other carrier structures.177
Biomarkers are now more sensitive increasing 
their ability to detect rare events. This has been 
achieved through the use of nanoparticles;172, 177 
signal amplification;177 and higher throughput using 
multiplexing techniques.177
3.2.4 Mass Spectrometry
Advances in mass spectrometry have contributed to 
our understandings of disease, facilitated detection 
of disease outbreaks as they occur, and identification 
of the agent responsible. Since the Seventh Review 
Conference platforms such as MALDI-TOF mass 
spectrometry have entered into routine use for 
detections and diagnosis.178
Mass spectrometry has been used for: 
•	 agent identification;123, 140, 179, 180 
•	 disease surveillance;123
•	 microbial forensics;123
•	 the detection of complex biological samples;181 
•	 the detection of functional characteristics 
in pathogens, such as antibiotic resistance 
properties,178 and 
•	 differentiation between strains of a pathogen.182
Mass spectrometry has been combined with other 
novel technologies, such as: 
•	 PCR driven Electrospray-Ionization Mass 
Spectrometry, enabling the identification and 
differentiation of agents of concern;140, 179
•	 combinations of high-throughput nucleic acids 
analysis and mass spectrometry for the analysis  
of agents difficult or impossible to culture;123 and 
•	 liquid chromatography–mass spectrometry for 
genome-wide discovery of protein-coding loci in 
mammals.183
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There have also been further technical developments  
in mass spectrometry, including:
•	 ionization methodologies for high-resolution  
mass spectrometry, increasing the number and 
range of molecules that can be detected;181, 184
•	 time-of-flight approaches to mass spectrometry, 
which may be more suitable for the detection of 
biological material;181, 184
•	 miniaturization of equipment;184
•	 Matrix Assisted Ionisation Vacuum mass 
spectrometry and Desorption Electrospray 
Ionisation mass spectrometry which simplify 
sample preparation.184
3.2.4 Microscopy and imaging
Advances in microscopy and imaging have 
contributed to our understandings of disease, 
facilitated detection of a disease outbreaks, and 
identification of the causative agent. 
Advances have enabled: 
•	 direct observation of proteins as they conform  
and move;185
•	 3D imaging on a sub-cellular level in live cells, for 
example mitochondria, filopodia, membrane ruffles, 
intracellular vesicles and mitotic chromosomes;186
•	 tracking the course of pathogens during infection  
of a living host;88 and 
•	 building all-atom models of viral capsids.32
These advances have drawn upon technical 
developments in: 
•	 combining fluorescent and other microscopy 
techniques;185
•	 scanned Bessel beams used in conjunction 
with structured illumination and/or two-photon 
excitation;186
•	 bioluminescence imaging;89
•	 cryo-electron microscopy and cryo-electron 
tomography;32 and 
•	 the development of rendering opaque living  
tissue transparent.117
Ultra-cheap microscopy equipment has also become 
available since the Seventh Review Conference, for 
example paper-based microscopes costing less than  
$1 and disease-specific microscopes for diagnostics  
in severely resource limited settings.187
There have also been examples of being able to 
repurpose equipment for use in imaging, for example 
a commercial DVD drive was converted into a 
laser scanning microscope that can analyse blood 
and perform cellular imaging with one-micrometre 
resolution.188
3.3 Diagnosis and surveillance
Improvements in diagnostics and disease surveillance 
can identify causative agents more rapidly, expediting 
the selection of optimal treatment options and preventing 
transmission. These developments strengthen capacities 
applicable to Articles VII and X of the BWC. 
Relevant improvements here include; rapid diagnosis 
of unknown pathogens; sequencing; PCR diagnostics; 
distributed diagnostics (see Box 2) and point-of-care 
devices; centralisation of certain types of laboratory 
capacity; genetic and molecular epidemiology; as 
well as the use of cheap and disposable equipment. 
Substantial improvements in diagnostic speed and 
accuracy were noted.
Box 2: Distributed diagnostics 
Developments in genetic 
sequencing technologies 
have not only made 
it faster and easier to 
sequence a genome but 
have made it possible to 
do it around the world. 
The MinION nanopore sequencer was deployed 
by the European Mobile Laboratories in Guinea in 
2015, as part of an effort to address a large scale 
Ebola Virus Disease outbreak. This new platform 
enabled Guinean authorities to obtain important 
diagnostic and epidemiological information within  
48 hours with the samples never leaving the country.
Image:
Left: Josh Quick, University of Birmingham, UK. 
Center: Dr. N’Faly Magassouba, Infectious and 
Tropical Diseases Department, National Hospital 
Donka, Conakry, Guinea. Right: Prof. Miles Carrol, 
Public Health England, Porton Downs UK.
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3.3.1 Diagnosis of unknown pathogens
Advances in metagenomics have enabled 
the identification of previously unculturable 
microorganisms,123, 189 previously unidentified 
pathogens,190, 191 and the identifications of pathogens 
from within mixed environmental samples.192
3.3.2 Bioforensics
Advances in diagnosis and surveillance can probe  
the origin of an outbreak and provided new and 
improved tools to identify, interdict and prosecute  
those undertaking prohibited activities (relevant to 
Articles I, III, IV, V and VI). 
A variety of different technologies and approaches 
have been used for bioforensics, including: 




•	 mass spectrometry;123 and 
•	 applications of nanotechnology.156
In some cases these tools have been validated for  
use in bioforensics, such as for high-throughput 
genome sequencing platforms.194
These technologies and approaches have increased 
our capacity for investigating the origins of a given 
pathogen by: 
•	 linking specific phenotypic qualities of an agent  
with sequence data;137
•	 using sequence data to differentiate an organism  
of interest from background microbes;137
•	 cataloguing genomic diversity and mapping 
circulating mutations, providing better reference 
data sets;3, 36, 193
•	 use of molecular epidemiology, to trace the 
evolution of an agent of interest more accurately;36
•	 distinguishing between samples of a pathogen 
indistinguishable using traditional tests;138, 193
•	 to detect any disconnect from a natural chain of 
infection;138
•	 linking whole genome information to existing 
datasets of genetic fingerprint, previously used  
for pathogen identification, increasing the  
available reference data;195
•	 giving‘insights into production methods, such as 
particle sizes, associated signatures, geographical 
origins, and intelligence information’;193
•	 characterizing mixed environmental samples;108
•	 establishing the relationship between a novel 
agent and known pathogens;196 and 
•	 determining evolutionary dynamics.196
Research into clinical waste management has 
revealed that fragments of genetic material survive 
standard cleaning and decontamination techniques, 
such as autoclaving. The persistence of such material 
and the application of metagenomics approaches 
to reconstruct fragments into longer sequences, 
could enable the identification of an agent even after 
attempts to destroy all traces of its presence.197
Significant challenges have also been noted, including 
a need for a predictive capability of function from 
sequence data.36
3.3.3 Sequencing
These advances have increased the amount of 
benchmark and background data available for 
diagnostics, enabled a wider set of samples to be 
used in diagnostics, decreased time for confirming 
a diagnosis, and enabled in-country diagnostic 
capacities, and facilitating genetic and molecular 
epidemiology. As a result, sequencing technologies 
have been increasingly used for diagnosis and 
surveillance during disease outbreaks including 
outbreaks of H1N1 influenza,189 Escherichia coli,19, 199, 200 
H5N1 influenza,3 tularaemia,199 meningoencephalitis,108 
malaria,201 Staphylococcus aureus,202 viral hemorrhagic 
fever outbreaks,203 anthrax,204 and wheat yellow rust.27 
Significant challenges have also been noted, 
including: a need for a predictive capability of 
function from sequence data;36 ‘to use genomic data 
to develop improved tools for managing infectious 
diseases’;36 manipulating and analysing the data 
and other bioinformatics challenges;205, 206 improving 
diagnostic sensitivity;200 speeding up and simplifying 
workflows;200 and further cost reductions.200
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Developments in sequencing technology include: 




•	 commercial production of novel nanopore-based 
sequencers;210 and 
•	 validation for use in investigating the use of 
biological weapons.194
New sequencing capabilities have been used for: 
•	 cataloguing genomic diversity; 3, 27, 36, 37, 201, 207, 211, 212
•	 molecular epidemiology and disease surveillance;3, 
19, 36, 136, 203, 208, 211, 213
•	 understanding pathogenesis; 19, 36, 37, 202, 204, 213, 214
•	 exploring metagenomics;36, 200, 214
•	 pathogen discovery and diagnostics;19, 36, 108, 136, 199, 202, 
203, 204, 205, 207, 209, 211 ,213 ,214, 215
•	 therapeutics and drug discovery;36 
•	 vaccines;36 
•	 diagnosis of hereditary diseases;216
•	 understanding transmissibility and host range;3, 214
•	 establishing antimicrobial characteristics;199, 201, 202, 214 
•	 determining infection control need;199, 202
•	 identifying agents in mixed environmental 
samples;108, 208, 214, 215
•	 informing clinical management;202, 206
•	 understanding host-pathogen interactions;214
•	 the identification of natural reservoirs;207 and 
•	 phylogenomic trees helping to explain the 
evolutionary relationships between pathogens, 
strains and clades.217, 218
There has also been progress in ensuring the 
‘backwards compatibility’ of sequence data, for 
example, using software tools to link whole genome 
sequence data on pathogens with earlier pathogen 
‘fingerprint’ data sets.195
3.3.4 PCR diagnostics
Using PCR assays to diagnose pathogens has proven 
to be ‘being highly specific and cost-effective’.212 It 
offers benefits over serological methods of diagnosis 
because fewer reagents are needed and it produces 
results that are more easily interpreted.219 Automated, 
rapid, and sensitive PCR-platforms capable of 
identifying over a thousand pathogens from clinical 
samples now exist.220 Cartridge-based diagnostic PCR 
platforms intended for use by non-specialists have 
been developed.221 Some are intended for in-field 
use,222 including detection of the potential use of 
biological weapons.141
Platforms using PCR techniques have been used for 
diagnostics since the Seventh Review Conference, 
including: 
•	 real-time reverse–transcription PCR–based 
genotyping;198
•	 multiplexed PCRs;223
•	 multiplexed RT-PCR;179, 224 and 
•	 digital droplet PCR.225
These platforms have been used to identify a range  
of pathogens, including:
•	 differentiation between influenza subtypes and 
reassortants;198, 224, 226
•	 Bacillus anthracis,179 including simultaneous 





•	 Burkholderia spp.;179 and 
•	 Rickettsia prowazekii.179
Alternative approaches using different techniques have 
been developed, for example: 
•	 isothermal amplification techniques offers similar 
information to the thermal heating traditionally used 
in PCR but at a reduced cost220, 227, 228
•	 loop-mediated isothermal amplification (LAMP) 
technology has streamlined DNA extraction and 
amplification steps.227
•	 PCR technologies are also more portable, for 
example through integration of sample preparation 
and data analysis steps into a single machine and 
through approaches reducing or removing energy 
requirements.227
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•	 using PCR to quantify the amount of pathogens 
present, rather than simply detect their presence, 
for example, digital droplet PCR has been used 
to quantify viral titer with better accuracy than 
traditional methods for establishing Ct values 
but with labour intensive purification steps, as an 
absolute quantification (negating the need for 
comparison against an external standard), and  
as part of a fully automated system.225
3.3.5 Distributed diagnostics  
(including point-of-care diagnostics)
Since the Seventh Review Conference, there 
has been a trend ‘to make sophisticated tests, or 
assays, more easily performed with less training, 
leading to decentralization and diagnosis closer to 
the point-of-care’.229 Their value in combating high-
impact infectious diseases has been noted, as rapid 
diagnostics and treatment here is critical.230 The 
application of nanotechnology has led to improved 
accuracy, increasing speed and reductions in costs 
of point-of-care diagnostics.231 Integration with 
modern information technology platforms, such as 
smart phones, has also enabled a more distributed 
approach towards diagnostics.232
Point-of-care diagnostics
There is global interest in point-of-care diagnostics 
with new products being developed in every 
region of the world.230 The cost of certain point-of-
care diagnostic tools has fallen since the Seventh 
Review Ronference.229 Point-of-care tests have been 
developed specifically for biological weapon agents.230
Developments in point-of-care diagnostics include,  
the ability to detect: 
•	 differentiation of bacterial and viral infections;154
•	 all strains of H5N1 influenza;233
•	 dengue fever;233
•	 chikungunya;233
•	 hand, foot and mouth disease;233 
•	 malaria;233
•	 tuberculosis;234 and 
•	 the goat disease Contagious caprine 
pleuropneumonia.222
Lab-on-a-chip technologies have continued to develop, 
for example, including for the detection of antibiotic 
resistance characteristics in pathogens.235 
 
Capabilities for point-of-care diagnostics based upon 
analysis of breath have been demonstrated since the 
Seventh Review Conference.231
Point-of-care diagnostics have also been used for 
the optimization of drugs and medication, thereby 
influencing clinical management decisions.230
Tools
A number of technical developments have contributed 
to advances in point-of-care diagnostics since the 
Seventh Review Conference, for example: 
•	 the use of nanoparticles to significantly reduce 
the physical space needed for chemiluminescent 
studies;154
•	 capillary driven and paper-based microfluidics;236
•	 multilayer soft lithography;236
•	 multiphase microfluidics;236




•	 the development of bio-based polymer beads;237 
•	 the use of cell phones to access remote data sets 
and analysis;149, 232 
•	 Mass/Piezoelectric detectors’;234
•	 field portable versions of classical ELISA (using 
lateral flow chromatography; 234
•	 advances in PCR technologies to make it more 
readily adapted to portable and in-field use;234
•	 microfluidic technologies with integrated sensors 
for processing bodily fluids such as blood or 
saliva;238
•	 the creation of paper-based gene circuits;231 and 
•	 the application of synthetic biology approaches 
to developing probiotics for the diagnosis of 
disease.144
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3.3.6 Laboratory capacity
Whilst certain diagnostics are becoming more 
distributed, ‘more advanced (and likely more 
expensive) diagnostic tests may require specialized 
equipment, resources and laboratories (e.g. reference 
laboratories)’ as a result, there has also been a trend 
towards the ‘consolidation of testing in larger labs, 
driven by economies of scale, availability of expertise, 
and the development of newer diagnostic approaches 
that have substantial complexity and costs’.239
3.3.7 Genetic and molecular epidemiology
Enhanced disease surveillance capabilities now plays 
an important role in dealing with disease outbreaks, 
such as the 2009 H1N1 influenza pandemic.240 
Advances in gene sequencing technologies are 
increasingly used in epidemiology. 36, 241
Sequence data has been used to: 
•	 gain insights into the geographic origins of 
pathogens;19
•	 demonstrate that the geographic distribution of 
pathogens is wider than previously thought;242
•	 map the current circulation of mutations known 
to affect certain phenotypic implications, such as 
enabling mammal-to-mammal transmission3 or 
antibiotic resistance;218 
•	 identify the most feasible epidemiological 
explanation of a diseases outbreak;138
•	 determine genetic diversity amongst geographically 
or temporally disparate pathogens;27, 243, 244
•	 determine the relationship of a novel pathogen to 
known relatives;196
•	 to study the emergence and spread of antibiotic 
resistance;245 and 
•	 confirm infection and transmission events.203
Sequence data has also been connected to 
phenotypic characteristics to determine whether 
transmission is a result of specific characteristics of the 
pathogen, or other factors such as vector dynamics 
and host susceptibility.246 There have been significant 
advances in analysis and interpretation of results209 and 
greater accuracy in the detection of genetic elements 
associated with virulence and drug resistance since 
the Seventh Review Conference.37
Other advances, such as those in mass 
spectrometry,123, 182 have improved the capacity for 
molecular epidemiology.
Genetic and molecular epidemiology have been used 
to investigate outbreaks of diseases since the Seventh 
Review Conference, including: 
•	 Escherichia coli, to provide insights into the 
origins of the bacteria and core aspects of its 
pathogenicity;19
•	 Yersinia pestis, enabling comparative analysis of 
factors such as pathogenicity with other currently 
circulating and historical strains;246
•	 Staphylococcus aureus, to characterise genome 
stability and the independent acquisition of disease 
characteristics in different locations;247
•	 MERS-CoV, including for evolutionary mapping;196
•	 four viral hemorrhagic fever outbreaks, to identify 
and confirm infection and transmission events;203
•	 wheat yellow rust, to track phenotypic changes and 
map the evolution of the pathogen throughout a 
country;27 and 
•	 evolutionary mapping of Peste des Petits Ruminants 
Virus217 and Ebola Virus Disease.248
Current shortcomings include the lack of background 
or normal data. 
Progress has been made in identifying the limits of 
and strategies for improving the global mapping of 
infectious diseases of clinical significance to humans.249
3.3.8 Cheap and disposable equipment
Diagnostic equipment, such as PCR, more suitable for 
use in resource limited settings has been developed 
by, for example removing the requirement for 
electricity, replacing traditional heating elements with 
chemical components taken from hand and boot 
warmers.250 Similarly, cheap, paper based microscopes 
have been developed with different levels of resolution 
and for specific diseases.187
3.3.9 Diagnostic speed and accuracy
Improvements in whole genome sequencing and its 
falling costs have led to more widespread use of the 
technique in diagnostics and epidemiology. It is faster 
and more accurate that other approaches251, 252 and has 
proven particularly useful in differentiating between 
closely related pathogens.224
The extraction of pathogenicity-related information 
from sequence data; a process which used to take 
weeks, can now be accomplished in a day.253
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There has also been progress in developing high-
throughput approaches to diagnostics, for example 
the use of Luminex microarray hybridization to identify 
influenza subtypes.254 Progress has also continued in 
lab-on-a-chip platforms including in terms of speed, 
versatility and user friendliness.235
Synthetic biology is reducing the time needed to 
produce specific antigens or antibodies for use in 
diagnostics tests.252
However, shortcomings continue to persist. For 
example, a lack of quality assurance in toxin 
diagnostics has been demonstrated internationally.78
3.4 Preventing, mitigating and treating 
disease using vaccines and drugs
The timely use of effective vaccines and therapeutics 
prevents or reduces the impact of outbreaks, 
regardless of cause. This is of direct relevance to 
Articles VII and X. Rapid detection and characterization 
of infectious agents reduces the time required to 
develop vaccines, drugs and other counter-measures. 
Outsourcing of key production steps has reduced the 
need for dedicated vaccine production infrastructure. It 
is increasingly simpler, faster and cheaper to industrialize 
production processes. Single-use equipment and 
modular production technologies shorten turn-around 
times. A more distributed production base in industry 
reduces the distance a product has to travel to its 
point of use. However, regulatory and liability issues 
associated with diagnostics, drugs and vaccines in 
health emergencies continue to limit potential for 
progress and this is an issue that should be addressed.
High-throughput platforms and ‘big-data’ approaches 
continue to reveal a wealth of potential new targets 
and candidates for drugs and vaccines. The design, 
testing and optimisation processes have been 
streamlined by the ‘digitalization’ of biology supported 
by better computational technologies, improved 
capacity for rational design, integration of synthetic 
biology approaches, more sophisticated modelling 
tools, enhanced synthesis technologies and a wider 
array of platform technologies (see Box 3). 
Online laboratories and facilities now offer all of 
these services at a single site, as an ‘organism design 
support service’. Throughput has been improved using 
machine-learning and semantic web-based approaches. 
Enhanced screening of drug candidates and other 
enabling tools have helped streamline the development 
pipeline. However, bioinformatics capabilities remain a 
major challenge in this area.
Since the Seventh Review Conference, a number of 
new drug classes have been developed and existing 
classes of drugs have been further exploited. Examples 
include: antibody-based drugs; novel drugs for diseases 
traditionally associated with biological weapons (e.g. 
anthrax, ricin); the use of drug combinations; drugs to 
target disease vectors; and in identifying useful off-label 
indications for existing drugs.
Vaccines have been developed for combating multiple 
agents or strains by targeting conserved regions and 
rendered more effective and stable through the use of 
virus-like particles and improved adjuvants. A number 
of new avenues for designing vaccines have been 
explored, utilising synthetic biology, DNA nanostructures 
and RNA viruses. 
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Box 3: An example of how the digitization of biology accelerates vaccine development.  
The Novartis H7N9 influenza vaccine response – Combining synthetic virus generation  
with flu cell culture platform 
Synthetic virus rescue in collaboration 
with Synthetic Genomics Vaccines Inc.




Monday 8 April 
Sequence confirmation of vaccine  
virus rescue
Tuesday 2 April 
Venter sythesizes HA & NA genes
Wednesday 3 April 
Sythesized genes received in Cambridge. 
1st transfection
Thursday 4 April 
Sythesized genes provided by NVD & 
Venter received at US CDC
Saturday 6 April 
1st evidence of rescue of vaccine virus
Thursday 11 April 
US CDC receives wild type virus from China
Friday 12 April 
Virus shipped to Uni MBG
Friday 19 April 
Virus released from customs to Uni MBG
Thursday 2 May 
1st round of limiting dilution subcloning 
completed
Monday 13 May 
2nd round of limiting dilution subcloning 
completed
Tuesday 14 May 
German autorities notify NVD that  
RG-ID-1603 can be manufactured at BSL2
Wednesday 15 May 
Sequence of HA & NA genes after 
subcloning confirmed
Thursday 16 May 
Virus PCR – for bovine, porcine 
adventitious agents, shipped to NDV  
MBG GMP seed lab
Friday 17 May 
Passing of virus in the seed lab begins
Monday 27 May 
Start of QC testing on seed lot
Friday 24 May 
Second Round of Passing in seed lab 
complete, start of seed lot manufacturing
FINISH
2013
Thursday 13 June 
2500L fermenter inoculated to start 
production of Ph I CTM
START Sunday 31 March 
China CDC reports human infections w/ H7N9 
influenza, post sequences on GISAID
May
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3.4.1 Drug development
A range of new techniques has improved the 
development of existing drugs and opened up 
opportunities for further discovery. 
High throughput systems
High-throughput platforms continue to provide a 
wealth of new information on potential new targets for 
drugs,255 including sequencing36, 256 and toxicological 
screening.257, 258
Connecting such data to biological function remains 
a significant challenge,36 although advances have 
been made in developing model systems can now 
recapitulate in vivo viral life cycles.18
Computational and bioinformatics
Computational and bioinformatics approaches have 
improved design strategies, including:
•	 designing proteins that bind a surface patch of 
interest on a target macromolecule;259, 260
•	 data-driven prediction of drug effects and 
interactions;261, 262
•	 prediction of novel drug-drug interactions using 
databases,263, 264, 265 machine learning,266 and 
semantic web-based approaches for data mining;267 
•	 development of tools for extracting machine-usable 
data from past publications;268
•	 computational design capabilities to stabilize 
enzymes;269 and 
•	 integration of multiple data sources and ‘big data’ 
approaches to drug discovery.270
Synthetic biology
Synthetic biology approaches have also been 
applied to drug discovery271 and have helped identify 
candidates for: new antibiotics, drugs to reverse 
antibiotic resistance, anti-diabetes drugs, and 
immunosuppressants; as well as cancer therapies, 
including bacterial synthetic devices, viral synthetic 
devices, and a transformation sensor.272
Synthetic biology approaches have resulted in 
strategies for controlling and measuring cell-
environmental interactions in vitro, including 
strategies for high-throughput analysis.273 
There has also been progress in developing chassis 
for clinical applications.274 Since the Seventh Review 
Conference, platforms offering remote support for 
designing, compiling, trouble shooting and optimizing 
custom biological organisms have appeared, for 
example with industrially focused, large scale 
platforms for the synthesis of genetic material.275
Handling and manipulating material has been 
improved, for example: the identification of a protein 
for purifying, immobilizing, and detecting all types of 
human and nonhuman immunoglobulin G’ antibodies;125 
and developments in rational enzyme design.271
Enhanced screening of drug candidates has streamlined 
the development pipeline and other tools important 
for drug development. Examples since the Seventh 
Review Conference include, a protocol for testing the 
ability of a specific protein to ‘rescue’ knock-out strains 
of bacteria276 and high-resolution dose – response 
screening using droplet-based microfluidics.277 Fully 
automated, remotely accessed laboratories have also 
emerged.278
Improved tools to explore important features of the 
target and host have been developed, for example: 
•	 a chip based method for producing uniform vesicles 
facilitating research into proteins in cell walls, 
common drug targets;289
•	 genome-scale RNA interference target sequencing 
to reveal the transporters, organelles, enzymes and 
metabolic pathways that function to facilitate drug 
action;280
•	 experimental-computational technology for inferring 
network models that predict the response of cells 
to perturbations;281 and 
•	 mice optimised for use with genome editing 
technologies.282
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3.4.2 Novel drugs
A number of new drug classes have been developed 




•	 proof of principle studies on using synthetic biology 
techniques to engineer microbes to sense and 
eradicate pathogens;284, 285
•	 nanoparticle-based drugs able to interact with 
viruses inside infected cells; 286
•	 the use of CRISPR/CAS9 to edit human genetic 
components linked with disease286 as cancer 
immunotherapies, and cell-based therapies for HIV, 
primary immune deficiencies, and autoimmune 
diseases.287, 288
Drug classes identified at previous review conferences 
are still yet to reach full development but are 
improving, for example, advances in developing 
siRNAs-based drugs289, 290 have improved stability, 
potency, reduced off-target effects, and increased 
efficient delivery and led to the development of 
therapeutics in Phase I and Phase II clinical trials.291
Progress has been made in developing antibody-
based drugs, against: 
•	 bacteria, such as Bacillus anthracis;292, 293, 294
•	 toxins, such as Ricin70, 74, 75, 76 and Abrin;59
•	 viruses, such as Ebola viral295 and 
•	 H1N1 influenza.296
The FDA licensed the first monoclonal antibody against 
inhalational anthrax since.297 Additional antibody 
therapies for inhalational anthrax have subsequently 
been licensed.294
Since the Seventh Review Conference a range of new 
drugs and drug candidates have been developed, 
including to target: 
•	 Bacillus anthracis;291, 292, 293, 294, 297, 298
•	 toxins, such as Botulinum neurotoxin,56 Ricin,58, 68, 70,  
71, 72, 74, 75, 76 and Abrin;59 








•	 H7N9 influenza;28 and 
•	 genetic factors known to influence disease in 
humans.286
Drugs have also been used in new combinations 
to increase efficacy. For example, research has 
demonstrated the value of administering both 
antibodies and antibiotics in treating anthrax.293, 298
There has also been progress in developing drugs 
to target important disease vectors, for example the 
Wolbachia bacteria303 and mosquitoes120, 304 important 
in malaria.
There has also been progress in identifying 
opportunities to use licensed drugs to treat other 
diseases, for example, to treat prion diseases,83 and 
H7N9 influenza.28
3.4.3 Vaccine design
The efficiency and speed of vaccine development has 
improved through a combination of stored datasets, 
design and techniques. 
This included the use of: 
•	 large quantities of genetic sequence data that 
provide many novel targets for vaccines;36
•	 improved understanding of pathogenicity and host-
pathogen interactions, thereby assisting vaccine 
design;305, 306
•	 improved computational design tools, for example 
in HIV vaccine design307 and structure based 
antigen design;308
•	 rational design and production tools,307, 308, 309, 310 in 
particular in bio-based processes310 and the ability 
to synthesize vaccine candidates from manipulated 
sequence data.312
There have been attempts to develop new approaches 
to designing vaccines: 
•	 advances in synthetic biology have been applied 
to vaccine development, including production of 
antigen-producing immunostimulatory liposomes 
as genetically programmable synthetic vaccines313 
and development of a methodology for synthetic 
attenuated virus engineering;314
•	 the use of DNA nanostructures as platforms for 
vaccines;312
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•	 the use of synthetic drug-like small molecules to 
inhibit viral infection of cells;315 and 
•	 the use of RNA viruses to produce vaccine 
antigens.316
Notable progress has been made in the development 
of more effective and stable vaccines, such as through 
the use of virus-like particles, for example: 
•	 synthetic capsids that confer immunity and offer 
significant benefits over live agent, or inactivated 
agent vaccines for diseases such as Foot-and-
Mouth Disease;312, 317, 318
•	 self-assembling influenza nanoparticle vaccines 
that elicit broader and more potent immunity than 
traditional influenza vaccines;312, 319
•	 the application of engineering principles for rational 
design;309 and
•	 the construction of virus like particles to confer 
immunity against H7N9 and H7N3 influenza 
viruses,320 and Hepatitis E and related diseases.321
Existing approaches to increase impact and efficacy 
continue to be developed, for example: 
•	 conjugate vaccines;311
•	 the use of baculovirus expression systems;306, 308, 322
•	 better targeting of conserved regions;296, 307, 312, 323
•	 use of mammalian cell culture production and 
synthetic vaccine seeds;324
•	 reduced reliance on generating sheep antisera;324
•	 better adjuvants;306, 308, 324, 325, 326 and 
•	 novel nucleic acid vaccines,308 including mRNA 
vaccines.327
New or improved vaccines have been designed and 
developed to prevent: 
•	 chikungunya virus;313
•	 Staphylococcus aureus;313
•	 Foot-and-Mouth Disease virus;317
•	 Ebola virus;315, 328





•	 flaviviruses;315 and 
•	 Hepatitis E.321
3.4.4 Vaccine and drug production
The space and resources required for biologics 
production has also decreased and the physical size 
of production equipment has been drastically reduced. 
Smaller facilities using more compact equipment 
increases the range of potential sites and reduces 
logistical challenges, in some cases also offering cost 
benefits. Scaling-up production to industrial levels 
has been simplified and can be accomplished more 
quickly, although it can still take years. 
In some cases, the costs of industrial scale-up have 
fallen, through improved ‘directed evolution’ techniques 
for example. In other cases, improvements in efficacy 
and efficiency, such as those associated with automation 
and miniaturization, may incur increased costs. 
Bio-based production and biosynthesis have 
become common methodologies, aided by particular 
developments in the use of yeast ‘chassis’ and 
‘scaffolds’ to control the spatio-temporal arrangement 
of components. There have been improvements in 
vaccine expression, in particular through insect cell 
line and suspended cell cultures and the use of bulk 
production material. 
The increase in usage of disposable or single-use 
equipment has also been noteworthy. The range 
of processes for which disposable equipment is 
available has increased in number and complexity 
and increasing standardization of parts, facilitates 
switching to disposable equipment. 
Outsourcing of production, including the advent of 
‘biofabs’, has also become a reality since the Seventh 
Review Conference. Post-production purification steps 
have been improved or simplified, as a result of the 
growing regulatory attention paid to ensuring viral 
removal or inactivation. 
Reduced size of production facilities 
The space required for drug and vaccine production 
has decreased. Examples since the Seventh Review 
Conference include: 
•	 the use of suspended cultures in vaccine 
production;329, 330
•	 the use of egg-free systems in vaccine 
production;331
•	 industrial use of microreactors for chemicals and 
small biological;332
•	 baculovirus/insect cell expression systems to 
produce recombinant proteins and vaccines;329, 333 
and 
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•	 the potential to use yeast-based systems for 
opinoid production.334, 335
The physical size of production equipment has been 
drastically reduced. Examples since the Seventh 
Review Conference include the use of suspended 
cultures in vaccine production329, 330 and industrial use 
of microreactors for chemicals and small biological.332 
Smaller facilities using smaller equipment increases 
the range of potential sites and reduces logistical 
challenges, in some cases also offering cost benefits.
Quicker simpler production
Improvement in the synthesis of genetic material and 
other synthetic genomics techniques has enabled 
the outsourcing of biological production, for example, 
vaccine candidates.336, 337 Multipurpose biological 
production facilities have been used for outsourced 
production, for example for the industrial production of 
a precursor for an anti-malarial drug.338
Disposable equipment has been used in the production 
of vaccines,339, 340, 344 monoclonal antibodies,341 
recombinant proteins,341 and are being developed for 
use with stem cells and personalised medicine.341 
The time required to scale up processes for large-
scale production has fallen in some cases, for 
example, increased automation and miniaturization of 
development processes has occurred.342 Whilst these 
processes happen faster, they can still take years.336
Certain scale-up processes have been simplified. 
Examples since the Seventh Review Conference 
include: the use of directed evolution to remove 
reliance on animal serum;329 the improved engineering 
of strains prior to scale up;338, 342 and increased use of 
virus-like particles instead of viruses.321
There have been improvements in microfluidic reaction 
vessels used for drug production, for example, there 
have been advances in flow microreactors since the 
Seventh Review Conference.332
The range of processes for which disposable 
equipment is available has increased in number and 
complexity. Examples since the Seventh Review 
Conference include: tangential flow filtration;343 
mixing and perturbing materials;343 and downstream 
processing equipment.339, 340 
There has been increasing standardization of parts, 
making it easier to switch to disposable equipment 
including ‘standardized, off-the-shelf assemblies 
for cell culture harvest and tangential flow filtration, 
disposable, aseptic, genderless, universal connectors, 
and non-proprietary films and materials of construction 
for its bags, connectors, and tubing’.343
Purification steps have been improved or simplified 
and there has been growing regulatory attention paid 
to ensuring viral removal or inactivation.344 Examples 
since the Seventh Review Conference include: 
•	 the improved use of directed evolution;329
•	 multimodal chromatography;345 
•	 increased automation and miniaturization;342 
•	 the use of UV-C irradiation for viral inactivation;346 and 
•	 research to determine the comparative efficacy of 
different viral inactivation techniques.347
Cost of production
Certain costs associated with industrial scale-up 
have fallen, for example, through improved directed 
evolution.329 In other cases, improvements in efficacy 
and efficiency have increased costs. Examples since 
the Seventh Review Conference include: increased 
automation and miniaturization of development 
processes.342 
Biobased production and synthesis
Bio-based production and biosynthesis have become 
more common methodologies for vaccine and drug 
production,348 including uses for: 
•	 new secondary metabolites with novel therapeutic 
activities, such as complex polyketides, 
halogenated and alkaloids;349
•	 hybrid materials for drug delivery;349 
•	 toxins;350 
•	 the industrial scale production of terpenoids;348 
•	 peptides;348 
•	 co-stimulators of immune responses for use with 
vaccines;351
•	 opinoids;352 and 
•	 delivery devices for vaccines.351 
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There have been significant developments in efforts 
to build designer yeast since the Seventh Review 
Conference. Such a yeast might offer opportunities 
for enhanced chassis for bio-based production and 
biosynthesis. Recent developments have included: 
•	 the use of tags enabling the differentiation of 
synthetic components from wild type counterparts, 
especially the development of a real-time PCR 
assay for their detection;353 
•	 an in vivo method for assembling designed DNA 
fragments;354 and 
•	 a novel genetic assembly system for compiling 
expression pathways.355
Scaffolds made of various materials have been used 
to increase the efficacy of production processes 
by controlling the spatio-temporal arrangement 
of components, including DNA scaffolds and 
nanostructures160, 356, 357 and proteins.358 Scaffolds 
have also been used to enhance the efficacy of 
the production of different vaccines and drugs, for 
example, resveratrol;356 mevalonate;356 and antigen-
adjuvant complexes.329 
Recombinant plants and animals
There have been improvements in the use of 
recombinant plants and animals to produce vaccines 
and drugs. 
Plants have been used to produce: 
•	 a treatment for Gaucher’s disease grown in  
carrot cells;359 
•	 a vaccine candidate for H1N1;360 
•	 monoclonal antibodies to treat Ebola;361, 362
•	 antigens for rabies;363
•	 antigens for hepatitis B;363
•	 antigens for measles;363 
•	 antigens for avian influenza;363 
•	 antigens for anthrax; 363 and 
•	 antibodies to bovine viral diarrhea virus.363
Animals have been engineered to produce 
recombinant proteins and vaccine candidates.363
Tools
There have been improvements in the tools enabling 
the controlled design and production of biological 
materials. Examples since the Seventh Review 
Conference include transient gene expression in 
serum-free suspension-growing mammalian cells 
for the production empty viral capsids,330 as well as 
progress in developing standardized biological parts 
and devices.349 Advances have also simplified the 
bulk production material.364
There have been developments in vaccine production, 
for example: 
•	 the application of recombinant DNA technologies  
to the development of conjugate vaccines;311 the 
use of synthetic genomics approaches to ‘print’ 
vaccine candidates;336, 337, 340
•	 the creation of virus-like nanoparticles that elicit 
broader and more potent immunity than traditional 
vaccines;340 and 
•	 the development of module designs for backbones 
using optimised backbones and key structural 
motifs from the virus.365
Different expression systems used since the  
Seventh Review Conference include: 
•	 the use of insect cell lines;322, 329, 333 
•	 the use of human cell lines;329 
•	 the use of suspended cultures;329, 330, 340
•	 the use of egg-free systems;331 
•	 the use of chemical peptide synthesis;340 and 
•	 the use of transgenic plants and animals.340
3.4.5 Vaccine and drug delivery
Significant hurdles to storing or shipping labile 
therapeutics have been overcome. There have been 
notable successes in replacing cold chains and 
increasing the environmental stability of vaccines and 
drugs. In some cases this enables room temperature 
storage, for example, using alternatives to live agents 
such as the use of empty viral capsids.317
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Automated design strategies and other tools have 
made it easier to engineer and tailor drug delivery 
systems. The range of drug delivery platforms, such as 
enhanced and novel viral vectors and ‘microneedles’ 
has increased. Trans-dermal delivery systems are more 
effective and the range of substances that can be 
successfully delivered this way has increased since the 
Seventh Review Conference, opening opportunities 
for the non-invasive use a wider range of drugs and 
vaccines. There have also been improvements in 
targeted delivery systems, ensuring enhanced drug or 
vaccine access to the desired sites, tissues or cell-
types following administration.
Elucidation of nanoparticle structure-function 
relationships has led to improved drug delivery 
vehicles. The range of nanoparticle-based drug 
delivery platforms has increased and now includes 
formulations that can cross barriers and penetrate 
previously unreachable sites. Nanoparticles can now 
be designed to enhance the activity of their payload 
or to overcome its rapid metabolism. This reduces 
costs and increases efficiency by reducing the amount 
of payload needed, reducing threshold activity 
requirements for effective payloads, or prolonging their 
action be extending their effective life time. Controlled 
release of payloads, for example by remote activation 
or environmental response, reduces side effects.
Vaccines
A number of different approaches have been 
developed to increase the environmental stability of 
vaccines and drugs and, in some cases enable room 
temperature storage, including: 
•	 self-standing silk protein biomaterial matrices 
to stabilize labile vaccines and antibiotics up to 
temperature of 60°C for over 6 months;366, 367 
•	 coating viral capsids with a mineral coat, or other 
materials to store a vaccine at 26 °C for more than 9 
days and at 37 °C for approximately 1 week;312, 368
•	 engineering structural changes into viral capsids to 
improve thermal stability.312, 318
Drug delivery vehicles
Improvements have also been made to drug delivery 
vehicles, such as nanoparticles, to make them more 
environmentally stable.369
New tools to engineer and tailor drug delivery  
systems have been developed: 
•	 applications of synthetic biology to construct 
biohybrid delivery materials;349
•	 design guidelines;370 
•	 more sophisticated ways to fabricate 
nanostructures;371
•	 the ability to build larger nanoparticles;372
•	 more refined controlled release;372, 373, 374
•	 enhanced drug loading;372
•	 the ability to build nano metal oxide frameworks;372
•	 the ability to self assemble particles from increasing 
numbers of sub-units;375
•	 self assembling (and disassembling) systems;376
•	 collocation of drugs, ligands and other 
functionalities;377
•	 highly automated design strategies for complex 
nanostructures;378 and 
•	 design guidelines to increase the penetration of 
targeted nanoparticles.379
The range of drug delivery platforms has  
increased since the Seventh Review Conference. 
Examples include: 
•	 the use of lipid-based liquid crystalline 
nanoparticles;380 
•	 magnetic core-shell nanoparticles for aerosol drug 
delivery; 381
•	 cubic phase nanoparticle for sustained release of 
ibuprofen;382 and 
•	 self-assembled liquid crystalline nanoparticles.383
Viruses have been used to deliver novel drugs, 
including CRISPR/CAS9 elements.384 Improved viral 
vectors for gene therapy have been identified, 
including the synthesis of ancestral Adeno-associated 
virus vectors.385
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Trans-dermal delivery
There has been notable progress in trans-dermal 
delivery: 
•	 more effective microneedles366, 386, 388, 389 
and characterization of kinetics to improve  
their efficacy;390
•	 skin patches;366, 391, 392
•	 electroporation;387, 393
•	 low-frequency sonophoresis;387
•	 iontophoresis;387 and 
•	 tattoo delivery patches.394 
The range of material that can be successfully 
delivered through the skin has also been expanded 
since the Seventh Review Conference, opening 
opportunities for the non-invasive use a wider range 





•	 the co-delivery of DNA and siRNA;126
•	 proteins;387
•	 inactivated virus vaccines;395 and 
•	 insulin.392
Considerable progress has been reported in the 
manufacturing methods used to produce transdermal 
delivery devices, in particular microfabrication 
techniques in silicon, metal, glass and polymers.396
Cellular delivery 
Advances have also been made in delivering 
materials into cells, for example, biodegradable  silicon 
nanoneedles.126, 397
There have also been developments that enable more 
precise targeting of the agent: 
•	 improved control over the placement of targeting 
ligands and nanoparticles and carriers;377
•	 improved capabilities to design and build 
antibody-drug conjugates;398
•	 engineered biomaterials for targeting;351
•	 the development of polymeric nanoparticles for 
targeting;399
•	 neurological targeting,364 targeting based upon 
genetic differences, such as SNPs;400
•	 active and passive targeting;401
•	 targeting to specific organs or cells;374, 385, 400, 403
•	 cell-type-specific targeting for siRNA-carrying 
nanoparticles;399 and 
•	 communication between nanoparticles to  
improve targeting.404
Nanoparticle delivery vehicles
An increasingly sophisticated understanding of the 
structural-function relationship of nano-particles has 
improved their use as drug delivery vehicles.370, 405, 406 
Progress has occurred since the Seventh Review 
Conference, with a July 2011 review noting they often 
fail to meet clinical expectations but progress was 
being made in re-engineering natural carriers with 
specific functions vivo that could be used as drug 
delivery carriers.407
By May 2012, a review noted nanoparticle carriers 
could be used to ‘ increase the therapeutic index of 
many components’ and listed a limited number that 
were already on the market or in phase III trials.312 
And April 2014 a review noted that ‘advanced drug 
delivery systems based on micelles, polymeric 
nanoparticles, and dendrimers’ and that ‘polymeric 
carbon nanotubes and many others demonstrate a 
broad variety of useful properties’.408
The range of nanoparticle-based drug delivery 
platforms has increased and now includes those 
designed to cross boundaries and penetrate 
previously unreachable sites: 
•	 enhanced tissue penetration;409
•	 a nanoparticle carrier designed to deliver siRNA 
through the skin;376, 410
•	 delivery across the blood-brain barrier;374, 411, 412 and 
•	 nanoparticles designed to penetrate cell 
membranes.286 
Chemical cofactors can be used to increase the  
uptake of proteinaceous drugs.413
Nanoparticles can now be designed to overcome 
specific challenges, such as: overcoming low oral 
absorption rates;383 overcoming rapid metabolization 
of drugs;381, 377, 383 improved activity;372, 377, 411, 413 reduced 
toxicity;370, 372, 374 and extended time circulating in the 
blood by reducing clearance by the liver.402 
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This reduces costs as well as hurdles in drug and 
vaccine design by enabling successful vaccination 
using less material, or material with lower activity, or 
which would normally be removed too quickly to  
have an effect. 
Notable progress has been made in controlling the 
release of payloads, further increasing efficacy and 
reducing side effects: 
•	 nanoparticles controlled by ultraviolet light;409
•	 a remotely activated protein-producing 
nanoparticle;414
•	 aerosol optimised delivery nanoparticles;376, 381
•	 environmentally-responsive nanocarriers;376, 403, 406, 415
•	 biodegradable nanoparticles;406
•	 delivery platforms intended to circumvent the 
immune system.374, 403
Nanoparticles have also been used as delivery devices 
for viral antigens to stimulate an immune response366 as 
well as co-stimulators for vaccines to help increase the 
immunological response393 and establish immunological 
memory.351
3.4.6 Antimicrobials and drug resistance
Past advances in treating disease are being reversed 
by the increasing antimicrobial resistance. For example, 
antiviral resistance and resistance to anti-malarial 
therapies have been growing in both numbers and 
geographic distribution.416, 417
However, there is now a better understanding of the 
mechanisms involved, including the identification  
and characterization of genetic components, 
structure-function relationships, metabolic processes, 
and community responses. Some new drugs have 
been developed, including additional antimicrobials 
(comprising both antibiotics and antivirals), therapies  
to re-sensitize microbes to existing antimicrobials,  
and drugs to target persistent organisms in biofilms  
or resistant cells. 
Understanding resistance
Notable progress has been made in understanding 
the mechanisms involved. There has been progress 
in the identification and characterization of genetic 
components associated with antimicrobial functions 
and drug resistance, including the mutations 
responsible for the following:
•	 artemisinin resistance in Plasmodium falciparum;418
•	 carbapenem resistance in Enterobacteriaceae,419 
Pseudomonas aeruginosa,420 E.coli,421  and 
Acinetobacter sp.;422
•	 methicillin resistance in Staphylococcus aureus);245 
•	 neuraminidase-inhibitor resistance or reduced 
sensitivity in influenza viruses,423 including 
neuraminidase-inhibitor resistance in H7N9 
influenza virus without loss of in vivo virulence or 
transmissibility;12 
•	 vancomycin resistance in Staphylococcus aureus 
and enterococcal bacteria424 and Staphylococcus 
aureus;425, 426 and
•	 oseltamivir resistance in influenza A viruses.427
Understanding how key structural elements affect 
antimicrobial functions and drug resistance has been 
elucidated through study of the following: 
•	 structural components used for exchanging 
plasmids, including those containing anti-microbial 
resistance factors;29 
•	 how biofilms protect pathogens from antibiotics;428
•	 differences of neuraminidase structure on the 
efficacy of inhibitors;423
•	 how the structure of the M2 ion channel impacts the 
antiviral drugs amantadine and rimantadine;429, 430
•	 how Influenza A polymerase binds to the viral RNA 
promoter;431 and 
•	 the mechanism for artemisinin resistance in 
P.falciparum.432
There has also been progress in understanding 
bacteria metabolic responses to sensing antibiotics 
in their environment and the range of responses 
triggered433 and the mechanisms that pathogen 
‘communities’ use to become resistant to antimicrobial 
therapy, for example the use of dormant persister 
cells in Mycobacteria,434 E.coli,435, 436, 437 Burkholderia 
pseudomallei438 and associated mechanisms.345, 435
Particular progress has been made in understanding 
of the interconnections between pathogenicity, 
transmissibility and drug resistance, for example 
specific mutations that can confer additional functional 
characteristics without degrading others.12
More sophisticated tools for identifying factors 
associated with antimicrobial function and drug 
resistance have been developed, for example: 
•	 improved understanding of how antibiotic 
resistance spreads in the wild, such as by  
horizontal gene transfer;38, 135
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•	 improved integration of sequence and structural 
analysis for more effective identification of genetic 
elements connected with drug resistance;37
•	 of CRISPR/CAS9 genome editing tools;439
•	 microfluidics;345
•	 reporter genes;345
•	 transcriptomics;432 and 
•	 the recreation of a centralised repository for 
pathogenicity islands and resistance islands.43
Pathogens with increased antimicrobial properties 




•	 Vibrio cholerae; 440 and
•	 P. falciparum.439
New drugs and drug targets
A limited number of new antimicrobial drugs and drug 
targets have been identified. A December 2014 review 
of antibiotics under development at the time, estimated 
that 37 candidates were in clinical development.441 This 
number had fallen from 45 candidates in February 
2014.442 
An April 2015 review of novel influenza therapies 
highlighted ‘several new classes of antiviral candidates 
targeting viral replication through individual domains 
of the polymerase and the nucleoprotein have been 
developed through structure-based design’.443
Novel antivirals identified since the Seventh Review 
Conference include: 
•	 a novel mechanism for inducing apoptosis in cells 
containing viral dsRNA;444 
•	 novel M2 ion channel targeting antiviral drugs 
that are unaffected by known resistance 
mechanisms;429, 445, 446, 447
•	 a novel antiviral drug which inhibits the cellular 
entry of many lipid-enveloped viruses;448
•	 the discovery and synthesis of novel benzofurazan 
derivatives which inhibits influenza A viruses;449
•	 a novel viral RNA polymerase inhibitor, Favipiravir 
which blocks the replication of a broad range of 
RNA viruses;450
•	 optimized small-molecule inhibitors of Influenza 
Virus Polymerase, which target new locations 
distinct from known antiviral resistance 
mechanisms;451
•	 potential drug targets identified as a result of the 
structural characterization of Influenza A polymerase 
binding to the viral RNA promoter;431 and 
•	 a hybrid small molecule capable of disrupting the 
function of Influenza A polymerases.452
Novel antibiotics identified or under development since 
the Seventh Review Conference include:
•	 compounds that resensitise multidrug resistance 
bacteria by blocking efflux;453, 454
•	 a novel class of antibiotics that remove their ability 
to do harm, rather than kill bacteria;455
•	 characterization of the antibiotic properties of 
silver;456
•	 a novel antibiotic from a marine-derived 
Actinomycete that demonstrated efficacy in killing 
both gram-positive and gram-negative bacteria;457
•	 reinvigoration of research into bacteriophage-
therapy, including purified lysins;454
•	 quorum-sensing inhibitors;454
•	 small molecule inhibitors of multi-drug efflux 
pumps;454 and 
•	 nanoparticles that can kill bacteria.454
Examples of other therapeutics identified since the 
Seventh Review Conference include: 
•	 disruption of biofilms428 including the use of motile 
bacteria exuding anti-bacterial factors;133
•	 an adjuvant that resensitises P. falciparum to 
artemisinin;417
•	 the identification of an FDA-approved anti-cancer 
drug which eradicates ‘persister’ cells;458 and 
•	 photodynamic therapy.454
3.5 Responding to, rolling back, and 
recovering from disease
The speed at which an outbreak can be terminated 
and normal life resumed, determines the overall impact 
of a disease event. These are important considerations 
for both Articles VII and X of the BWC. 
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Given the advances in science in technology, and 
provided that the remaining logistical, economic and 
technical challenges can be surmounted, it should now 
be possible to assemble patchwork capabilities into a 
diffuse but integrated system for countering global or 
local outbreaks. Obviously this highly desirable objective 
would only be successful if backed by political will and 
the fostering of international support and collaboration. 
Such a system could scale from local needs through 
to international responses. A structure that enabled 
data, such as pathogen sequences, to be shared 
more effectively and efficiently would facilitate a rapid 
an effective response. As expertise and ‘know-how’ 
matures, opportunities for technological leapfrogging 
appear, as was the case with mobile communication 
systems. Developing countries can then access 
opportunities and capabilities in the field that match,  
if not surpass, those found in developed countries.
A co-ordinated response to a disease outbreak can 
only be effective if the communities involved are 
prepared to work with the emergency responders. 
Anthropological studies have identified and developed 
‘good practice’ guidelines for obtaining community 
cooperation. Equally, improved access to drugs and 
vaccines has enhanced infection control, using, for 
example, pre-emptive vaccination whilst a more 
judicious choice of infection control approaches (such 
as quarantine and travel restrictions) can be matched 
appropriately to specific situations. ‘Microbial forensics’ 
can be used to help establish attribution if a malevolent 
deployment is suspected.
New tools have improved the medical management 
of disease outbreaks, including intentional releases. 
Context-specific guidance to optimise response 
preparedness, for example for the use of anti-microbial 
drugs and decontamination options is now available. 
Superior protective equipment is now available, 
reducing the burden placed on responders and allowing 
them to work for longer, increasing the efficiency of a 
response. A wider range of decontaminants, and the 
optimisation of approaches for developing and using 
them, have reduced environmental transmission risks 
and released contaminated sites more quickly.
3.5.1 Improving community buy-in for responders
A response to an outbreak will only be effective if 
the communities involved are prepared to work with 
responders. Advances from anthropological studies 
have provided for significant progress in identifying 
and developing best practice for obtaining community 
buy-in for responding to disease outbreaks. Such 
buy-in is critical to speed the adoption of response 
and control measures,459, 460 for ensuring that such 
measures are comprehensively applied460 and to 
improve epidemiology and disease tracking efforts.461
Lessons learned from recent disease outbreaks 
included active engagement by anthropologists to: 
•	 help communities adopt proven interventions;459
•	 scale up the adoption of these measures;459
•	 overcome cultural barriers from within 
communities;459
•	 overcome wariness of engaging with responders;459
•	 adapt measures to conform with traditional 
beliefs;459
•	 listening to the community and integrating their 
views into response efforts;461
•	 providing psychological assistance to families 
and people who have come into contact with the 
disease.461
3.5.2 Medical management and infection control 
(including quarantine)
Research since the Seventh Review Conference noted 
the most important driver in preventing pandemics is 
the breakdown or lack of public health infrastructure.462 
There have been indicators of increasing capacity for 
the prevention and control of certain infections, such 
as pandemic influenza.463
Technical developments discussed in the previous 
section of this report have had significant implications for 
medical management and infection control. Increased 
access to drugs, such as antivirals, has offered improved 
infection control options.464 Pre-emptive vaccination in 
cases like pandemic influenza, has been demonstrated 
to be as effective at preventing death, and more cost 
effective, than reactive vaccination.465
New modelling tools have been developed for 
medical management of disease outbreaks, including 
intentional releases, including: 
•	 modelling tools for pathogen movements and 
concentrations in indoor environments;466
•	 approaches for assessing the cost effectiveness  
of different interventions;464 
•	 approaches for the eradication of key disease 
vectors, or the elimination of their ability to transmit 
the disease;304
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•	 improving hospital designs to limit the transmission 
of pathogens whilst reducing energy usage;467 and 
•	 modelling disease transmission with different levels 
of community buy-in.468
 
These tools have allowed the development of context-
specific guidance to optimise response preparedness, 
for example on the use of antibiotics,466 approaches for 
evaluation and decontamination466, 469 and assisted in 
the optimisation of response preparedness.464
Scientific research has been conducted to provide 
evidence as to the utility of some infection control 
measures, for example determining that patients 
wearing surgical masks do reduce aerosols 
responsible for viral transmission in influenza,470  
and the use of PPE in preventing the transmission  
of Ebola in health care settings.471
Traditional approaches to infection control, such as 
quarantine and travel restrictions, have continued to  
be used. Research on the use of quarantine as a 
disease control measure has highlighted political, 
ethical, and socioeconomic issues and stressed the 
importance of finding a careful balance between 
public interest and individual rights.472 The value of 
social distancing in combating disease outbreaks 
like pandemic influenza has been demonstrated 
but has also been demonstrated to be a major 
contributor to the costs associated with low severity 
infections.464 Domestic travel restrictions have also 
been demonstrated to limit transmission of pathogens, 
shortening the outbreak and enabling efforts to be 
focused on affected areas.468
3.5.3 Protective equipment
There have also been advances in protective equipment 
reducing the burden placed on responders and allowing 
them to work for longer, improving the efficiency of a 
response. Convergence of different scientific disciplines 
has led to improvements in protective equipment, in 
particular systems which enhance protection but with 
reduced physiological burden for the wearer, and which 
are less cumbersome. There are also research efforts to 
develop self-decontaminating protective clothing, e.g. 
with the incorporation of enzymes and/or catalysts’.473 
Advances in nanomaterials are also being applied to 
the filters and absorbents used in mask canisters and in 
‘protective clothing which may have a lower burden for 
the wearer than current systems’.473
3.5.4 Decontamination
A wider range of decontaminants, and approaches 
for developing them, have helped to reduce 
environmental transmission risks and release 
contaminated sites more quickly. Novel developments 
in nanotechnology have provided opportunities to 
improve existing decontaminants.156, 474, 475 Advances 
in rational enzyme design provide new avenues for 
developing decontaminants.475
Research has optimised the use of decontaminants. 
There has been progress in assessing the efficacy of 
different decontaminants, for example sporicides476, 
477  and aerosol decontaminants.478 Such assessments 
have also examined the impact of other factors, such 
as the type of material to be decontaminated,476, 
477, 478 and the structural design of the space to be 
decontaminated.479 The impact on the type of agent 
used on decontamination efforts has also been 
explored, for example with Bacillus anthracis,476 and 
Brucella suis.477
Studies have also been conducted to assess the 
potential for further aerosolization and spread of 
agents from decontamination efforts.478
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Advances that reduce risks relevant to 
the BWC
There have been a number of developments that reduce overall risks relevant to the  
BWC. These include:
•	 Greater ability to identify indicators of prohibited 
activities (relevant to Article I). For example: 
increased opportunities for off-site sampling 
and bioforensic investigations derived from the 
persistence of genetic fragments throughout 
standard autoclaving techniques;197 and improved 
tools to mark and identify synthetic biological parts, 
devices and products;481
•	 Barriers to acquiring biological agents for activities 
prohibited by the BWC in a manner that does not 
restrict their use for permitted purposes (relevant 
to Articles III, IV and X). For example, many gene 
synthesis companies have signed up to industry-
led initiatives to screen customers and orders 
to prevent the use of their services in activities 
prohibited by the BWC;480
•	 Functional alternatives to capabilities which  
might be used for prohibited activities, that can  
be used for permitted purposes (relevant to 
Articles III and X), for example a reduced need for 
high containment facilities, facilities for culturing 
or holding live pathogens, and individuals skilled 
and experienced in culturing live pathogens: (a) 
for diagnostics, resulting from the development 
of metagenomics approaches for identifying 
pathogens from environmental samples without 
needing to culture them;200 and (b) in vaccine 
production, resulting from the use of synthetic 
nanoparticles or virus-like particles in vaccine 
production and other developments.365, 482 
•	 Alternatives to agents which might be used for 
prohibited activities without impacting their use for 
permitted purposes (relevant to Articles III and X) for 
example: the use of genome editing techniques to 
remove Ricin toxin production from castor plants;483 
and Novel biocontainment approaches designed 
to reduce the risk of gain-of-function research by 
negating the pathogenicity of an agent;484
•	 Progress in identifying activities with potential 
biosecurity concerns (relevant to Articles III and 
IV), for example, progress in developing risk-based, 
rather than taxonomic-based methodologies, for 
example, as part of the safety screening process of 
the International Genetically Engineered Machines 
competition.485 
4
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Developments in science and technology 
posing future risks for the BWC
The same innovations that have led to many of the positive benefits, have also facilitated 
prohibited activities relevant to every step of a biological weapons programme. This has 
resulted in the barriers to acquiring and using a biological weapon having been conspicuously 
eroded since the Seventh Review Conference. This has significant implications for Articles I, III 
and IV of the BWC.
Many of these developments are at the leading 
edge of current capabilities. They are expensive 
and complicated to acquire and deploy successfully. 
Making use of them for prohibited purposes would 
probably require the resources of a state. This situation 
may change in the future, reinforcing the need for 
on-going efforts to review relevant developments in 
science and technology.
This section provides a review of S&T developments 
with implications for any part of the process of making, 
producing and delivering a biological or toxin weapon 
can be considered as a potential biosecurity risk factor. 
The following sections consider each of the different 
stages of such a process:
•	 Developing a biological agent
•	 Producing and stockpiling a biological agent
•	 Dispersal and delivery of a biological agent
5.1  Developing a biological agent
Since the Seventh Review Conference there has been 
headway in: 
•	 Acquiring agents from nature; including an 
expanded range of possible agents and locations 
in which they are to be found, as well as tools for 
characterising previously ‘unculturable’ microbes; 
•	 Synthesising existing agents; non-specialists 
can now compile gene ‘cassettes’ coding for, for 
example, virulence factors and ‘reboot’ some viruses; 
pathogens responsible for historical epidemics 
can now be synthesised or reactivated; and many 
small peptides, bioregulators and toxins can now be 
produced by chemical synthesis;
•	 Designing and synthesising novel agents, this is 
now easier through using genome engineering 
platforms, ‘cloud-labs’, ‘biofabs’, and more 
sophisticated tools, and the availability of standards 
for designing, manipulating and compiling microbes, 
their parts, and proteins. This allows novel pathogens 
to be produced. 
Neurobiology has also seen an exponential increase of 
output, improving our understanding of neural network 
responses associated with behaviours, such as anger 
and aggression, and physiological conditions such as 
addiction, fear and narcolepsy. Neural networks can 
now be manipulated to induce some of these states 
and work has begun to translate these findings to non-
human primate models. 
There is potential to develop other novel agents, 
including those produced using CRISPR/CAS9-
mediated ‘gene drives’, ‘gene silencing’ technologies, 
proteins, or nanoparticles. Some of these types of 
constructs have already been inserted into vectors 
and demonstrated to produce effects in a host when 
administered by inhalation. The potential to target the 
microbiome to cause or exacerbate a disease state 
has also been highlighted.
Virulence and other biological features of pathogens 
are now more easily optimised for use in biological 
weapons and some ‘enhanced pathogens’ have 
been produced. This has been made possible by 
improvements in:
•	 Identification and characterization of the  
genetic components and key structural elements 
controlling pathogenicity, transmissibility, host 
range, antimicrobial defences, drug resistance, 
as well as in the mechanisms through which 
pathogens avoid the host’s immune system; 
5
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•	 Applying an improved understanding of 
immunopathology to model the immune responses 
in a host;
•	 Using coatings and shells to confer environmental 
stability; and
•	 Developing tools for identifying and integrating 
desirable factors into biological agents. 
Modern genome ‘editing’ technologies, such as 
CRISPR/CAS-9 do not leave ‘fingerprints’ indicating that 
that organisms has been altered. This could conceal 
attempts to enhance the organism’s effectiveness, 
hampering forensic investigations and complicating the 
differentiation between unusual and unnatural  
disease events (see Box 4).
Technological advances have made it easier to  
access and characterise biological agents. An increased 
understanding of the properties of natural agents, such 
as pathogenicity and transmissibility, together with new 
tools enabling the design and redesign of biological 
agents, means that novel pathogens and toxins with 
enhanced properties can be generated. 
5.1.1 Obtaining agents from nature
Access and characterization of a broad range of 
potentially harmful natural agents has become easier, 
faster and more accurate. 
•	 The potential to develop a wider range of biological 
agents into weapons has been highlighted, for 
example, one report noted the role of fungal 
diseases in significant plant epidemics as well as 
characteristics desirable in a biological weapon’s 
agent, such as environmental stability.79
•	 The identification of novel biological agents 
present in mixed environmental samples, including 
pathogens, is much faster, reliable and more 
accurate using recent metabolomics techniques.190 
•	 The characterization of pathogens that have been 
traditionally unculturable has become possible with 
synthetic genomics approaches.7
•	 The number of locations from which it is possible 
to isolate agent has increased as our knowledge 
of the geographic distribution of certain pathogens 
has expanded, for example, discovering a Europe 
filovirus, a viral species previously only thought to 
exist naturally in sub-Saharan Africa.242 
5.1.2 Synthesizing an existing agent 
Since the Seventh Review Conference, it is possible 
to synthesize a wider range of pathogens and toxins, 
and DNA synthesis has become a lot more accessible 
and affordable. 
•	 The tools and technology available for 
synthesizing agents have improved and become 
more accessible. For example, a desktop gene 
synthesizer is now commercially available.486 The 
potential for non-specialists to use DNA synthesis 
to acquire pathogens has been demonstrated 
since the Seventh Review Conference, with two 
information technology professionals compiling and 
rebooting a virus from commercially-produced gene 
cassettes.487 
Box 4: An example of a novel  
biological agent to target plant and  
animal populations 
The development of CRISPR-based ‘gene drives’ 
could enable individual laboratories to unilaterally 
alter the traits of wild populations and ecosystems 
without regard for national borders. Hundreds 
if not thousands of laboratories will have this 
capability within a few years. In principle, alterations 
can be undone by subsequent gene drive 
countermeasures, but must first be detected by 
environmental monitoring of at-risk species. This 
clearly requires detailed knowledge of whether 
those species can be affected. 
There are currently only a handful of laboratories 
working in the CRISPR-gene drive field. 
Representatives of these groups as well as 
those in related areas have already called 
for transparency and safeguards to prevent 
accidental releases. Researchers in the field are 
now calling for all CRISPR gene drive research 
to publicly disclose experimental designs and 
safeguards against accidental release in advance 
of experiments. Transparency could ensure 
compliance with the BWC, accelerate the science 
by encouraging international collaborations, 
and promote early deliberations and community 
guidance of potential applications in public 
health, sustainable agriculture, and ecological 
conservation.
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•	 A wider range of strains of pathogens can be 
generated using DNA synthesis:
 - Pathogens responsible for major historical 
epidemics, including extinct ancestral viruses, 
can be generated using sequence data and 
attendant analysis;244, 246, 385 
 - Agents difficult or impossible to culture from 
the wild,201 organisms such as plasmodium201 
and highly pathogenic viruses such as 
Schmallenberg Virus44 have been rescued  
and/or manipulated.
 - The synthetic design of yeast chromosomes488 
has progressed, and could lead to further 
developments in the manipulation of eukaryotic 
genomes. 
•	 The range of small peptides, bioregulators and 
toxins it is possible to produce has expanded due 
to developments in chemical synthesis.489, 490
5.1.3 Adding functions to existing agents – 
Pathogenicity 
The understanding of pathogenicity, its genetic and 
molecular basis, mechanisms and intensity modulation, 
have progressed. This is linked with the development 
of better tools in this domain.
•	 Genetic components conferring pathogenicity have 
been identified and characterised,105 in particular in: 
 - lethal bacterial strains, including Escherichia 
coli (O104:H4),19 methicillin-resistant 
Staphylococcus aureus,22 Bacillus anthracis491 
and Mycobacterium tuberculosis;22
 - influenza viruses, including influenza A H1N1,21 
H5N1,21 and H7N9;23, 24
 - enteroviruses type 71;21 
 - Dengue fever virus;21
 - an unculturable bat virus;7 
 - wheat yellow rust.27
•	 Key structural elements affecting pathogenicity 
have been mapped and characterised, for example:
 - infection-specific structures in rice blast;30
 - structural changes in the HA and NA regions of 
human and bat influenza viruses.7
•	 Pathogens with increased virulence have been 
produced. Examples since the Seventh Review 
Conference include: 
 - the evolution of viruses with increased 
virulence, using serial passaging in animals, 
including Schmallenberg Virus in a mouse 
model,44 an engineered reassortant swine 
influenza virus in pigs;9 Ebola virus in guinea 
pigs13 and influenza H7N1 in ferrets as a 
preferred surrogate host for humans.6
 - the creation of a novel virus that is functionally 
similar to the causative agent of the 1918 
pandemic, but with increased pathogenicity, 
using recombination of influenza viruses;8 
•	 There has been progress in identifying ways in 
which pathogens cause damage by manipulating 
their host, for example, modulating the damage 
caused by cytokine storms and opportunities for 
conferring these abilities to other pathogens.93
•	 Our understanding of how pathogenicity factors 
spread in the wild, such as by horizontal gene 
transfer, has improved;38 
•	 More sophisticated tools have been developed for 
identifying factors associated with pathogenicity and 
how they are integrated into agents, for example: 
 - computational approaches and software tools 
for the identification of pathogenicity islands  
and virulence factors;22, 39, 40 
 - synthetic biology approaches;16, 41, 65
 - bioinformatics tools for manipulating 
pathogenicity data;41
 - systems biology and understanding the impacts 
of systems modulation on disease;41, 492
 - whole genome directed evolution;16
 - methodological approaches for testing the 
clinical and public health significance of 
microbe-disease associations;42
 - replacing wild-type regulatory networks 
controlling biological function with better 
characterized engineered versions;492
 - improved tools for identifying biological parts 
which can be used in designing and building 
engineered systems and functions;492
 - approaches for predicting the virulence of a 
pathogen from its sequence information;22
 - the creation of a centralised repository for 
pathogenicity islands and resistance islands;43
 - model systems that recapitulate in vivo viral  
life cycles.18
5.1.4 Adding functions to existing agents – 
Circumventing host immunity
The understanding of host-pathogen relationships  
has improved, including how pathogens can avoid  
or modulate the immune responses in their hosts.  
A broader range of pathogens have been studied.  
The development of better tools has supported  
these advances. 
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•	 The understanding of host-pathogen relationships 
enabling the modulation of immune responses in  
the host has improved. Examples include: 
 - reducing or removing cytokine storms;93
 - the inflammatory mechanism in gut bacteria, 
including the horizontal gene transfer of key 
factors;38
 - the identification of a novel neutrophil-based 
immune response to viruses;97
 - the use of non-structural proteins to interfere 
with a host’s epigenome and make cells more 
susceptible to viruses;84
 - modulation of host proteins which inhibit viral 
replication;85
 - infection kinetics and the impact of the physical 
location of pathogens in a host on the speed of 
infections;88
 - the use of natural (e.g. polysaccharide) or 
manmade (e.g. polyelectrolyte based nano-thin 
polymer) coatings to isolate cells from the host’s 
immune system;89, 100
 - gene silencing in a virus to enable a dormant 
state in the host’s neuron’s, dramatically 
increasing the persistence and re-emergence of 
infections;22
 - degradation of the functional capacity of host 
macrophages, enabling pathogens to survive 
inside them.87
•	 The understanding of the mechanisms through 
which pathogens avoid the host’s immune system 
has progressed. Examples include: 
 - proteins used by pathogens to suppress 
immunity in plants;102
 - mechanisms for negating innate immunity;22, 35, 47, 
86, 87, 89, 91
 - mechanism for negating vaccine-acquired 
adaptive immunity;22, 89
 - modulation of the production of viral proteins 
used to block interferon production in the host;44
 - a viral mechanism using RNA motif’s to avoid a 
host’s immune system;103
 - chemical modification of the pathogen’s genetic 
material to void detection;87
 - the production of proteins by a pathogen to 
interfere with the host’s ability to trigger an 
immune response,87 including type III secretion 
processes; antigenic variation;87
 - the use of TAM receptors to inhibit innate 
immune response;87
 - interference with receptor proteins on host 
immune cells;87
 - broadly reactive antibody-binding proteins used 
to block antibody-antigen binding.87
•	 Host-pathogen relationships have been studied for 
an expanding range of pathogens. Examples include: 
 - Enterobacteriacea,38 Yersinia pestis,35, 47, 87, 
89, 90 Salmonella enterica,87 Brucella sp.,87 
Mycoplasma sp.;87 E.coli,87 Staphylococcus 
aureus;92
 - influenza viruses,84, 85, 86, 87 Schmallenberg 
Virus,44 flaviviruses,91 Dengue virus,87 SARs 
coronavirus,87 West Nile virus,87 varicella zoster 
virus,22 vaccinia virus.87 
•	 More sophisticated tools for modulating host-
pathogen interactions have been developed,  
for example: 
 - synthetic biology approaches;41, 65 
 - systems biology and understanding the impacts 
of systems modulation on disease;41, 492
 - replacing wild-type regulatory networks 
controlling biological function with better 
characterized engineered versions;492
 - improved tools for identifying biological parts 
which can be used in designing and building 
engineered systems and functions;492
 - model systems that recapitulate in vivo viral  
life cycles.18
5.1.5 Adding functions to existing agents – 
Transmissibility and host range
The identification and characterization of genetic and 
structural components conferring transmissibility and 
host range has progressed. Pathogens with altered 
transmissibility or host range have been isolated 
or produced. The development of better tools has 
supported these advances. 
•	 There has been progress in the identification and 
characterization of genetic components conferring 
transmissibility and host range.105 Examples include: 
 - specific mutations which confer aerosol 
transmission in mammals, in influenza viruses 
including in H5N1,1, 2, 3, 4, 5 H7N1,6 and H1N1;8, 9 
 - mutations in HA region of H5N1 influenza 
virus that improve affinity for humanlike airway 
receptors;5 
 - sequencing of a H7N9 influenza virus adapted 
for efficient growth in human lung tissue;11
 - mutations in H7N9 influenza virus conferring 
antiviral resistance with no impact on 
transmissibility;12
 - a specific mutation in H7N9 influenza that 
confers an ability to bind to both human and 
avian receptors,10 and specific mutations in 
H1N1 influenza virus mutations associated with 
host range.13
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•	 Pathogens with increased transmissibility have 
been produced or isolated. Examples include: 
 - a H5N1 and H1N1 recombinant influenza viruses 
capable of aerosol transmission in ferrets;1, 5
 - the use of site-directed mutagenesis and 
serial passaging in ferrets to confer airborne 
transmission on the H5N1 and H7N1 influenza 
viruses;2, 6
 - a H7N9 influenza virus adapted for efficient 
growth in human lung tissue was isolated;11
 - a recombinant human and bat influenza virus;7
 - and the use of serial passaging of an engineered 
reassorted H1N1 influenza virus in pigs.9
•	 Our understanding of how key structural elements 
affect host range has progressed, for example, 
how the structure of HA regions affect H5 influenza 
viruses ability to bind to avian and human receptors14 
and similar insights for H7N9 influenza viruses.10
•	 Pathogens with an altered host range have been 
produced. Examples since the Seventh Review 
Conference include: enteroviruses type 71, H1N1 
influenza virus, H5N1 influenza virus, and Dengue 
fever virus.4
•	 More sophisticated tools for identifying factors 
associated with transmissibility and host range and 
integrating them into agents have been developed, 
for example: 
 - tools to study genetic evolution of viruses and 
monitor for mutations known to confer altered 
transmissibility;3 
 - synthetic biology approaches; 16, 41, 65
 - systems biology and understanding the impacts 
of systems modulation on disease;29, 41, 492
 - replacing wild-type regulatory networks 
controlling biological function with better 
characterized engineered versions;492
 - improved tools for identifying biological parts 
which can be used in designing and building 
engineered systems and functions;492
 - model systems that recapitulate in vivo viral life 
cycles.18
5.1.6 Adding functions to existing agents – 
Antimicrobial and drug resistance
Advances in tools have allowed the identification  
and characterisation of genetic and structural elements 
that affect antimicrobial functions and drug resistance. 
Pathogens with increased antimicrobial properties and 
drug resistance have been produced. In addition, we 
have a better understanding of mechanisms at the 
community level explaining how pathogens become 
resistant to antimicrobial therapy.
•	 An increasing number of specific mutations 
associated with antimicrobial functions and 
drug resistance have been identified and 
characterised.213, 493 Examples include specific 
mutations conferring: 
 - vancomycin resistance in Staphylococcus 
aureus426 and enterococcal bacteria;424 
 - Carbapenem resistance in E.coli,421 in 
Enterobacteriaceae,419 in Pseudomonas 
aeruginosa494 and in Acinetobacter sp.;422
 - neuraminidase-inhibitor resistance or reduced 
sensitivity in influenza viruses,423 including in 
H7N9 influenza virus without loss of in vivo 
virulence or transmissibility;12
 - methicillin resistance in Staphylococcus 
aureus;245
 - artemisinin resistance in P.falciparum;418
 - resistance to oseltamivir in influenza A viruses;427
•	 Our understanding of how key structural elements 
affect antimicrobial functions and drug resistance 
has progressed. Examples include: 
 - differences of neuraminidase structure on the 
efficacy of inhibitors;423
 - how the structure of the M2 ion channel 
impacts the antiviral drugs amantadine and 
rimantadine;429, 430
 - and the mechanism for artemisinin resistance in 
P.falciparum.432
•	 There have been advances in understanding 
mechanisms at the community level taken by 
pathogens to become resistant to antimicrobial 
therapy, for example the use of dormant persister 
cells in Mycobacteria,434 E.coli,436, 494 Burkholderia 
pseudomallei438 and associated mechanisms.435, 495
•	 Pathogens with increased antimicrobial properties 
and drug resistance have been produced. 
Examples include: Salmonella;440 Bacillus 
anthracis;440 E.coli;440 Vibrio cholerae;440 and  
P. falciparum.439
•	 More sophisticated tools for identifying factors 
associated with antimicrobial function and drug 
resistance and integrating them into agents have 
been developed, for example: 
 - improved understanding of how antibiotic 
resistance spreads in the wild, such as by 
horizontal gene transfer;38
 - synthetic biology approaches;41, 65
 - bioinformatics tools for manipulating drug 
resistance data;41
 - systems biology and understanding the impacts 
of systems modulation on disease;41, 492
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 - CRISPR/CAS9 genome editing tools;439
 - microfluidics;495
 - reporter genes;495
 - replacing wild-type regulatory networks 
controlling biological function with better 
characterized engineered versions;492
 - improved tools for identifying biological parts 
which can be used in designing and building 
engineered systems and functions;492
 - transcriptomics;432
 - the creation of a centralised repository for 
pathogenicity islands and resistance islands;43
 - model systems that recapitulate in vivo viral  
life cycles.18
5.1.7 Adding functions to existing agents – 
Environmental stability
The understanding of how structure affects the 
environmental stability of biological agents has 
increased. More environmentally stable pathogens 
were produced, and stability has also been artificially 
conferred using coatings and shells. Advanced tools 
have been developed: 
•	 Our understanding of how structure affects 
environmental stability has progressed, for example, 
how electrostatic repulsion inside the capsid of 
Foot-and-Mouth Disease viruses is responsible for 
its thermolability.318
•	 Coatings and shells have been developed to  
confer environmental stability, examples include: 
 - environmentally-responsive smart delivery 
platforms, such as nanoparticles;376
 - artificial spores protecting agents against 
osmotic pressure, shear force, heat, UV 
radiation, and lytic enzymes;157
 - polyelectrolyte based nano-thin polymer 
coatings.100
•	 Pathogens with increased environmental  
stability have been produced, examples include 
lactic acid bacilli, Francisella tularensis,and 
Salmonella sp..496
•	 More sophisticated tools for identifying factors 
associated with environmental stability and 
integrating them into agents have been  
developed, for example: 
 - improved understanding of how antibiotic 
resistance spreads in the wild, such as by 
horizontal gene transfer;38
 - synthetic biology approaches;41, 65
 - bioinformatics tools for manipulating 
environmental stability data;490
 - systems biology and understanding the impacts  
of systems modulation on disease;41, 492
 - computation tools for the rational design of 
stabilised enzymes;269
 - replacing wild-type regulatory networks 
controlling biological function with better 
characterized engineered versions;492
 - as well as improved tools for identifying biological 
parts which can be used in designing and 
building engineered systems and functions.492
5.1.8 Designing a novel agent 
Advances in genome engineering technologies, 
nanoparticles, neurobiology, and protein science 
could be used to design or redesign biological 
agents. Genome engineering technologies have 
significantly advanced, in particular new gene editing 
tools (e.g. CRISPR/CAS9) could potentially lead to the 
development of novel pathogens and/or alter entire 
populations. 
•	 There has been significant progress in being able 
to design and build an agent from scratch.493, 497 
Examples include: 
 - progress in the rational redesign and synthesis 
of the yeast genome;498, 499
 - advances in controlling and measuring cell-
environmental interactions in vitro;273
 - designed organisms to produce lysine, xanthan 
and acarbose.500
•	 The potential to target the microbiome to cause 
or compound a disease state has been noted.501 
Probiotics have been engineered to detect 
and record environmental signals in the gut as 
diagnostics, but potentially they might also be  
engineered to cause harm.144, 163
•	 Genome engineering technologies facilitating 
the comprehensive redesign of agents have 
significantly advanced. Examples include: 
 - preassembled zinc-finger arrays for rapid 
construction of Zinc Finger Nucleases;502
 - increased understanding of optimized 
transcription activator– like effectors;503
 - a mechanism for genome-wide codon 
replacement enabling the precise manipulation 
of chromosomes in vivo;504
 - improvements in designed transcription 
activator-like effector nucleases (TALENs);500, 505
 - CRISPR/CAS9 genome engineering tools,506 
including for viral delivery,384 editing higher 
primates;500
 - associated computational design tools.507
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•	 Novel pathogens have been produced, for example: 
 - an engineered microbe to sense and eradicate 
Pseudomonas aeruginosa284
 - a highly virulent, recombinant H1N1 influenza 
virus;8
 - warnings have been made on the potential to 
develop other novel pathogens, for example 
using CRISPR/CAS9 mediated gene drives 
to ‘alter populations of agricultural plants or 
livestock by actors intent on doing harm’.508, 509 
CRISPR/CAS9 elements (without gene drives) 
have been inserted into viral vectors and used 
to edit a target genome via inhalation in a 
mouse model.384
•	 Particular progress has been reported in 
understanding the neurobiology of physiological 
conditions such as narcolepsy, addiction and 
fear.114, 116 Publications in the field have expanded 
exponentially since the Seventh Review 
Conference:510
 - Novel techniques have allowed neurological 
responses to be studied in real time and 
have helped identify neurological pathways 
associated with addiction and fear, offering 
potential new targets for agents.115, 511 
 - Progress has also been made in modulating 
behaviours.116 For example application of 
advances in understandings have enabled 
researchers to initiate sleep in mice by triggering 
certain neurons.118
 - They have also linked responses in neuron 
networks to psychological conditions, for 
example characterizing neurological states that 
provoke anger or aggression.119
 - Recent work has also translated tools for 
characterizing and manipulating these states 
into non-human primate models.510
•	 Novel agents based upon genetic material have 
entered into clinical trials, including those based on 
siRNAs.291
•	 Novel protein-based agents have also been 
identified.156, 512 Examples include: 
 - small molecule drugs that could be used to 
initiate dangerous hypersensitivity reactions;104
 - the identification of a range of proteins critical 
for the survival of E.coli, which is sometimes 
used as a chassis for biosynthesis;276
 - the misuse of neuropharmacology and 
neuropeptides;257, 513
 - misuse of bioregulators;156, 257, 514
 - a protein able to bind with high affinity to all 
types of human and nonhuman immunoglobulin 
G’ antibodies, blocking antibody-antigen 
union;125
 - a computationally designed protein to stimulate 
cells infected with the Epstein Barr virus to kill 
themselves;260
 - chemically modified, metabolically-resistant 
analogues of peptides with increased potency 
and toxicity.514
•	 Novel agents based on nanoparticles that can 
penetrate cells have also been developed.500
•	 There have also been advances in delivering 
these agents, for example with environmental 
responsive,374 or remotely activated414 nanoparticles. 
•	 More sophisticated tools for designing, 
manipulating and compiling agents have been 
developed, for example: 
 - synthetic biology approaches;284, 364, 497, 501, 515, 516, 
517, 518
 - improved computational enzyme design;269, 518, 
519, 520
 - bioinformatics approaches for extracting data 
from past publications;268
 - rational design principles for virus-like 
particles;309
 - experimental-computational technology for 
inferring network models that predict the 
response of cells to perturbations;309
 - improved understanding and engineering of 
regulatory elements of synthetic metabolic 
pathways;492
 - directed evolution;518
 - computational methods,259, 269, 519, 520, 522 
 - software tools and programming languages 
that compress the time required for converting 
design of a recombinant vector to its delivery;500
 - larger scale, higher fidelity production platforms 
for genetic material;282
 - as well as an integrated design suite for 
manipulating yeast, including software tools 
‘for the prediction of biochemical pathways, 
molecular biology methods for assembly of 
DNA parts into pathways, and for introducing 
the pathways into the host, and finally 
approaches for optimizing performance of  
the introduced pathways’.521
 - Cloud-based laboratories offering fully remote 
services and facilities offering services designed 
to support each of these steps have begun to 
appear since the Seventh Review Conference.278
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•	 More sophisticated tools for designing, 
manipulating and producing proteins have been 
developed, for example: 
 - general design tools for proteins;276, 364
 - design tools for proteins to bind with surface 
structures;259
 - data-driven predictions of drug effects and 
interactions;261
 - high throughput approaches to toxicological 
screening;257
 - improved computational enzyme design;269, 518, 
519, 520
 - and computation design of proteins to inhibit 
enzyme function.522
5.1.9 Toxins
The genetic components and mechanisms of action 
of toxins are increasingly well characterized and their 
characteristics can be manipulated. More sophisticated 
tools for researching and manipulating toxins have 
been developed. Biosynthesis metabolic pathways can 
now be engineered providing alternative production 
routes for toxins. This could be particularly important in 
the case of those toxins that are awkward to extract in 
large quantities from natural sources.
Advances in tools have made it easier to produce 
toxins on a large-scale, which has commercial 
applications but also means it complicates efforts to 
prevent the use of toxins as bioweapons.
Shortcomings in the quality assurance of current 
detection capacities have revealed vulnerability in 
our ability to deter or mitigate the use of toxins as 
weapons. Novel agents, or those with altered or 
enhanced characteristics have been identified or 
produced since the Seventh Review Conference. 
There is also a need for better standards in detecting 
toxins to be enforced.
•	 More genetic components associated with  
toxins have been identified and characterized, 
examples include: 
 - 743 mutations over 12 human genes important 
for intoxication by four different cytolethal 
distending toxins;50
 - determining human genetic variation determines 
sensitivity to the anthrax toxin;51
 - publication of sequence and transcription data 
for king cobra venom.52
•	 Our understanding of mechanisms of action 
associated with toxins has improved,156, 493 
examples include: 
 - increased understandings in the cellular mode 
of action of Ricin toxin;55
 - characterization of the metabolic pathway to 
produce Saxitoxin;57
 - modulation of binding immunoglobulin protein to 
increase cytotoxicity;58 
 - characterization of structural interactions 
between Botulinum toxin and host cells.63
•	 Novel toxins, or those with altered or enhanced 
characteristics have been identified or produced, 
examples include: 
 - an anthrax toxin with altered receptor specificity;66
 - a recombinant Botulinum type A – tetanus toxin;69
 - a novel form of Botulinum toxin.67
•	 The existence of relatively large-scale industrial and 
cosmetic uses of toxins, such as Botulinum toxin, 
complicates efforts to prevent its use as a weapon.350
•	 Use of metabolic pathway engineering and 
biosynthesis provides alternative production routes 
that could overcome challenges of harvesting 
sufficient toxins from nature.65, 241, 350, 523
•	 Current shortcoming in ensuring standards 
in detecting toxins highlighted vulnerability in 
deterring or mitigating their use as weapons.78
•	 More sophisticated tools for researching and 
manipulating toxins have been developed, for 
example: 
 - synthetic biology approaches;41, 523
 - bioinformatics tools for manipulating 
environmental stability data;41
 - systems biology and understanding the impacts 
of systems modulation on disease;41
 - metabolic pathway engineering;64
 - computational design tools leveraging advances 
in understanding in structural-functional 
relationships.66, 524
5.2 Producing and stockpiling biological agents
Since the Seventh Review Conference, there has  
been notable progress or changes in:
•	 Concealing prohibited activities. Changes to 
production signatures and a shift towards the use  
of multiple smaller reactors compromises efforts  
to identify sites of biological weapons production; 
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•	 Industrialising biological production processes. 
Less space and time are now required for scale up, 
narrowing windows for interdiction. The process 
can also be simplified using new technologies, 
though at significant cost;
•	 Producing biological agents. The increased use  
of biosynthesis and bio-based production, scaffolds, 
and ‘biopharming’ accelerates the speed and yield. 
This also applies to vaccine production;
•	 Switching production from permitted to prohibited 
activities. The use of single-use, disposable and 
modular production equipment offers possibilities 
for faster technological breakout;
•	 Acquiring relevant equipment. Critical laboratory 
materials such as reaction vessels (including those 
currently covered by control lists) can now be 
fabricated using 3-D printing technology, reducing 
the costs and potentially lowering barriers to 
prohibited activities. Once again, this complicates 
efforts to enforce non-proliferation measures.
•	 Distributed production. The decoupling of design 
and manufacture has led to the growth of stand-
alone fabrication and production facilities. Whilst 
limited in number of geographic distribution at the 
moment at the moment, the potential for the growth 
of such facilities and their impact in changing the 
footprint of prohibited activities might warrant closer 
attention over the coming years; 
•	 Outsourcing biological production. Multipurpose 
biological production facilities suitable for varying-
scale production of biological agents as well as for 
the synthesis of genetic material and other synthetic 
genomics techniques are now commonplace. The 
existence of many ‘virtual’ biotech companies 
demonstrates the potential in this space;
•	 Storing biological agents. Increasing the 
environmental stability of biologics, together 
with the use of other approaches removes 
the requirements for cold-chain storage and 
its associated infrastructure. Improvements in 
production techniques have reduced the need for 
‘stockpiling’ whilst the proliferation of freeze-drying 
capabilities enables this should it prove desirable.
5.2.1 Changing footprint of production
Production signatures have changed and made it 
easier to potentially conceal prohibited activities. Both 
the equipment size and timeframe for production have 
been significantly compressed. 
•	 Developments in scale-up and production 
technologies have changed production signatures, 
potentially helping to conceal prohibited activities 
and reduce windows for interdiction. The space 
required for production has been drastically 
reduced, examples include: 
 - the use of suspended cultures in vaccine 
production;329, 330, 525
 - the use of egg-free systems in vaccine 
production;331
 - industrial use of microreactors for chemicals and 
small biological;526
 - baculovirus/insect cell expression systems to 
produce recombinant proteins and vaccines;329, 333
 - and the potential to use yeast-based systems for 
opinoid production.334, 335
•	 The physical size of production equipment has 
been drastically reduced, examples include: 
 - the use of suspended cultures in vaccine 
production330, 525
 - industrial use of microreactors for chemicals and 
small biological.526
•	 There have been changes in the acquisition of 
relevant equipment, for example, through: 
 - the potential to 3D print reaction vessels 
(including those currently covered by control 
lists);527
 - synthetic biology approaches have also been 
used to produce plastics for use in 3D printing 
machines, potentially altering the usual supply 
chains.528
•	 The timeframes needed to develop production 
processes have been compressed, for example, 
through the use of computational methods, 
software tools and programming languages.527
5.2.2 Industrial scale up
Scaling up has been simplified and made faster and 
cheaper in some cases. 
•	 The time required to scale up processes has fallen 
in some cases. For example, increased automation 
and miniaturization of development processes has 
occurred since the Seventh Review Conference, 
in some cases process rated ‘increased by 
magnitudes’.529 Whilst these processes happen 
faster, they can still take years.336
•	 Certain costs associated with industrial scale 
up have fallen, for example, an estimated 90% 
reduction of the cost of purification by removing 
reliance on animal serums during production.530
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•	 In other cases, improvements in efficacy and 
efficiency have increased costs, examples include: 
 - more wide-spread use of cell culturing 
production, potentially increasing production 
costs by 2 – 3 fold;530
 - full automation and miniaturization of 
development processes requiring significant 
initial investments of hundreds of millions of 
dollars.529
•	 Certain scale-up processes have been simplified, 
examples include: 
 - the use of directed evolution to remove 
reliance on animal serum thereby removing a 
challenging purification step that has caused 
regulatory concern;530
 - improvements in the media used in separation 
processes, which can account for 60% of 
downstream processing costs;345
 - the improved engineering of strains prior to 
scale up, especially for replicability and strain 
stability;338, 529
 - and use of virus-like particles instead of 
viruses, enabling 50 fold increased yield in 
some cases.321
•	 Purification steps have been improved or simplified 
and there has been growing regulatory attention 
paid to ensuring viral removal or inactivation,344 
examples include: 
 - the improved use of directed evolution;530
 - multimodal chromatography;345
 - increased automation and miniaturization of 
processes;529
 - the use of UV-C irradiation for viral 
inactivation;346
 - research to determine the comparative efficacy 
of different viral inactivation techniques.347
5.2.3 Microengineering and microfluidics
Progress in microengineering and microfluidics make 
it possible to experiment with small samples, thus 
reducing cost and increasing efficiency.
•	 There have been improvements in producing 
biological components for experimentation  
and production at the microscopic scale,  
examples include: 
 - ‘a chip-based method that creates uniformly 
sized vesicles in assembly-line fashion’;279
 - the use of nanoparticles for partitioning bulk 
material.531
•	 The reaction vessels used for experimentation and 
production at the microscopic scale have been 
improved, for example, there have been advances 
in flow microreactors.532
5.2.4 Bio-based production and biosynthesis
Bio-based production and biosynthesis have become 
increasingly common methodologies. One 2012 
review ‘identified 68 products across seven sectors 
(including biofuels, chemicals, energy, food, materials, 
and medicine) being developed by companies in 10 
countries’.533 A subsequent report by the US National 
Academy of Sciences recognized the increasing 
industrialization of biology and the importance 
of biological-based processes for the advanced 
manufacturing of chemicals.481
•	 There have been improvements in the tools 
enabling the controlled design and production  
of biological materials, examples include: 
 - the application of recombinant DNA 
technologies to the development of conjugate 
vaccines;311
 - transient gene expression in serum-free 
suspension-growing mammalian cells for  
the production empty viral capsids;330
 - increasing ranges of microbial chassis,533  
in particular for clinical applications;274
 - directed evolution of enzymes;533, 534
 - the use of TALENs genome editing platforms;534
 - increased miniaturization and automation of 
equipment;534 and
 - progress in developing standardized biological 
parts and devices349, 534, 535 and advances in 
controlling and measuring cell-environmental 
interactions in vitro, including strategies for  
high-throughput analysis.273
•	 There have been significant developments in efforts 
to build designer yeast since the Seventh Review 
Conference. Such a yeast might offer opportunities 
for enhanced chassis for bio-based production and 
biosynthesis. Recent developments have included: 
 - the use of tags enabling the differentiation 
of synthetic components from wild type 
counterparts, especially the development of a 
real-time PCR assay for their detection;353
 - an in vivo method for assembling designed  
DNA fragments;354
 - a novel genetic assembly system for compiling 
expression pathways.355
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•	 Bio-based production and biosynthesis 
approaches have been applied to, or enabled  
the production of, a wider range of materials  
and agents, examples include: 
 - new secondary metabolites with novel 
therapeutic activities, such as complex 
polyketides, halogenated and alkaloids;349
 - opinoids;352
 - toxins;350, 534, 536
 - peptides;533
 - an expanded range of biochemical reactions;64
 - biohybrid materials for drug delivery;349
 - delivery devices for vaccines;351
 - the industrial scale production of a precursor  
for an anti-malarial drug;338
 - additional industrial scale production of 
ethanol;533
 - the industrial scale production of biofuels, 
anthranilic acids, terpenoids; 533
 - the commercial production of lysine,534 
xantham,534 acarbose,534 algal betaine 
surfactant;537
 - the commercial production of co-stimulators  
of immune responses for use with vaccines;351
 - proof of principle studies have also 
demonstrated the ability of similar approaches  
to produce plastics for 3D printers.528
•	 Advances have also simplified the bulk production 
material.364
5.2.5 Scaffolds
Molecular scaffolds have been applied to increase the 
efficacy of production of various products, and can be 
used for industrial production.
•	 Scaffolds made of various materials have been used 
to increase the efficacy of production processes 
by controlling the spatio-temporal arrangement of 
components, examples include, DNA scaffolds and 
nanostructures;356, 357and proteins.358
•	 Scaffolds have been used to enhance the  
efficacy of the production of different products, 
examples include: 
 - resveratrol;356
 - 1, 2 – propanediol;356
 - mevalonate;356
 - antigen-adjuvant complexes;357
 - discrete and complex chemicals.357
•	 Scaffolds have also ‘been developed for use in 
bacteria and yeast used for industrial production’.357
5.2.6 Biopharming
Increasingly, genetically engineered plants and 
animals are used to produce pharmaceutical 
substances for use in humans or animals.
•	 Plants have been used to produce an increasing 
number of products, examples include: 
 - a treatment for Gaucher’s disease grown in 
carrot cells which received licensing approval;359
 - a vaccine candidate for H1N1;360
 - monoclonal antibodies to treat Ebola;361, 362
 - antibodies to bovine viral diarrhea virus;363
 - antigens for rabies, hepatitis B, measles, avian 
influenza, anthrax.363
•	 Seeds have been engineered to act as storage 
devices for biological products.538
•	 Animals have also been engineered to produce 
useful products, such as recombinant proteins and 
antigens for vaccine candidates against malaria 
expressed in the milk of transgenic goats. ‘In the 
short term, the aim is to harvest and purify the 
protein from the milk for vaccine production and 
testing, but the long term vision  
is to deliver the vaccine orally in the milk’.363
•	 Improved tools enable the controlled design 
and production of modified plants and animals, 
examples including the use of TALENS genome 
editing tools;539 and the development of 
standardized biological parts and devices.535
5.2.7 Outsourced production and modular facilities
New ways to outsource productions, and modular 
facilities, mean that there are more ways to undertake 
prohibited activities.
•	 Improvement in the synthesis of genetic material 
and other synthetic genomics techniques has 
enabled the outsourcing of biological products, 
for example vaccine candidates,336, 337 allowing for 
decentralised, compartmentalised development 
and production approaches. 
•	 There are multipurpose biological production 
facilities suitable for outsourcing production, for 
example a multipurpose fermentation facility was 
used for the industrial production of a precursor  
for an anti-malarial drug.338
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•	 Proof of principle for the development and 
production of biotechnology-based products 
have also been realised, for example through the 
advent of virtual biotech companies which in some 
cases ‘have no employees or laboratory space but 
outsource all the work to consultants’.540
5.2.8 Disposable, synthesized and repurposed 
equipment
The shift towards the use of single-use, disposable 
and modular production equipment reduces the 
production time, offering possibilities for faster 
technological breakout, as well as complicating 
efforts to detect prohibited activities. The use of 
multiple smaller reactors, rather than one large one, 
challenges traditional proliferation controls that tend 
to focus on large scale production capacity to reduce 
regulatory burdens. In addition, the development 
of equipment for use in resource limited settings 
reduces costs for prohibited activities. 
•	 The prevalence of single-use equipment is growing:
 - one industry study ‘estimates that more than 
40% of integrated single-use systems are 
now used in GMP manufacturing’. The authors 
noted ‘several large biotech companies 
employ fully disposable processing, including 
chromatography, for smaller, mid-titre, clinical 
trial manufacturing processes’.343
 - An April 2013 review highlighted single-use 
reactors made from advanced polymers was 
expanding and that ‘a number of bioprocess 
analysts estimate that the entire single-use 
market has been growing at about 15 – 20% 
per year’.541
 - An August 2012 industry survey of 300 
biomanufacturers ‘indicated a clear preference’ 
for single-use bioreactors. Two-thirds of 
respondents indicated that they expected to 
implement batch-fed single use bioreactors at 
the clinical scale (as opposed to just under a 
third who expected to use stainless steel batch–
fed bioreactors). At the commercial scale, over 
half of respondents expected to still be using 
stainless steel (which is a significant reduction 
from the current market share).542
•	 Disposable equipment has been used, or is being 
developed for use, in the production of: 
 - vaccines;339, 341, 543
 - monoclonal antibodies;344
 - recombinant proteins;341
 - stem cells and personalised medicine.341
•	 The range of processes for which disposable 
equipment is available has increased in number 
and complexity, examples include: 
 - tangential flow filtration;343
 - mixing and perturbing materials;343
 - downstream processing equipment;339, 543
 - there have also been reports as to the potential 
to use 3D printing to produce complex reaction 
vessels, including those covered by control 
lists potentially further complicating export 
controls.544
•	 There has been increasing standardization of parts, 
making it easier to switch to disposable equipment 
including ‘standardized, off-the-shelf assemblies 
for cell culture harvest and tangential flow 
filtration, disposable, aseptic, genderless, universal 
connectors, and non-proprietary films and materials 
of construction for its bags, connectors,  
and tubing’.343
•	 The operating volumes of single use equipment 
have also increased, for example ‘working volumes 
for integrated single-use bioprocess containers, 
systems, and support equipment have steadily 
risen from sub-1,000 – L levels (50 – 500 L) to the 
2,000 L range, with prototypes exceeding 5,000 
L for some applications’.343 An April 2014 review 
noted ‘17 manufacturers offer around 80 – 90 
models of single-use bioreactors with working 
volumes ranging from as low as few millilitres to up 
to 2000L’.341
•	 There has also been a trend towards using multiple 
smaller reactors, rather than a single large batch 
production for two reasons: 
 - ‘end-users feel comfortable with “scaling out” 
through the use of multiple 500 L or 2,000 L 
systems rather than scaling up to 5,000 L and 
higher’;343 
 - ‘targeted therapeutics and higher titres are 
causing the slow extinction of mega-processes. 
Those that remain increasingly turn to multiple 
1,000 L or 2,000 L disposable bioreactors to 
mitigate risks associated with batch loss’.343
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•	 Equipment has also been developed for use in 
extremely resource-limited settings, for example:
 - PCR diagnostics which can work in the complete 
absence of electricity.250
 - A paper-based microscope has been produced, 
including both lower and higher resolution 
versions costing $0.5 and $1 respectively. 
Disease specific versions have also been 
developed, for example for malaria.187
 - An alternative approach has been to repurpose 
equipment, for example, a commercial DVD 
drive can be converted into a laser scanning 
microscope that can analyse blood and 
perform cellular imaging with one-micrometre 
resolution.188
5.2.9 Modification of agents, freeze-drying and non-
cold chain storage
Although production trends could negate the need for 
stockpiling agents or reduce barriers substantially, the 
modification of agents to increase their environmental 
stability, and the proliferation of freeze-drying capacity 
have increased access to stockpiling capabilities 
should it be necessary. In this area, knowledge that 
was once almost exclusively in the hands of offensive 
and defensive biological weapons programmes has 
been published and made widely available. In addition, 
seeds can be engineered to act as storage device for 
biological agents.
•	 Agents have been successfully modified to 
increase their environmental stability and to remove 
the requirements for cold-chain storage, thereby 
simplifying the stockpiling of biological agents.
•	 The mechanisms through which biological 
agents tolerate environmental stresses are 
better understood, for example in fungi,545 and 
the identification of key properties in conferring 
tolerance to freeze drying.546
•	 Alternatives to live agents have been developed, 
negating the need for cold chains, for example the 
use of empty viral capsids.317
•	 A number of different approaches have been 
developed to increase the environmental stability  
of biological agents and, in some cases enable 
room temperature storage, examples include: 
 - self-standing silk protein biomaterial  
matrices;366, 367
 - coating viral capsids with a mineral coat,  
or other materials;368, 547
 - engineering structural changes into viral 
capsids.318, 547
•	 Formulae for freeze-drying bacteria, and an 
assessment of their comparative efficacy have been 
published.546
•	 Improvements have also been made to drug 
delivery vehicles, such as nanoparticles, to make 
them more environmentally stable.369
•	 Seeds have been engineered to act as storage 
devices for biological products.538
5.2.10 Microencapsulation and smart particles
Drug delivery technologies have greatly progressed. In 
particular, the understanding, development and uses of 
nanoparticles has expanded. 
•	 An increasingly sophisticated understanding of the 
structural-function relationship of nanoparticles has 
led to improvements in using them as drug delivery 
vehicles.370, 405, 548
•	 Drug delivery devices have improved. Some have 
translated into marketable products, and novel 
types of drug delivery carrier have been created:
 - A July 2011 review noted that they often fail to 
meet clinical expectations but progress in re-
engineering natural carriers which are ‘highly 
optimized for their specific functions in vivo  
and possess features that are often desired in 
drug delivery carriers’.407
 - A May 2012 review suggested that nanoparticle 
carriers were making ‘it possible to increase 
the therapeutic index of many components’. 
The authors listed a limited number of 
nanocarriers that were already on the market  
or in phase III trials.372
 - An April 2014 review noted ‘advanced drug 
delivery systems based on micelles, polymeric 
nanoparticles, and dendrimers’ and that 
‘polymeric carbon nanotubes and many 
others demonstrate a broad variety of useful 
properties’.408
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•	 The range of drug delivery platforms has increased, 
examples include: 
 - the use of lipid-based liquid crystalline 
nanoparticles;380
 - magnetic core-shell nanoparticles for aerosol 
drug delivery;381
 - cubic phase nanoparticle for sustained release 
of ibuprofen;382
 - self-assembled liquid crystalline nanoparticles;383
 - nanoparticles controlled by ultraviolet light;409
 - a remotely activated protein-producing 
nanoparticle;414
 - aerosol optimised delivery nanoparticles;376, 381
 - environmentally-responsive nanocarriers;376, 403, 
415, 548
 - biodegradable nanoparticles;548
 - delivery platforms intended to circumvent the 
immune system.403, 541
•	 Drug delivery devices have been developed  
with increased abilities to cross barriers,  
examples include: 
 - enhanced tissue penetration;409
 - a post-facto undetectable nanoparticle carrier 
designed to deliver siRNA through the skin;376, 410
 - delivery across the blood-brain barrier;411, 412, 549
 - nanoparticles designed to penetrate cell 
membranes.550
•	 Drug delivery technologies have been developed 
to overcome specific challenges, examples include: 
 - overcoming low oral absorption rates;383
 - overcoming rapid metabolization of drugs;377, 383
 - improved activity;372, 376, 377, 413
 - reduced toxicity;372, 408, 549
 - extended time circulating in the blood by 
reducing clearance by the liver.551
•	 Developments have also enabled the encapsulation 
or coating of biological agents to make them 
more environmentally stable, for example using 
nanobiological membranes411 or polyelectrolyte 
based nano-thin polymer coatings.100 An August 
2013 review of artificial spores highlighted that they 
could be used to confer ‘extensive cytoprotective 
capabilities that encompass exposure to osmotic 
pressure, shear force, heat, UV radiation, and lytic 
enzymes’.157
•	 Nanoparticles have also been used as delivery 
devices for viral antigens to stimulate an immune 
response366 as well as co-stimulators for vaccines 
to help increase the immunological response393 and 
establish immunological memory.351
•	 New tools to engineer and tailor drug delivery 
systems have been developed, examples include: 
•	 applications of synthetic biology to construct 
biohybrid delivery materials;349
•	 design guidelines;370
•	 more sophisticated ways to build nanostructures;371
•	 the ability to build larger nanoparticles;372
•	 more refined controlled release;372, 413, 549
•	 enhanced drug loading;372
•	 the ability to build nano-metal oxide frameworks;372
•	 the ability to self assemble particles from increasing 
numbers of sub-units;375
•	 self assembling (and disassembling) systems;376
•	 collocation of drugs, ligands and other 
functionalities;377
•	 highly automated design strategies for complex 
nanostructures;378
•	 design guidelines to increase the penetration of 
targeted nanoparticles.379
The Biological and Toxin Weapons Convention   55
5.3 Dispersal and delivery of  
biological agents
Advances in several key areas could simplify the 
delivery of a biological weapon:
•	 Nanotechnology. A wider range of nanoparticles, of 
different sizes, can more efficiently deliver complex 
payloads to diverse targets. Nanoparticles can now 
target previously inaccessible physiological sites 
and cell types (e.g. by crossing the blood-brain 
barrier). Nanoparticles also add other desirable 
characteristics to agents, such as increased 
persistence in the body and immune avoidance. 
Nanoparticles suitable for aerosol release have been 
developed since the Seventh Review Conference;
•	 Aerobiology. Offers powerful tools for modelling 
the release of bioweapons, including both 
environmental and indoor dispersal patterns, 
helping optimise the release of an agent. There 
have also been advances in equipment for 
generating and modelling aerosol dispersion have 
also been developed;
•	 Use of chemical co-factors to increase the uptake 
of biological agents. These have been identified 
for use with biologically active proteins; and 
•	 Increasing capacity to deliver biological weapons 
via the alimentary route. The use of sophisticated 
formulations can improve absorption from the 
gastro-intestinal tract.
5.3.1 Aerobiology and modeling a release
•	 Tools for simulating how an agent reacts in the 
environment have improved, for example, an 
integrated model of environmental transport and 
human health exposure to biological pathogens  
in an indoor setting466 or modelling the impact  
of architectural design on the movement of 
biological agents.552
•	 There have been developments in studying 
aerosol releases in the environment, for example, 
improved tagging mechanisms.553
•	 Drug delivery particles optimised for aerosol 
release have been developed376, 381 as well as 
nebulisers and other devices for their delivery.412
5.3.2 Targeted and improved delivery
•	 Nanoparticles and drug delivery platforms have  
led to an increasing range of targeting options,413, 554 
examples include: 
 - neurological targeting;376
 - targeting based upon genetic differences, such 
as SNPs;400
 - active and passive targeting;401
 - targeting to specific organs or cells;385, 403, 551, 555
 - cell-type-specific targeting for siRNA-carrying 
nanoparticles.172
•	 Improved viral vectors for gene therapy have been 
identified, including the synthesis of ancestral 
Adeno-associated virus vectors.385
•	 There have been developments that enable more 
precise targeting, examples include: 
 - improved control over the placement of 
targeting ligands and nanoparticles and 
carriers;377
 - improved capabilities to design and build 
antibody-drug conjugates;556
 - engineered biomaterials for targeting;351
 - the development of polymeric nanoparticles  
for targeting;399
 - communication between nanoparticles to 
improve targeting.404
•	 Research has demonstrated that chemical  
cofactors can be used to increase the uptake  
of proteinaceous drugs.557
5.3.3 Alimentary delivery
A 2013 review highlighted ‘increasing capacity to 
deliver biological weapons via the alimentary route’.493
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Advances that increase risks relevant to 
the BWC
There have been a number of developments that increase overall risks relevant to the BWC  
by increasing capacity to circumvent detection, response, control and forensics capabilities. 
These include:
•	 The use of the ‘dark-web’ and other information 
technology platforms to enable the proliferation 
of biological resources for prohibited uses, for 
example, the convictions for attempts to acquire, 
and the acquisition of toxins such as Ricin and 
Abrin.558 A recent report noted that ‘the rise in 
biotechnology e-commerce will significantly disrupt 
the effectiveness of current [export control] efforts’.559
•	 The potential to develop pathogens from parts not 
on any control list, or not traditionally considered 
to be pathogenic, for example using CRISPR/CAS9 
mediated gene drives;508, 509
•	 The potential to alter the receptor binding 
specificity of key toxins, such as the anthrax toxin 
to provide ‘receptor-redirected forms’,66 which 
could complicate identification and therapeutic 
intervention;
•	 Alterations to pathogens which ‘will make it 
difficult to identify them by existing means of 
identification’;560
•	 Alteration to pathogens ‘which will lead to the 
failure of traditional prevention and treatment of 
infectious diseases and make efficient prevention 
and control more difficult’;213
•	 It is now possible to sequence a virus, email 
its sequence, alter its physical properties and 
synthesise an altered agent at a second physical 
location faster than it is possible to ship and alter 
such an agent.336, 337 This reduces the window for 
identifying and interdicting prohibited activities 
and alters the footprint of relevant activities 
and increases the importance of intangible 
technologies; 
•	 The use of CRISPR/CAS9 genome editing to  
alter the drug susceptibility of a key vector for 
the transmission of an infectious disease439 which 
offers an alternative mechanism for negating the 
efficacy of interventions to treat or control the 
spread of disease;
•	 The presence of virtual biotechnology companies540 
demonstrating the potential for complete 
outsourcing design, scale up and production 
of biological agents, increasing the importance 
of considering intangible technologies, altering 
the footprint of relevant activities and enabling 
increased compartmentalisation and geographic 
distribution of prohibited activities; and
•	 The potential for advances in 3-D printing to be 
used to:
 - make laboratory equipment, including controlled 
items ‘offers a means to subvert traditional 
controls on process equipment made of high 
performance and corrosion resistant materials’;561
 - print biological tissue, ‘potentially offered actors 
the possibility of lower production costs and 
materials used and, significantly, a smaller 
footprint for production’.561
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Topics covered during the intersessional 
process 2012 – 2014
2015 
Producing and stockpiling biological agents 
Dispersal and delivery of biological agents
2014
Pathogenicity and virulence 
Transmissibility and host range 
Toxins 
Immunology and host-pathogen interactions 
Antimicrobial and drug resistance
2013
Detection technology 
Diagnosis and surveillance 
Drugs (Including vaccines and therapeutics) 
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Annotated references
(Endnotes)
1   In May 2012, Iami et al reported having inserted a key binding 
structure from H5N1 influenza (that can infect but not spread 
in humans) into a H1N1 backbone. The authors identified four 
specific mutations to the binding structure that enabled the 
recombinant virus to spread via aerosols in ferrets.
2   In June 2012, Herfst et al reported having used site-directed 
mutagenesis and serial passage in ferrets to confer airborne 
transmission on the H5N1 influenza virus. The authors 
identified five specific mutations that confer airborne 
transmissible in ferrets.
3   In June 2012, Russell et al reported having used sequence data 
collected from disease surveillance efforts to map the current 
circulation of mutations known to affect mammal –to-mammal 
transmission in H5N1 influenza virus. The authors determined 
that two out of five known mutations are currently circulating 
and used modelling to ‘to study factors that could increase and 
decrease the probability of the remaining substitutions evolving 
after the virus has infected a mammalian host’. The authors 
identified the specific mutations affecting transmission.
4   A July 2012 working paper by the Russian Federation for the 
BWC Meeting of Experts highlighted ‘research in selection of 
strains with altered host specificity and/or high pathogenicity’ 
including ‘A number of scientists published their research 
findings on enteroviruses type 71 (Australia), influenza A H1N1 
virus and superinfections agents (USA) and Dengue fever 
virus (Brazil)’.
5   In May 2013, Zhang et al reported having produced 127 
reassortments of H5N1 and H1N1 viruses to create pathogens 
capable of mammalian aerosol transmission. The authors 
identified ‘the H1N1 virus genes encoding acidic polymerase 
and nonstructural protein made the H5N1 virus transmissible 
by respiratory droplet between guinea pigs without killing 
them. Further experiments implicated other H1N1 genes in the 
enhancement of mammal-to-mammal transmission, including 
those that encode nucleoprotein, neuraminidase, and 
matrix, as well as mutations in H5 HA that improve affinity for 
humanlike airway receptors’.
6   In April 2014, Sutton et al reported having used serial passage 
of the virus in ferrets to produce a highly pathogenic H7N1 
influenza virus capable of aerosol transmission in mammals. 
The authors identified four specific internal mutations and a 
single mutation in the stalk region of the hemagglutinin protein 
which together conferred airborne transmission. The authors 
determined that this ‘transmission was not associated with 
loss of virulence’. They concluded that ‘avian influenza virus 
can be adapted to become capable of airborne transmission 
in mammals without mutations altering receptor specificity. 
Changes in receptor specificity have been shown to play a 
role in the ability of avian influenza viruses to cross the species 
barrier, and these changes are assumed to be essential. The 
work reported here challenges this paradigm, at least for the 
influenza viruses of the H7 subtype’.
7   In October 2014, Zhou et al reported having used a replicative 
synthetic virus to characterize an uncultivable bat influenza 
virus. Whilst the authors were unable to rescue the wild type 
bat virus, they did rescue a modified bat-influenza virus that 
had the HA and NA coding regions replaced with those of 
H1N1. Their chimeric virus replicated efficiently in vitro and in 
mice, resulting in severe disease. By manipulating the HA and 
NA coding regions they identified a novel pathogenicity factor. 
Further studies enables the authors to both attenuate and 
increase the pathogenicity of their mutated virus. The authors 
demonstrated ‘that bat-influenza has very limited genetic and 
protein compatibility with Type A or Type B influenza viruses’. The 
asserted that they ‘pose little, if any, pandemic threat to humans’.
8  In June 2014, Wanatabe et al reported having created a novel 
influenza virus that resembles the causative agent of the 1918 
pandemic by stitching together avian influenza segments. The 
authors then characterised the virus, demonstrating increased 
pathogenicity (when compared to any of the avian influenza 
viruses that donated parts) in mice and ferrets. The authors 
identified seven specific mutations needed to confer mammalian 
respiratory droplet transmission to the virus. This research was 
also highlighted in an August 2014 working paper submitted by 
the United States of America to the BWC Meeting of Experts, 
the authors of which noted that the recombinant virus was 
more virulent than any of the donor viruses and resembled the 
virulence of the 1918 pandemic strain.
9   In October 2014, Wei et al reported that ‘an engineered 
reassortant swine influenza virus, with the same gene 
constellation pattern as the pandemic H1N1/2009 virus and 
subjected to only nine serial passages in pigs, acquired greatly 
enhanced virulence and transmissibility’. The authors identified 
a series of mutations ‘able to confer respiratory droplet 
transmission as effectively as the pandemic H1N1/2009 virus’. 
They concluded ‘pigs can readily induce adaptive mutational 
changes to a precursor pandemic-like virus to transform it into a 
highly virulent and infectious form akin to that of the pandemic 
H1N1/2009 virus’.
10  In September 2013, Shi et al reported the structures and receptor 
binding of hemagglutinins from human-infecting H7N9 influenza 
viruses. The authors identified a single mutation that allowed 
the virus to bind to both avian and human receptors. The results 
published convinced the authors that ‘that other amino acid 
substitutions contribute to the receptor-binding switch’.
11   In October 2013, Knepper et al reported having identified a 
H7N9 influenza virus isolate adapted for efficient growth in 
human lung tissue. The authors evaluated the replication, 
tropism, and cytokine induction of the virus, demonstrating 
that it ‘replicated similarly well as a seasonal IAV in explanted 
human lung tissue, whereas avian H7 subtype viruses 
propagated poorly’.
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12   In December 2013, Hai et al reported the H7N9 influenza virus 
gains neuraminidase inhibitor resistance without loss of in 
vivo virulence or transmissibility. The authors also identify the 
specific mutations involved.
13   In November 2014, Dowall et al reported having used serial 
passage of Ebola virus in guinea pigs to identify a number of 
mutations associated with host range. The authors also identified 
‘genome modification and coding changes that are associated 
with increasing virulence, pathogenesis and disease pathology’.
14  In May 2013, Zhang et al reported the atomic structures of H5 
influenza virus Hemagglutinin (HAs). The authors ‘determined 
the complex structures of wild-type and mutant HAs derived 
from an Indonesia H5N1 virus bound to either avian or human 
receptor’. They demonstrated the ‘structural and biophysical 
basis for the H5N1 adaptation to acquire human, but maintain 
avian, receptor-binding properties’.
15   In June 2013, Zhang et al reported the conformational changes 
necessary for the H5N1 influenza virus to alter its receptor-
binding preference from avian to human receptors. The authors 
provided the ‘structural and biophysical basis for the H5N1 
adaptation to acquire human, but maintain avian, receptor-
binding properties’. In December 2013, Xu et al reported that 
whilst these receptors were capable of binding with human 
receptors, that they bound preferentially with avian receptors. 
The authors concluded ‘the current human H7N9 viruses are 
poorly adapted for efficient human-to-human transmission’.
16   A July 2012 working paper by China for the BWC Meeting of 
Experts highlighted ‘confirmation of the correlation between 
genetic variation and disease sensitivity makes it possible to 
improve the specific microbes’ pathogenicity, infectivity, and 
host specificity using combinatorial approaches of synthetic 
biology, reverse genetics and whole genome in vitro directed 
evolution’. The authors also noted ‘revelation of pathogenic 
microbes’ genome evolution and its relation with infectivity and 
pathogenicity and greatly enhance the surveillance, diagnosis 
and therapy of related infectious diseases. There is no doubt 
that such DNA sequence information can also be used for the 
modification of antigenicity, infectivity, toxicity and drug resistance 
of traditional pathogens, even for the artificial design and 
synthesis of totally new pathogens, which will lead to the failure 
of traditional prevention and treatment of infectious diseases and 
make efficient prevention and control more difficult’.
17   In November 2012, Streicker et al reported the evolutionary 
routes rabies virus took to establish itself in a new host 
following repeated host shifts among bats. The authors 
demonstrated ‘that although rabies viruses shared consistent 
three-stage processes of emergence in each new bat species, 
host shifts involving greater numbers of positively selected 
substitutions had longer delays between cross-species 
transmission and enzootic viral establishment’. The authors 
noted that there ‘are multiple evolutionary routes to host 
establishment in a zoonotic RNA virus that may influence the 
speed of viral emergence’.
18   A 2014 review of the application of tissue engineering 
approaches to the modelling of viral infections highlighted 
progress in overcoming shortcoming in other model 
systems, noting “Standard tissue culture models lack critical 
emergent properties driven by cellular organization and in 
vivo–like function, whereas animal models suffer from limited 
susceptibility to relevant human viruses and make it difficult 
to perform detailed molecular manipulation and analysis”. The 
authors conclude recent developments in tissue engineering 
“faithfully recapitulate the in vivo viral life cycle”.
19   In August 2011, Rasko et al reported having sequenced the 
organism for a particularly lethal Escherichia coli (O104:H4). The 
authors used the sequence data to provide insights into the 
origins of the bacteria and core aspects of its pathogenicity.
20   A January 2012 review of biomedical applications of synthetic 
biology highlighted development for understanding pathogen 
mechanism, including for influenza, SARs and HIV.
21   A July 2012 working paper by the Russian Federation for the 
BWC Meeting of Experts highlighted ‘Findings of the study 
on orthoreoviruses and influenza A (People’s Republic of 
China), brucellosis (Spain) were published’ as well as ‘Italian 
scientists… studying the formation of Shigella (dysentery agent) 
pathogenic strains by means of loss of some genetic elements 
of Escherichia coli. Such a mechanism can significantly increase 
the hazardous properties of entero-haemorrhagic Escherichia 
coli (O104: H4)’. The authors also took note of ‘research in 
selection of strains with altered host specificity and/or high 
pathogenicity’ including ‘A number of scientists published their 
research findings on enteroviruses type 71 (Australia), influenza 
A H1N1 virus and superinfections agents (USA) and Dengue 
fever virus (Brazil)’.
22   An August 2014 working paper submitted by the United States 
of America to the BWC Meeting of Experts highlighted research: 
•	 Enabling the prediction of the virulence of an emerging 
pathogen from its sequence information. The authors 
highlighted recent work on methicillin-resistant 
Staphylococcus aureus. The authors noted ‘such knowledge 
would improve and hasten development of vaccines, 
therapeutics, and diagnostics with increased specificity 
for virulence factors. Such knowledge could also enable 
mitigation of the host immune response, turning it up or 
down to minimize host damage’;
•	  Identifying how varicella zoster virus (VZV) manipulates the 
host immune system. That authors noted there are ‘several 
mechanisms by which VZV proteins prolong infection, 
including: (i) promoting survival of infected T cells and skin 
cells, (ii) enabling VZV to go unrecognized by the immune 
system, and (iii) inducing “gene silencing” that enables the 
virus to go dormant in neurons’;
•	  On virulence factors contributing to persistent infections. 
The authors noted recent research with Mycobacterium 
tuberculosis (Mtb) ‘to identify potential virulence factors in 
the pathogen’s genome in order to understand the ability of 
Mtb to survive for long periods in human lungs. This research 
suggested Mtb enzymes as virulence factors that allow 
survival within host cells under different in vivo conditions’.
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23   In October 2014, Ayllon et al reported a single specific mutation 
that increased the virulence of H7N9 influenza virus.
24   In January 2015, Bi et al reported having identified specific 
mutations to a series of internal genes of H7N9 influenza virus 
that increase the pathogenicity of the virus in vitro and in vivo.
25   In August 2013, an international group of authors published their 
intent to study the host range, virulence and transmission of 
H7N9 influenza viruses as well as to evaluate the effectiveness 
of antiviral drugs and vaccine candidates. The authors provided 
the rationale for conducting such work.
26   In December 2014, Jeon et al reported that B. anthracis DNA 
may contribute to anthrax pathogenesis by enhancing LT 
activity via cytokines mediated by toll-like receptors.
27   In February 2015, Hubbard et al reported have used 
transcriptomics approaches to gain insights into wheat yellow 
rust populations in the UK. The authors demonstrated a major 
shift in the causative agent in recent years – with four distinct 
lineages being tracked and correlating to different phenotypes 
identified by previous virulence assays. The authors noted that 
the methods described ‘circumvents the difficulties associated 
with obligate plant pathogens. In principle, this strategy can be 
widely applied to a variety of plant pathogens’.
28 In September 2014, Morrison et al reported having characterised 
the host immune response to H7N7 and compared it to those 
of H5N1, H1N1 and the 1918 influenza viruses and identified a 
common transcription signature connected to pathogenicity. 
The authors screened this signature against existing drugs and 
identified six FDA-approved drugs that could potentially be 
repurposed as H7N9 influenza therapeutics.
29   In February 2011, Dubey and Ben-Yehuda reported having 
identified a novel signalling mechanism in bacterial 
populations. The authors identified intercellular nanotubes 
and demonstrated that bacteria use them to exchange 
cytoplasmic molecules, non-hereditary antibiotic resistance and 
plasmids. The demonstrated that ‘nanotubes also formed in an 
interspecies manner, between B. subtilis and Staphylococcus 
aureus, and even between B. subtilis and the evolutionary 
distant bacterium Escherichia coli’. 
30  In February 2012, Soanes et al reported a high-resolution 
analysis of gene expression changes associated with rice blast 
infections in plants. The authors mapped and analysed global 
patterns of gene expression during appressorium (a specialised 
infection structure) development. They demonstrated gene 
expression changes over time and revealed the activity of key 
regulators.
31   In June 2012, Loquet et al reported the structure of the type III 
secretion system used by pathogens to manipulate host cells. 
The authors reported compiling the complete atomic structure 
of the Salmonella typhimurium T3SS needle.
32  In May 2013, Zhao et al reported the structure and molecular 
dynamics of a mature HIV-1 capsid. The authors used cryo-
electron microscopy and cryo-electron tomography to 
identify the structure of the protein assembly and the its core, 
respectively. They used the data to produce an all-atom model 
of the capsid. Mutagenesis studies demonstrated that the 
hydrophobic structures in the core were ‘crucial for capsid 
assembly and stability, and for viral infectivity’.
33   In July 2013 Zhou et al reported the biological features of a 
novel strain of H7N9 influenza proving fatal to humans. The 
authors demonstrated that the virus could bind to both human 
and avian receptors. The also detailed its ability to infect human 
tissues, partially characterised the host response and provided 
insights into its pathogenicity.
34   In July 2013, Coggeshall et al reported a new model to explain 
the pathology of inhalational anthrax. The authors use their 
model to ‘propose that death in inhalation anthrax results from 
an overwhelming bacteraemia that leads to severe sepsis’, 
rather than from toxaemia.
35   A March 2014 review outlines progress in understanding life 
cycle of Yersinia pestis, focusing in particular on how the 
bacteria ‘survive and suppress the host immune response 
during the initial phase of the infection when the bacteria have 
not been acclimated to the mammalian host temperature’ 
necessary for the expression of virulence factors.
36   A July 2011 review of microbial genomics and infectious diseases 
highlighted that ‘the revolution in DNA-sequencing technology 
has to a large extent democratized microbial genomics and 
altered the way infectious diseases are studied… Today, the 
major challenges in microbial genomics are to predict the 
function of gene products and the behaviour of organisms and 
communities from their sequences and to use genomic data 
to develop improved tools for managing infectious diseases’. 
The author highlighted progress in cataloguing genomic 
diversity, molecular epidemiology, understanding pathogenesis, 
metagenomics, pathogen discovery and diagnostics, 
therapeutics and drug discovery, and vaccines.
37   In May 2012, OpGen announced the formation of ‘a public health 
consortium to evaluate… Whole Genome Mapping technology 
for strain typing microorganisms that cause health outbreaks’. 
They noted that ‘comprehensive structural analysis of microbial 
genomes… combined with sequencing, [creates] a new genetic 
analysis workflow… that more accurately detects genetic 
elements associated with virulence and drug resistance’.
38   In January 2012, Strecher et al reported that gut inflammation 
can boost horizontal gene transfer between pathogenic and 
commensal Enterobacteriaceae. The authors demonstrate 
that ‘pathogen-driven inflammatory responses in the gut can 
generate transient enterobacterial blooms in which conjugative 
transfer occurs at unprecedented rates. These blooms may 
favour reassortment of plasmid-encoded genes between 
pathogens and commensals fostering the spread of fitness-, 
virulence-, and antibiotic-resistance determinants’.
39   In February 2012, Soares et al reported having developed a 
software suite to identify pathogenicity islands that ‘harbour 
clusters of virulence genes that mediate the adhesion, 
colonization, invasion, immune system evasion, and toxigenic 
properties’. The authors demonstrated their software package 
was more accurate than existing tools. The used the software 
to identify seven putative pathogenicity islands in the animal 
pathogen Corynebacterium pseudotuberculosis.
40   A January 2014 review of computational approaches to 
identifying pathogenicity islands highlighted that they ‘have 
some detectable properties, such as having different genomic 
signatures than the rest of the host genomes’. The authors noted 
progress in computational approaches to identifying them.
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41   A July 2012 presentation by Japan to the BWC Meeting 
of Experts highlighted the dual use potential of recent 
developments, including in:
•	  Synthetic biology enabling ‘virus development/modification 
using artificial/modified genetic information’ as well as more 
efficient integration of disease causing and toxin related 
genes;
•	  Bioinformatics, increasing the efficiency of comparing and 
retrieving data related to pathogencity and toxins;
•	  Systems biology, assisting in ‘estimating effects of disease-
causing agents on human cells’ functions’ and more efficient 
analysis of disease causing agents and opportunities to 
increase the damage done to the target.
42   An August 2013 review of the genomics of emerging pathogens 
highlighted “advances in methods for microbial discovery and 
characterization, as well as strategies for testing the clinical and 
public health significance of microbe-disease associations”.
43   In January 2015, Yoon et al reported the creation of a database 
to house details of pathogenicity islands and resistance islands. 
The authors report ‘223 types of PAIs with 1331 accessions, and 
88 types of REIs with 108 accessions’.
44   In January 2013, Varela et al reported having used a synthetic 
biology approach for the rapid rescue and manipulation 
of Schmallenberg Virus and developed a mouse model to 
study infection. The authors demonstrated that one of the 
non-structural proteins protein encoded in the virus blocks 
a key part of the host’s innate immune system. They also 
demonstrated that serial passages in cell culture increased the 
virulence of their cloned virus in mice.
45   In October 2013, Pechous et al reported the early host-
pathogen interactions of Yersinia pestis that leads to the 
progression of pulmonary infection in pneumonic plague. The 
authors describe a two-step progress with ‘an initial pre-
inflammatory phase facilitating bacterial growth in the absence 
of host inflammation, followed by a pro-inflammatory phase 
marked by extensive neutrophil influx, an inflammatory cytokine 
storm, and severe tissue destruction’.
46   In March 2015, Sivaraman et al reported a novel cytokine 
activation which occurs early after bacteria enter the lung, and 
which ‘eventually contributes to pulmonary inflammation and 
pathology during the later stages of infection’. The authors 
also demonstrate ‘Y. pestis also activates the induction of IL-1 
receptor antagonist… and this activation likely contributes to the 
ability of Y. pestis to establish the initial pre-inflammatory phase 
of disease’.
47   In April 2014, Caulfield et al reported a novel mechanism 
through which Yersinia pestis manipulates innate immunity 
during pneumonic plague. The authors demonstrate that Y. 
pestis degrades an apoptotic signalling molecule, thereby 
altering the host inflammatory responses, enables enhanced Y. 
pestis growth in the lungs, and enabling its full virulence.
48   An October 2014 review of the convergence of biology and 
chemistry highlighted:
•	  ‘The technical capability for chemical synthesis of toxins 
exists, and synthetic biology approaches could also be used 
for toxin production and modification’. The authors noted 
recent research with Saxitoxins; 
•	  ‘Growing research interest in toxins for applications in medical 
treatment, life sciences research, pharmaceuticals, and 
agriculture shows that technological advances are changing 
the way in which toxins are being produced and used’.
49   In August 2011, Moreau et al reported genome-wide RNAi 
screens identifying genes required for intoxication from Ricin 
and Pseudomonas exotoxin. The authors demonstrated striking 
differences in the pathways used by the two protein toxins.
50   In May 2011, Carette et al reported ‘global gene disruption 
in human cells to assign genes to phenotypes by deep 
sequencing’. The authors demonstrated that this approach 
could be used to ‘identify 743 mutations distributed over 12 
human genes important for intoxication by four different CDTs’ 
(cytolethal distending toxins).
51   In February 2012, Martchenko et al reported that human 
genetic variation alters anthrax toxin sensitivity. The authors 
demonstrated that extensive human diversity impacts toxin 
binding and uptake, which in turn alters cell lethality. They 
identified individual differences in a key binding domain 
expression levels which was a ‘determinant of this diversity’.
52   In December 2013, Vonk et al reported having ‘sequenced the 
genome of a venomous snake, the king cobra, and assessed the 
composition of venom gland expressed genes, small RNAs, and 
secreted venom proteins’. The authors demonstrated ‘dynamic 
gene evolution and adaptation in the snake venom system’.
53  A June 2014 review of Botulinum neurotoxins (BoNT) highlighted 
‘recent studies that have improved our understanding of the 
genetics and structure of BoNT complexes… [and] recent insights 
into the mechanisms of BoNT entry into the general circulation, 
neuronal binding, membrane translocation and neuroparalysis.
54   In February 2013, Bassik et al reported a two-stage strategy 
for developing genetic interaction maps and then applied it to 
Ricin. Genetic interaction maps measure of how strongly the 
function of one gene depends on the presence of a second. 
They enable ‘the systematic exploration of gene function in 
microorganisms’. The authors demonstrate that the Ricin map 
‘broadly recapitulates known pathways’ but ‘provides many 
unexpected insights’ including ‘a noncanonical role for COPI, 
a previously uncharacterized protein complex affecting toxin 
clearance, a specialized role for the ribosomal protein RPS25, 
and functionally distinct mammalian TRAPP complexes’.
55   In September 2011, Pincus et al reviewed the cellular mode 
of action, clinical symptoms and pre- and post-exposure 
approaches to prevent intoxication from Ricin toxin.
56   In September 2011, Herper et al reported using fluorescence 
and electron microscopy to reveal how Botulinum neurotoxins 
are taken up at the pre-synaptic nerve terminal. The authors 
used these insights to identity a compound that blocks the 
mechanism. They found that this compound, a novel potent 
Dynasore analog, conferred a ‘significant delay of >30% in the 
onset of botulism… in mice’. In October 2013, McCluskey et al 
reported having improved the efficacy of Dynadore analogues.
57   In January 2013, Orr et al reported having characterized the 
gene involved in the second step of Saxitoxin biosynthesis. 
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58   In May 2013, Gregers et al reported that overexpression of 
the endoplasmic reticulum chaperone BiP ‘inhibited Ricin 
translocation and protected cells against the toxin. Furthermore, 
shRNA-mediated depletion of BiP enhanced toxin translocation 
resulting in increased cytotoxicity’.
59   In July 2013, Bagaria et al reported insights into the mechanism 
of action of the only monoclonal antibody demonstrated to 
neutralize the Abrin toxin.
60   In September 2013, O’Hara and Mantis reported the mechanism 
of action of antibodies against both Ricin chains.
61   In October 2013, Dover et al reported the molecular 
characterization of the novel botulinum neurotoxin. The authors 
demonstrated that the gene sequence was significantly 
different from previously identified toxin types but did not 
publish the full sequence.
62   In April 2014, Dong et al reported characterising the absorption, 
distribution and pathological injury in mice due to ricin 
poisoning via the alimentary pathway.
63   A May 2015 review of the use of botulinum toxin as a painkiller 
highlighted recent research that revealed that the detailed 
structural bases of these neurotoxins interactions with their 
cellular receptors. The authors noted progress in understanding 
the molecular and cellular mechanisms related to the efficacy of 
botulinum toxins.
64 A February 2013 review of the impact of scientific 
developments on the Chemical Weapons Convention 
highlighted ‘the production of toxic chemicals, including toxins, 
through biological synthesis (an aspect of the convergence 
of chemistry and biology); encapsulation and delivery through 
nanotechnology; and flow microreactors, which enable types of 
chemical reactions under conditions that were not previously 
technically feasible’.
65 An August 2014 presentation by the OPCW to the BWC Meeting 
of Experts highlighted enabling technologies having resulted in 
‘an expanded capability to redesign or manipulate organisms’ 
and ‘to design and engineer improved enzymes’. The authors 
noted metabolic pathways ‘have been published for production 
of Saxitoxin, ricin… and many other toxins’. They highlighted that 
‘in vitro biosynthesis of Saxitoxin and ricin has been described’ 
but that ‘there are practical limitations with regard to scale and 
complexity. Obtaining ricin and small quantities of Saxitoxin 
from their natural sources is simpler than employing metabolic 
engineering strategies’.
66  In May 2012, Mechaly et al reported having changed the 
Receptor specificity of anthrax toxin. The authors the receptor 
specificity of the transport protein of anthrax toxin may be 
readily changed, raising the possibility that receptor-redirected 
forms of protective antigen (PA) and PA homologs may 
be useful for research and medical applications requiring 
modification or ablation of designated populations of cells’.
67  In October 2013, Barash and Arnon reported discovering a 
new type of toxin from Clostridium botulinum – the first to 
be discovered in more than 40 years. The authors used a 
mouse bioassay to demonstrate the new isolated toxin was 
different from known types. This research was highlighted in 
an August 2014 working paper submitted by the United States 
of America to the BWC Meeting of Experts, where the authors 
noted ‘immunological approaches indicated that antibodies to 
known botulinum toxin (types A through G) did not react with 
the new toxin; genome sequencing revealed its similarities 
and differences to other botulinum toxins; and animal studies 
demonstrated its extreme toxicity as well as the potential for 
vaccine development’.
68  In December 2013, Redmann et al reported having developed 
‘a robust high-content screen was developed to discover 
novel compounds that stabilize intracellular Ricin and limit Ricin 
intoxication’. The authors focused on compounds that target 
Ricin toxin chain-A retrograde translocation.
69  In October 2013, Ferrari et al reported having combined the 
botulinum type A protease with the tetanus binding domain, 
which natively targets central neurons. The parts, although 
produced separately, were joined using site-specific protein 
stapling. The authors demonstrated that the synthetic 
molecule was able to block pain in a rat model and neuron 
activity in the visual cortex.
70  In September 2012, Hu et al reported having developed and 
characterized a monoclonal antibody capable of neutralizing 
the Ricin toxin. The authors demonstrated that it could rescue 
100% of mice injected with a low dose of the toxin after 4 hours 
post exposure and 50% of mice 6 hours post exposure.
71  In September 2012, Yermakova et al reported having identified 
sub-domains of Ricin’s B subunit as targets of toxin neutralizing 
and non-neutralizing monoclonal antibodies.
72  In December 2012, Saito et al reported having synthesized 
and tested a number of competitive active-site inhibitors 
of Ricin Toxin A. The authors studied the binding dynamics 
involved and identified a number of additional key factors not 
predicted by modelling.
73  In April 2013, Song et al reported that antibodies against Ricin 
A Chain offered greater protection than those targeting the B 
Chain. Ricin A Chain antibodies hinder intracellular routing of 
toxin and protect cells even after toxin has been internalized.
74  In September 2013, Yermakova and Mantis reported that 
monoclonal antibody fragments ‘neutralize Ricin in a cell based 
assay, and in a mouse challenge model as effectively as their 
respective full length parental IgGs’.
75  In December 2013, Vance et al reported having identified 
monomeric single-chain camelid antibodies capable of 
neutralizing Ricin in vitro and engineered a heterodimeric 
version that neutralized Ricin in vivo.
76  In January 2014, Hu et al reported using intact IgG from goat 
anti-ricin hyperimmune sera to provide immediate protection 
following ricin exposure and to confer an active immunity 
against ricin that subsequently results in long term protection 
(up to 5 months).
77  In April 2014, Yermakova et al provided additional functional 
information about antibody mediated neutralisation of ricin.
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78  An August 2014 presentation by Germany to the BWC Meeting 
of Experts highlighted advances in assessing the quality 
of detection technologies for toxins. The authors noted 
existing shortcomings at the national and laboratory level and 
identified technical deficits including needs for: detection and 
identification criteria for individual methods; accepted SOPs/
ROPs for different technological approaches; closing analytical 
detection gaps; reference material; reagents and methods; 
exchanges of know-how; training capabilities; and regular ring 
trials with increasing level of difficulty on selected techniques.
79  In 2011, the US National Academies of Sciences published a 
report reviewing the threat posed by fungal diseases to human, 
animal and plant health. The report was derived from a public 
meeting on this issue, the first ever held by their Forum on 
Microbial Threats. The report addresses fungi as pathogens, 
noting their ability to ‘cause disease in healthy humans and 
animals’ as well as to ‘endure adverse environmental conditions 
and thrive outside their host’. The impact on plants was 
also stressed, noting that fungal plant pathogens had been 
responsible for the Irish Potato Famine, the Southern Corn Leaf 
Blight epidemic of the 1970s as well as Dutch Elm disease.
80  In November 2013, Li et al reported having identified three 
genes associated with infections of Plasmodium falciparum 
(the causative organism of malaria) in the vector mosquito, 
Anopheles gambiae.
81  In August 2012, Grizenkova et al reported that the 
overexpression of a gene associated with heat shock proteins 
could reduce the incubation of prion diseases. The authors 
demonstrated that an eight fold overexpression of the gene 
could reduce the incubation time by up to 16%.
82  In February 2013, Ciaiti et al reported that the mis-folded 
proteins responsible for neurodegenerative prion diseases play 
an important role in brain development, in particular regulating 
synaptic plasticity in the developing hypocampus.
83  In March 2013, Karapetyan et al reported having developed and 
used a new screening process to identify two therapies against 
prion diseases. The authors demonstrated that two drugs 
already approved for human use (astemizole and tacrolimus) 
reduce cell-surface prion proteins and inhibited prion 
replication in neuroblastoma cells. Tacrolimus reduced total 
cellular prion protein levels by a nontranscriptional mechanism. 
Astemizole stimulated autophagy, a hitherto unreported 
mode of action for this pharmacophore. Astemizole, but not 
tacrolimus, prolonged the survival time of prion-infected mice’.
84  In March 2012, Marazzi et al reported a novel mechanism by 
which influenza viruses suppress the host’s anti-viral response. 
The authors described a mechanism by which the influenza 
virus uses a non-structural protein to interfere with the host 
cell’s epigenome. The viral protein mimics a key regulator 
reducing antiviral gene expression and rendering cells more 
susceptible to viruses.
85  In April 2012, Everitt et al reported that a set of proteins known 
to inhibit the replication of certain pathogenic viruses play an 
important role in protecting against severe viral pneumonia 
present in certain cases of influenza. They demonstrated that 
mutations in the genes responsible for these proteins reduce 
their antiviral activity and can profoundly alter the course of 
influenza infections in humans and mice.
86  In August 2014, Yoshizumi et al reported the mechanism by 
which Influenza A virus protein  PB1-F2 impairs innate immunity.
87  An August 2014 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlights:
•	  Pathogen-specific mechanisms for avoiding the immune 
system, including for vaccinia virus;
•	  Dengue virus’ ability to hide from host immune defences by 
avoiding recognition by components of the innate immune 
system through the use of enzyme known as MTase to 
‘chemically modify its genetic material and escape detection’;
•	  Severe acute respiratory syndrome coronavirus (SARS-
CoV)’s use of the enzyme PLpro (or papain-like protease) to 
remove host cell proteins involved in triggering the innate 
immune response;
•	 ‘An outer protective layer formed of capsular 
polysaccharides’ used by Escherichia coli and other 
pathogens ‘which prevents them being recognised and 
destroyed by the host immune system’;
•	  Antigenic variation, used by viral, bacterial, fungal and 
parasitic pathogens to sidestep antibodies created in 
response to previous infections;
•	  Modulation of the protein-protein interactions involved in 
the signalling pathway that activates an innate immune 
response. The authors highlight recent research suggesting 
that Salmonella enterica, Brucella sp., E.coli and Yersinia 
pestis all use this approach;
•	  The ‘mechanism by which viruses such as influenza, West 
Nile and dengue activate a class of molecules, known as 
TAM receptors, which are central inhibitors of the innate 
immune response to pathogens’;
•	  The mechanism through which ‘Yersinia pestis… disrupts the 
host immune system by interacting with a receptor protein 
on immune cells’;
•	  The Type III secretion process used by many bacteria 
to hijack host cells by the injection of microbial proteins 
which ‘assist their survival and block the host cell immune 
response’;
•	  The recently discovered broadly-reactive antibody-binding 
protein used by Mycoplasma species ‘to bind with high 
affinity to all types of human and non-human antibodies 
through attachment to conserved regions, thus blocking 
antibody-antigen binding’;
•	  The mechanism used by pathogens such as Y.pestis to 
survive inside macrophages by degrading the compound 
itaconate, which interferes with bacterial metabolism.
88    I n April 2012, Nham et al used bioluminescence imaging to 
track the course of Yersinia pestis infections in a living host. 
They demonstrated that the high variability of the kinetics of 
infection was determined by the time taken for the bacteria to 
move from the site of infection to the draining lymph nodes. 
They noted that when the infection reached this point, ‘the 
disease progresses extremely rapidly, leading to the invasion 
of the entire body within two days and to death of the animals. 
This highlights the extraordinary capacity of Y. pestis to 
annihilate the host immune response’.
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89   A July 2012 working paper by the Russian Federation for the 
BWC Meeting of Experts highlighted ‘research in immunity 
overcoming strains’ including ‘studies of American and Italian 
scientists on the plague agent, including on the analysis and 
design of molecular mechanisms that enable overcoming both 
artificial (vaccine-generated) and natural human immunity’.
90  A September 2013 review highlighted progress in 
understanding the relationship between Mycobacterium 
tuberculosis and its host. The authors note ‘The host resists 
infection by releasing damaging free radicals, pushing the 
pathogen towards lysosomal degradation, releasing an arsenal 
of cytokines for triggering adaptive immunity and facilitating 
apoptosis for effective T cell antigen presentation. The 
bacterium counters these mechanisms and also metabolically 
reprograms the macrophage to its own benefit’.
91  In February 2014, Akey et al reported the structures used by 
flaviviruses to avoid the host immune system.
92  In May 2012, Habets and Brockhurst reported having 
experimentally evolved Staphylococcus aureus to be resistant 
to ‘human-neutrophil-defensin-1, a key component of the innate 
immune response to infection. This unintended consequence of 
therapeutic use could drastically undermine our innate immune 
system’s ability to control and clear microbial infections’.
93   In September 2011, Teijaro et al reported a mechanism 
responsible for inducing cytokine storms in response to certain 
infections. The paper describes the cellular and signalling 
mechanisms responsible and demonstrates that it is possible 
to modulate them, reducing the innate immune response 
and offering potential therapeutic interventions to prevent 
cytokine storms. Elucidation of this mechanism may also offer 
opportunities to confer the ability to initiate cytokine storms to 
other pathogens.
94   In September 2013, Bradley-Stewart et al reported having 
identified cytokine concentrations associated with clinical 
outcome in patients infected with pandemic H1N1 influenza. 
The authors demonstrated ‘a number of cytokines were found 
to be substantially elevated in patients with severe influenza’ 
supporting earlier work ‘suggesting a role for proinflammatory 
cytokines in influenza-induced lung pathology’. The authors 
also demonstrated that another cytokine ‘was significantly 
lower in patients with severe infection suggesting it is actively 
suppressed. As EGF has a role in role in cell proliferation 
and tissue repair, it may protect the lung from host or virus 
mediated damage’.
95   A January 2012 review of biomedical applications of synthetic 
biology highlighted development for understanding immune 
systems, including B cells and autoantigens.
96  In February 2012, Martchenko et al reported that human 
genetic variation alters anthrax toxin sensitivity. The authors 
demonstrated that extensive human diversity impacts toxin 
binding and uptake, which in turn alters cell lethality. They 
identified individual differences in a key binding domain 
expression levels which was a ‘determinant of this diversity’.
97  In March 2012, Moseman et al reported a previously unreported 
mechanism through which the innate immune system combats 
viral infections. In a second paper during the same month, 
Jaeger et al reported that neutrophils (the most common type 
of white blood cell) played a critical role in guiding antimicrobial 
natural killer cells to their targets. Disrupting the function of 
neutrophils was demonstrated to impair a host’s ability to mount 
an effective response.
98  In June 2012, Lee and Groisman reported that a Salmonella 
virulence locus is controlled by an ATP-sensing leader 
messenger RNA. The authors noted the results ‘indicate that 
pathogens can interpret extracellular cues by the impact they 
have on cellular metabolites’.
99  An October 2013 review of structural insights into plant–
pathogen interactions highlighted advances in understanding 
the molecular mechanisms of plant disease. The authors 
noted ‘genomic, bioinformatic, proteomic, biochemical and 
cell biological analyses of plant–pathogen interactions, three-
dimensional structural studies of virulence proteins deployed by 
pathogens to promote infection, in some cases complexed with 
their plant cell targets, have uncovered key insights into the 
functions of these molecules’. The highlighted that ‘structural 
information on plant immune receptors, which regulate the 
response to pathogen attack, is also starting to emerge’.
100  A January 2014 review of the nanoencapsulation of cells 
highlighted ‘recent research and development of the systems 
of nano-thin layers coated cells for biomedical applications. 
Polyelectrolyte based nano-thin polymer coatings… are a 
promising part of the systems involving cells for biological 
processes regulation. The purpose of the layer-by-layer coating 
technique application is to minimize capsule void volume and 
separate cells from the host immunological system eliminating 
immunosuppressive therapy during transplantation’.
101  In February 2015, Pechous et al reported a novel bacterial 
mediator of pulmonary inflammation in pneumonic plague. The 
authors used in vivo transcriptional profiling to identify ‘five Y. 
pestis genes that contribute to the development of pneumonic 
plague. Deletion of one of these genes, ybtX, did not alter 
bacterial survival but attenuated host inflammatory responses 
during late-stage disease’. 
102  In May 2012, Feng et al reported biochemical basis of how 
one pathogen-injected effector protein inhibit plant immunity. 
The authors demonstrate the effector modifies two ‘receptor-
like cytoplasmic kinases known to mediate immune signaling’, 
thereby reducing their kinase activity and consequently 
inhibiting downstream signaling. This effectively enhances 
virulence of this plant pathogen and inhibits plant immunity.
103  In January 2014, Hyde et al reported one evasion mechanism 
by which viruses use RNA structural motifs to avoid immune 
restriction.
104  In June 2012, Illing et al reported having used a drug used 
to treat HIV to modify the set of antigens that activates the 
immune system, triggering life-threatening auto-immune 
responses. This provides a critical insight into mechanisms 
responsible for hypersensitivities to small molecule drugs  
and a potential new agent as small molecule drugs could be 
used to initiate dangerous hypersensitivity reactions.
The Biological and Toxin Weapons Convention   66
105 An August 2013 statement by Iran on behalf of the Group 
of NAM and other States Parties to the BWC highlighted 
that ‘advances in enabling technologies like bioinformatics; 
computational biology; DNA microarrays; gene synthesis 
technology; high-throughput mass spectrometry; high-
throughput sequencing; nanotechnology; synthetic biology; 
systems biology; and whole-genome directed evolution are 
critical for future life sciences research and development. 
These enabling technologies have many benefits in faster, 
cheaper, and easier application of biological science and 
technology for both public health and security purposes, 
increased capacity and better understanding of disease and 
healthcare technologies by more people in more locations 
throughout the world’. The same statement was repeated at the 
August 2014 BWC Meeting of Experts and the December 2014 
BWC Meeting of States Parties.
106  In October 2014, Andoh et al reported having created a fully 
functional atomic scale molecular model of the capsid of Foot-
and-Mouth Disease virus. The used the model to successfully 
explain physical characteristics of the virus.
107  In January 2015, Han et al reported modelling the three-
dimensional structure of foot-and-mouth disease virus and its 
biological functions. The authors reported significant insights 
into ‘virus assembly and dissociation, formation of capsid-like 
particles and virus-receptor complexes, and viral penetration 
and uncoating’.
108   A July 2012 presentation by Mexico to the BWC Meeting 
of Experts highlighted the use of metagenomics for the 
identification of organisms present in a mixed environmental 
sample. They noted its use in identifying and tracking a 
specific agent. The author provided an example of the use of 
metagenomics approaches to study the cerebrospinal fluid of 
patients with meningoencephalitis.
109   In July 2012, Dreyfuss et al reported having mathematically 
derived the absolute limits of heritability and prevalence of 
predicting disease course using genetic factors. They argue 
that determining ‘such limits is valuable in understanding 
the implications of genetic testing even before additional 
associations are identified’.
110   In September 2011, Suhre et al reported ‘a comprehensive 
analysis of genotype-dependent metabolic phenotypes 
using a GWAS with non-targeted metabolomics’. The authors 
‘identified 37 genetic loci associated with blood metabolite 
concentrations’ and noted these ‘associations provide new 
functional insights for many disease-related associations that 
have been reported in previous studies’.
111  A July 2012 presentation by Pitt to the BWC Meeting of Experts 
highlighted a range of advances and technologies in the life 
sciences, including distributed computing technologies to 
address bioinformatics and big data challenges.
112   A March 2012 review of structural analysis of receptors 
highlighted a series of technological developments to address 
the challenges of being able to use x-ray crystolography 
to determine the structures of G-protein-coupled receptors 
(‘ubiquitous cell-surface molecules that are activated by 
light, odours, hormones and neurotransmitters’). The authors 
describe how proteins are used to stabilize restive sections 
of the receptor and a special ‘medium called the lipidic 
cubic phase’ to enable the receptors to pack into crystals. In 
May 2012, Wu et al reported using these developments to 
determine the structure of opinoid receptors in humans.
113   In April 2014, Owen et al reported significant progress in 
room-temperature macromolecular crystallography. This is 
an important tool in determining the physical structure of 
macromolecules.
114   An October 2013 review of optogenetics explore the history of 
how a bacterial sensing mechanism used to detect light had 
been used to turn off and on neurons in model organisms, such 
as mice. The ability to manipulate specific neurons provided a 
higher fidelity research tool to determine the function and role 
of those neurons and has proven valuable in studying what 
causes neuropsychiatric disorders and how brain diseases can 
be treated. Similar tools have also been used to determine the 
neurological characteristics of addiction.
115   In June 2014, Gunaydin et al reported a new methodology 
(fiber photometry) to “optically record natural neural activity… to 
elucidate the realtime role of specified pathways in mammalian 
behavior”. The authors also demonstrated that manipulating 
neural patterns could induce certain types of behaviour.
116   A January 2014 review described progress in understanding 
“the concrete mechanistic distinctions between adaptive, 
physiological behavioural states and psychiatric-disease-
related behavioural states”. The authors review a series of 
“investigations have revealed that control of projection-specific 
dynamics is well suited to modulating behavioural patterns that 
are relevant to a broad range of psychiatric diseases”.
117   A December 2014 review of developments in microscopy 
highlighted series of techniques to “render opaque tissue 
transparent. Their use helps to image, label and identify 
structures at single-cell resolution”. The authors highlighted 
their use in imaging of structurally intact brain circuits
118  In December 2013, Shiromani et al reported having manipulated 
the activity of neurons to modulate symptoms associated with 
narcolepsy. The authors reported having stimulated neurons to 
induce sleep on demand.
119   A December 2012 review of the applications, challenges, and 
opportunities of optogenetics for psychiatry highlighted an 
increasing synergy between capabilities for modulation of 
defined neural projections with an ability to alter function along 
pathways of neural communication, an important characteristic 
of psychiatric disease. The authors review work demonstrating 
an ability to manipulate neurons to influence mood and 
behaviour (such as inducing violence and aggression) as well 
as mental health (such as inducing anxiety disorders such as 
PTSD) in mice.
The Biological and Toxin Weapons Convention   67
120  An August 2014 commentary on reports of the use of CRISPR/
CAS9 gene drives highlighted potential beneficial applications 
including ‘reprogramming mosquito genomes to eliminate 
malaria, reversing the development of pesticide and herbicide 
resistance, and locally eradicating invasive species’.
121  A November 2013 review of emerging nanotechnology-based 
tools for biology and medicine, highlighted the potential to 
use nanopores ‘patterned at high densities around single 
cells’ to enable ‘highly localized measurements at submicron 
and subcellular length scales’. The authors highlight potential 
applications to measure the cellular secretion of growth 
factors, cytokines, and other signalling molecules into 
extracellular spaces.
122  In October 2013, Yeow et al reported on the ‘fabrication, 
characterization, and testing of a polymer microprojection array, 
for the direct and selective capture of circulating biomarkers 
from the skin of live mice’. The authors demonstrated in vitro 
and in vivo results comparable with other more expensive and 
complex arrays.
123  A July 2012 working paper by China for the BWC Meeting of 
Experts highlighted ‘Mass spectrometry… can also be used for 
high-throughput nucleic acids analysis, which is particularly 
useful for the detection of uncultivable microbes. Hence, the 
development of high-throughput MS technologies will facilitate 
the surveillance and diagnosis of BWC relevant agents, and 
forensic medicine’.
124  In January 2014, Organovo announced a new partnership to 
3D-print living human tissues for medical research. Such tissues 
are intended to provide researchers ‘a much more accurate 
view of how drugs will behave in human beings before those 
drugs ever enter clinical trials’.
125  In February 2014, Grover et al reported having identified a 
protein able to ‘binds with high affinity to all types of human and 
nonhuman immunoglobulin G’ antibodies. The authors note that 
the protein also blocks antibody-antigen union involving large 
antigens. These broadly reactive antibody-binding proteins 
‘have been widely exploited both in the laboratory and in 
industry for purifying, immobilizing, and detecting antibodies’.
126  In February 2014, Chiappini et al reported having developed 
and use biodegradable  silicon nanoneedles to deliver nucleic 
acids into cells. The authors demonstrated significant progress in 
overcoming the challenges of delivering genetic material in vivo - 
co-deliver DNA and siRNA with efficiency greater than 90%.
127  A September 2014 review of –omics and imaging technologies 
on assessing the host immune response to biodefence 
agents highlighted technological advances which allow the 
interactions between host and pathogen to be studied in much 
greater detail. The authors noted progress in next generation 
sequencing as well as DNA and protein microarrays for 
‘dissecting the underlying host response to infection at the 
molecular level’. They noted the utility of flow cytometry and 
fluorescence microscopy for assessing cellular responses to 
infection, and biophotonic imaging for visualising the infectious 
disease process.
128  A July 2012 working paper by China for the BWC Meeting 
of Experts highlighted ‘primary results of human microbiome 
researches… indicate that our normal physiological functions 
are closely related to our second genome, whose disorder 
might affect normal physiological metabolism of humans and 
even cause illness’.
129  In June 2012, the Human Microbiome Project Consortium 
published details of the structure, function and diversity of the 
health human microbiome. This provides a useful normal data 
set against which disease states can be compared.
130  An April 2013 review of horizontal gene transfer in the 
human intestine highlighted the potential for the spread of 
antibiotic resistance genes from commensal organisms to 
potential pathogens. The authors discussed progress in using 
culture-independent techniques and metagenomic studies 
to provided insights into the distribution of mobile genetic 
elements and the extent of horizontal gene transfer in the 
human gastrointestinal tract.
131  In October 2013, Chagnot et al reported significant progress in 
characterizing the role of secreted proteins in biofilm formation.
132  In January 2015, Karimi et al presented an overview of the role 
of relevant physical processes in biofilm formation, including 
propulsion mechanisms, hydrodynamic effects, and transport 
of quorum sensing signals. The authors also examined 
opportunities for future microfluids work on biofilms.
133 In August 2012, Houry et al reported having using motile 
bacteria exuding anti-bacterial agents to kill a heterologious 
biofilm population. Such biofilms can be an important 
element of the growth of pathogenic bacteria, for example 
Staphylococcus aureus, helping to protect them from 
antibiotics, hydrodynamic shear and environmental challenges.
134  In January 2015, Sanchez-Vizuete et al reported that products 
from non-pathogenic bacteria were vital for protecting 
pathogenic strains in biofilms.
135  In April 2013, Savage et al reported that biofilm growth of 
Staphylococcus aureus ‘dramatically increases horizontal 
transfer of plasmid-borne antibiotic resistance determinants by 
conjugation/mobilization and that standard laboratory practices 
to induce conjugation in staphylococci achieve optimal 
efficiency owing to the presence of a biofilm’.
136  A July 2012 working paper by the Russian Federation for 
the BWC Meeting of Experts highlighted ‘DNA sequencing 
and genomic microorganisms’ certification methods allow 
in the shortest time possible to carry out the accurate multi-
parameter identification of any pathogen, thus playing a key 
role in investigating the causes and origins of the outbreaks of 
infectious diseases.
137  In March 2011, Rasko et al reported the use of whole-
genome sequencing and comparative genomics in a forensic 
investigation. The authors were able to identify unique 
phenotypic qualities of an agent, link it to changes in sequence 
data and then used those sequences to differentiate samples 
connected with the event from background microbes, including 
bacteria from the same species and strain.
138  In February 2012, Grad et al reported use of whole genome 
sequencing and other molecular epidemiological approaches 
to study isolates from outbreaks in France and Germany 
that were indistinguishable using traditional tests. Similar 
approaches could provide insights into the origins of an agent, 
its evolution or reveal a possible disconnect from a natural 
chain of infection.
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139  A July 2012 presentation by Sweden to the BWC Meeting of 
Experts highlighted recent developments in high-throughput 
sequencing and bioinformatics, and their potential benefits 
to the Convention. The author noted the application of these 
technologies for the detection of covert illegitimate release 
by helping to identify anomalies in antibiotic resistance, 
mutational bias, geographic distribution of genetic group, 
transmission routes, outbreak intensity and dynamics, and 
clinical manifestations.
140  In June 2012, Sampath et al reported a methodology for 
combining PCR approaches with Electrospray-Ionization 
Mass Spectrometry to be able to identify agents of concern, 
differentially from their close relatives.
141  Biodefence specific PCR applications include those offered 
by BioFire Defense, which according to their own promotional 
material “develops, manufactures, and sells the fastest, 
highest-quality machines in the world for real-time detection of 
pathogens and emerging infection diseases. This technology 
including DNA amplification, real-time thermocycling and Hi-Res 
Melting. Our complement of products include the FilmArray and 
RAZOR EX instruments along with our Hi-Res Melting dyes and 
kits and our expanding line of freeze-dried reagents and DNA/
RNA purification kits”.
142  In March 2012, Rodriguez-Lorenzo et al reported developing 
a biosensor for prostate cancer biomarkers over ten times 
more sensitive than those produced previously. The new 
device, which can be used in whole serum, makes used of 
nanoparticles as part of a novel signal-generation mechanism 
that induces a signal that is larger when the target molecule is 
less concentrated.
143  In March 2014, Grilli et al reported using nano-dispensing for 
the active accumulation of very diluted biomolecules, enabling 
easy detection below the fentomolar range. The authors 
demonstrated being able to detect oligonucleotides down 
to a few hundreds of attomoles. They used the approach to 
provide a 60-fold sensitivity improvement of traditional ELISA 
techniques. The authors envisage developing the approach ‘for 
sensing molecules at very low concentrations, in environmental 
as well as in diagnostics applications’.
144  In May 2015, Danino et al reported hacving designed and 
built programmable probiotics for detection of cancer in urine. 
Harmless E. coli were engineered to carry and enzyme which 
would break down a specific molecule when it was present. 
The E. coli were then fed to mice where they moved to the 
liver and began to reside in any liver cancers. When fed the 
molecule in question, the modified E.coli broke it down into 
other compounds, one of which emits light. That compound 
makes the urine glow. The strength of the glow is proportional 
to the amount of bacteria present, which in turn correlates to 
the amount of cancerous tissue present.
145  An April 2012 review of nanotechnology applications in 
diagnostics highlighted benefits for simplifying sample 
preparation, the size of equipment and the speed at which 
results can be generated. The authors highlighted their use as 
“bioreceptors and transducers in the diagnosis of infectious 
diseases in diverse settings” as well as progress in integrating 
nanomaterials in new approaches, such as surface plasmon 
spectroscopy, amperometry and magnetic relaxation.
146   In August 2012, Krivitsky et al reported using nanowires for on-
chip filtering, separation and concentration of blood samples, 
removing the need for desalination and centrifugation steps in 
sample preparation.
147   An August 2013 presentation by Poland at the BWC Meeting 
of Experts highlighted the development of biosensors for 
Bacillus anthacis. The author notes that the sensor can 
quantify the concentration of the bacteria as well as detect its 
presence. 
148  In December 2013, Gracie et al reported ‘a new quantitative 
assay for detection of three pathogens that result in bacterial 
meningitis using a combination of lambda exonuclease… and 
surface enhanced Raman scattering’. The authors demonstrated 
‘three meningitis pathogens were successfully quantified in a 
multiplexed test with calculated limits of detection in the pico-
molar range, eliminating the need for time consuming culture 
based methods that are currently used for analysis’.
149 A February 2013 review of the impact of scientific developments 
on the Chemical Weapons Convention highlighted ‘the 
combination of sensors with mobile applications and databases 
(e.g. accessible from a smart phone) may become a powerful 
method for rapid interpretation of results and access to 
information on targeted methods of treatment’.
150  In January 2012, Prindle et al reported having engineered ‘the 
synchronization of thousands of oscillating colony ‘biopixels’ 
over centimetre-length scales through the use of synergistic 
intercellular coupling involving quorum sensing within a 
colony and gas-phase redox signaling between colonies’. The 
authors noted that ‘given the repertoire of sensing capabilities 
of bacteria such as Escherichia coli, the ability to coordinate 
their behavior over large length scales sets the stage for the 
construction of low cost genetic biosensors that are capable of 
detecting heavy metals and pathogens in the field’.
151  In January 2013, Handy et al reported the discovery of a DNA 
aptamer that targets Saxitoxin. The authors used a surface 
plasmon resonance sensor to demonstrate concentration-
dependent and selective binding.
152  In March 2013, Meneeley et al reported having developed 
‘a rapid, sensitive, portable and easy-to-use assay’ using an 
innovative planar waveguide device to detect paralytic shellfish 
toxins in marine algae.
153  In July 2013, Anderson et al reported having developed an 
antibody–quantum dot conjugate for Ricin detection. The 
authors used fluoroimmunoassays and surface plasmon 
resonance assays for the sensitive detection of Ricin.
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154  In April 2011, Prikutsky et al reported using the functional 
changes of phagocytes during an infection to be able to 
distinguish between bacterial and viral infections. The authors 
used a chemiluminescent by-product reaction and data mining 
algorithms to develop classification models for differentiation. 
The best model demonstrated 88.9% accuracy in differentiating 
between viral and bacterial infections in a test involving actual 
clinical samples. Such a test could help ensure that appropriate 
therapeutics are used, helping to reduce the use of antibiotics. 
The authors highlight the potential for developing the approach 
into a point-of-care test. There have been subsequent 
developments towards such a point-of-care test, for example, 
In June 2013, Syed et al reported using nanoparticles to be 
able to significantly reduce the physical space needed for 
chemiluminescent studies, which ‘may be readily adapted for 
developing various miniaturized multiplex biosensors for rapid 
chemical/biochemical analyses’.
155   A July 2012 presentation by Japan to the BWC Meeting 
of Experts highlighted the dual use potential of recent 
developments, including nanobiology ‘enabling detection of 
disease-causing or toxic agent(s) via nanobiosensors’.
156   A July 2012 working paper by Australia for the BWC Meeting 
of Experts highlighted ‘convergence of chemistry and biology 
(and related aspects of nanotechnology) for the BWC, 
including developments in detection of pathogens and toxins 
(biosensors), medical countermeasures, decontamination, and 
laboratory analysis and identification techniques, including 
bioforensics. However, it is also recognised that these 
developments could potentially be misused, including an 
increased potential for misuse of toxins and bioregulators for 
hostile purposes’.
157   An August 2013 review of artificial spores highlighted that 
‘robust cell-in-shell structures have displayed unprecedented 
characteristics, which include the retardation of cell division and 
extensive cytoprotective capabilities that encompass exposure 
to osmotic pressure, shear force, heat, UV radiation, and lytic 
enzymes. Additionally, the nanothin shells act as highly versatile 
scaffolds for chemical functionalization to equip cells for 
implementation in tissue engineering, biosensors, cell therapy, 
or other biotechnological applications’.
158   A June 2014 review of the implications of the convergence 
of biology and chemistry highlighted ‘nanoparticles are also 
finding applications in sensor and detection technologies’. The 
authors noted ‘recent trends… towards miniaturised disposable 
devices, many constructed with nanosized materials for 
transduction, and as a support for the sensing element’.
159   In June 2013, Lu et al reported the potential to use synthetic 
biology to develop bacteriophage-based ‘near-real-time 
microbial diagnostics… for food, clinical, industrial, and other 
environmental settings’. These concepts have subsequently 
been commercialised and Sample6 Technologies offers ‘the 
first in-plant, in-shift pathogen detection for listeria, approved 
by the USDA & AOAC’ intended to ‘help shift food safety from 
reaction to prevention’.
160   A March 2013 review of DNA origami highlighted the use of 
DNA nanostructures to create ‘spatially organized enhanced 
enzymic cascades’. These were then used to improve the 
efficiency of bioassays for use in medical diagnostics and 
environmental modeling. The spatial control of enzymic 
cascades is also believed to influence the rate of catalysis,  
with potential to offer benefits for increased yields.
161   In May 2013, Hirtz et al reported an improved way to make 
use of the graphene surfaces used in biosensors. The authors 
replaced the traditional silicon dioxide substrate used to attach 
functional elements with a phospholipid membrane which 
spread more evenly. They also used a different application 
methodology enabling the multiplexing of membranes, allowing 
‘different functionalities in close proximity to each other’.
162   In April 2014, Krejcova et al reported using two different 
cadmium quantum dots for the sub-typing and quantification  
of hemagglutinin.
163  In February 2014, Kotula et al reported having designed and 
built Programmable bacteria detect and record an environmental 
signal in the mammalian gut. The bacteria, a harmless E. coli, had 
two devices added – a bi-stable switch and a memory unit. In the 
presence of a specific antibiotic, an inserted gene transcribed 
which in turn causes a conformational change in the memory 
device, which remains in that state for many cell divisions. The 
authors demonstrated that the sensor and memory system work 
in mice treated with the antibiotic. They then moved the system 
into another E. coli strain naturally found in the guts of mice.
164  In May 2011, Bendall et al reported having ‘used single-cell “mass 
cytometry” to examine healthy human bone marrow, measuring 
34 parameters simultaneously in single cells’. The authors 
monitored the ‘signalling behaviour of cell subsets’ using ‘18 
simultaneous markers of functional signalling states’ whilst the 
system was ‘perturbed by a set of ex vivo stimuli and inhibitors’.
165   In May 2012, Dove et al reported having identified a number of 
protein changes in lung cells infected with H1N1 influenza virus. 
The authors note the potential to detect the protein changes as 
a diagnostic marker.
166   In June 2015, Xu et al reported a method for comprehensive 
analysis of antiviral antibodies in human sera. The authors 
assert that a ‘complete history of viral exposure over a lifetime 
can be deduced from a drop of blood’. They demonstrated the 
approaches effectiveness for determining viral exposure and 
characterizing viral B cell epitopes in high throughput and at high 
resolution. The potential for clinical application has been noted.
167  In December 2012, Kwong et al reported having developed 
a range of synthetic biomarkers for diseases, including liver 
fibrosis and cancer. The biomarkers are comprised of peptides 
joined to nanoparticles, capable and are detectable in urine 
using multiplexed mass spectrometry. They used their approach 
to detect relevant conditions in a mouse model and reported 
effective monitoring “without the need for invasive core 
biopsies” and improved early detection when compared with 
current clinically used blood biomarkers. 
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168 In March 2014, Warren et al reported having “designed 
nanoscale agents that are administered to reveal the presence of 
diseased tissues by producing a biomarker in the urine that can 
be detected using paper strips similar to a home pregnancy test”. 
The authors demonstrated in a mouse model that it is possible 
to “detect diseases as diverse as solid cancer and blood clots 
using only a single injection of our diagnostic followed by urine 
analysis on paper”. They noted such approaches do “not require 
expensive instruments, invasive procedures, or trained medical 
personnel, and may allow low-cost diagnosis of diseases at the 
point-of-care in resource-limited settings”.
169  In October 2014, Warren et al reported built upon earlier 
work to produce nanoparticle-based biomarkers for non-
communicable diseases which can be detected in urine. The 
authors reported the development of novel detection assays 
enabling the diagnosis of a new disease.
170  In October 2011, Tran et al reported a top-down approach to 
identifying gene products in human cells. The authors used 
‘a new four-dimensional separation system, identification of 
1,043 gene products from human cells that are dispersed into 
more than 3,000 protein species created by post-translational 
modification (PTM), RNA splicing and proteolysis’. The authors 
noted a ‘greater than 20-fold increases in both separation 
power and proteome coverage, enabling the identification of 
proteins up to 105 kDa and those with up to 11 transmembrane 
helices’. The asserted that this ‘technology promises to improve 
the link between proteomics data and complex phenotypes in 
basic biology and disease research’.
171  In January 2013 two papers were published detailing preclinical 
genetic signatures for different human infections. Woods et al 
reported a gene signature for H1N1 influenza present in 94% of 
infected cases, detectable as soon as 29 hours post infection 
and reaching maximal accuracy after 43 hours. The authors 
reported using the approach to be able to distinguish patients 
in an Emergency Department infected with H1N1 influenza with 
92% accuracy. Ahn et al reported using the gene expression 
associated with host inflammatory responses to differentiate 
between S. aureus and E. coli infections in humans and mice.
172  A 2013 review of nanotechnology applications in public 
health highlighted approaches for improved measuring and 
perturbing of living systems. The authors concluded that 
nanotechnology can be used to characterize single molecules 
or cells at extraordinarily high throughput and deliver 
therapeutic payloads to specific locations as well as “to exhibit 
dynamic biomimetic behavior”. Resulting tools had produced 
improvements in understanding disease, especially in terms of 
systems biology, as well as novel therapeutic strategies.
173  An April 2013 review of clinical applications of molecular 
diagnostics examined genetic testing to identify clinical 
conditions and to influence the treatment course. The authors 
highlighted clinical testing by sequencing the coding regions 
of the genome but noted the scale of bioinformatic analysis 
required. The authors also addressed testing for genetic 
components that influence drug metabolism or interaction of a 
drug with its cellular target.
174  An August 2013 working paper submitted by South Africa to the 
BWC Meeting of Experts highlighted a number of developments 
relevant to biomarkers, including:
•	 RNA-seq, using next generation sequencing technology 
which can ‘be conducted without a priori knowledge of 
the transcript’s sequence’ and ‘may be used to determine 
comparative gene expression data’
•	 It is now possible ‘to simultaneously determine the pathogen 
as well as the host’s gene expression profile during 
infection’; and
•	 ‘This technology may be utilised for the early diagnosis  
of exposure to chemical or biological weapons, based 
on the expression patterns of a set of predetermined 
biomarker genes’.
175   In January 2014, Siddle et al reported having used genome-
wide expression profiling revealed that ~40% of miRNAs 
are differentially expressed upon infection Mycobacterium 
tuberculosis. The authors identified two infection-specific 
response expression quantitative trait loci.
176  In September 2013, Zaas et al reported having used a reverse 
transcription polymerase chain reaction (RT-PCR) TaqMan 
low-density array (TLDA) platform to classify respiratory viral 
infection. The authors demonstrated that the host gene 
expression signatures they had developed for H3N2 and H1N1 
influenza infections could be used to classify infections in 102 
individuals presenting at an emergency room. They reported a 
sensitivity of 89% and a specificity of 94%.
177   A November 2013 review of emerging nanotechnology-based 
tools for biology and medicine, highlighted the potential 
to use nanostructure for isolating rare biomarkers from the 
complex and heterogeneous mixtures of proteins. The authors 
note that their ‘high surface areas can be used to capture 
clinically relevant biomarkers through molecular recognition 
processes. The enhanced chemical and physical properties 
can be then be used to detect or isolate these biomarkers’. 
They provide two examples where such approaches have 
enabled multiplexed readout of up to 12 separate biomarkers 
with high dynamic ranges. The authors also reviewed 
approaches for ‘amplifying the initial signal, increasing 
sensitivity using stable synthetic peptides that do not occur 
biologically (low background), and multiplexing’.
178  A January 2013 review of the use of Matrix-assisted laser 
desorption ionization–time of flight mass spectrometry (MALDI-
TOF MS) for detection of antibiotic resistance mechanisms 
in pathogens. The authors noted “MALDI-TOF MS has been 
successfully applied as an identification procedure in clinical 
microbiology and has been widely used in routine laboratory 
practice because of its economical and diagnostic benefits”. 
Recognising that MALDI-TOF has become a common diagnostic 
tool, the authors examined developments in “the detection of 
antibiotic modifications by degrading enzymes, the detection of 
resistance mechanism determinants through proteomic studies 
of multiresistant bacteria, and the analysis of modifications of 
target sites, such as ribosomal methylation”.
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179  In October 2013, Jeng et al reported using reverse transcription 
PCR and Electrospray ionization mass spectrometry to detect a 
range of relevant pathogens in human respiratory samples in 8 
hours. The authors were detecting Bacillus anthracis, Yersinia 
pestis, Francisella tularensis, Brucella spp., Burkholderia spp., 
and Rickettsia prowazekii. They reported 73.6% specificity and 
81.8% sensitivity for bacterial pathogens, 97.3% specificity and 
93.3% sensitivity for viral pathogens, and 97.8% specificity and 
42.6% sensitivity for fungal pathogens.
180  In January 2015, Filipiak et al reported having used gas 
chromatography-mass spectrometry to detect pathogens in 
the lower respiratory tract of ventilated patients. The authors 
concluded the “study provides proof of the concept that the 
appearance and the concentration profile of pathogen-derived 
metabolites… in the breath of ventilated patients… correlates 
with the presence of a particular pathogen”.
181 A February 2013 review of the impact of scientific 
developments on the Chemical Weapons Convention 
highlighted:
•	 ‘Recently developed ionization methodologies for high-
resolution MS that enable analysis with minimal sample 
preparation. These methods are appropriate for analysis 
of complex compounds at trace concentration levels in 
complex matrices, such as biological samples’; and
•	 ‘Work using matrix-assisted laser desorption ionization-time 
of flight (MALDI-TOF) that uses a so-called “soft” ionization 
method that enables the direct analysis of large biological 
molecules’. 
182  A May/June 2013 review of Matrix-assisted laser desorption 
ionization–time of flight mass spectrometry (MALDI-TOF MS) 
for profiling of bacteria at the strain level highlights that strain 
categorization, strain differentiation, and strain identification 
have been enabled through the use of library-based and 
bioinformatics-enabled approaches. Current challenges are 
also noted including that “library-based approaches can be 
limited by effects of sample preparation and culture conditions 
on reproducibility, whereas bioinformatics-enabled approaches 
are typically limited to bacteria, for which genetic and/or 
proteomic data are available”.
183  In November 2013, Branca et al reported ‘a liquid 
chromatography–mass spectrometry (LC-MS)-based method 
permitting unbiased… genome-wide discovery of protein-
coding loci in higher eukaryotes’. The authors demonstrated 
having ‘probed the six-reading-frame translation of the human 
and mouse genomes and identified 98 and 52 previously 
undiscovered protein-coding loci, respectively. The method 
also enabled deep proteome coverage, identifying 13,078 
human and 10,637 mouse proteins’.
184  An August 2013 working paper submitted by South Africa to  
the BWC Meeting of Experts highlighted:
•	 ‘The miniaturisation of various MS [mass spectrometry] 
instruments and the development of field-amenable MS 
sources (sample introduction and ionisation interfaces’;
•	 ‘Smaller molecules are readily made volatile and analysed by 
gas chromatography mass spectrometry (GC-MS)’;
•	 ‘The advent of electrospray ionisation (ESI) and matrix 
assisted laser desorbtion/ionization (MALDI) ion sources’ 
increased the number and range of biological molecules that 
can be analysed;
•	 ‘Methods of sample introduction (without pre-preparation) 
continue to evolve with the development of techniques such 
as Matrix Assisted Ionisation Vacuum (MAIV) and Desorption 
Electrospray Ionisation (DESI)mass spectrometry’; and
•	 ‘Time of flight (TOF) seems most amenable to biological 
analyses as it is not as limited by analyte molecular weight; 
also, the technology may be made field portable and is 
compatible with ionisation techniques’.
185  In February 2011, Comstock et al reported having combined 
fluorescent microscopy techniques (which ‘allow researchers to 
observe proteins as they conform and move, but often lack the 
spatial range to track the protein’s motion over distance) with 
optical traps (which ‘enable researchers to study a protein’s 
translocation, but not its conformation’).
186  In May 2011, Planchon et al reported having used scanned 
Bessel beams in conjunction with structured illumination 
and/or two-photon excitation for three-dimensional (3D) 
subcellular imaging. The authors used this approach to image 
‘mitochondria, filopodia, membrane ruffles, intracellular vesicles 
and mitotic chromosomes in live cells’.
187 A July 2015 review of ‘frugal science’ highlighted the 
development of cheap, paper based microscopes. The author 
noted that both lower and higher resolution versions had 
been developed and cost $0.5 and $1 respectively. They 
also highlighted the existence of disease specific versions, 
for example for malaria, to aid diagnostics in resource limited 
settings.
188  In February 2013, Ramachandraiah et al reported converting a 
commercial DVD drive into a laser-scanning microscope that 
can analyse blood and perform cellular imaging with one-
micrometre resolution.
189  In February 2012, Iverson et al reported a novel approach 
to reconstructing genomes from fragments captured during 
metagenomic analysis. The authors demonstrated the ability of 
their approach by identifying as-yet uncultured marine group II 
Euryarchaeota from a seawater sample. The authors note that 
this approach ‘can overcome assembly difficulties caused by 
interstrain variation in complex microbial communities, enabling 
inference of ecosystem functions for uncultured members’.
190  In August 2012, Tse et al reported using high-throughput 
sequencing and metagenomics approaches of rectal swabs 
from bats, dogs, cats, and monkeys to identify a previously 
unidentified papillomavirus. An ability to identify previously 
unknown pathogens increases the range of potential 
weapons agents. 
191 An August 2013 working paper submitted by South Africa 
to the BWC Meeting of Experts highlighted that ‘often times, 
the causative agent of disease cannot be determined using 
techniques such as PCR. In these instances a shotgun 
metagenomic approach has led to the identification of novel 
pathogens as well as a number of unknown genetic sequences’.
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192  A July 2012 presentation by Mexico to the BWC Meeting 
of Experts highlighted the use of metagenomics for the 
identification of organisms present in a mixed environmental 
sample. They noted its use in identifying and tracking a 
specific agent. The author provided an example of the use of 
metagenomics approaches to study the cerebrospinal fluid of 
patients with meningoencephalitis.
193  A July 2012 presentation by Sweden to the BWC Meeting of 
Experts highlighted recent developments in high-throughput 
sequencing and bioinformatics, and their potential benefits 
to the Convention. The author noted the application of these 
technologies for bioforensics, including:
•	 Providing background data, such as agent population 
structure data, genotype distribution data, and high-
resolution matching with possible sources; and
•	 Insights into production methods, such as particle 
sizes, associated signatures, geographical origins, and 
intelligence information.
194  In July 2014, Budowle et al reported having developed criteria 
that should be considered for validating high-throughput 
sequencing technologies for use in microbial forensics. 
The authors detail how performance and limitations of 
such platforms, including analytical processes, assays and 
data interpretation, can impact the interpretation of results, 
influencing their reliability for security-related investigations.
195  In July 2012, Inouye et al reported a software tool that enables 
whole genome studies involving bacterial pathogens to 
correlate their results against multi-locus sequence typing 
databases – the former gold standard for genetic identification 
of bacterial species. This backwards compatibility provides 
historical context for ongoing studies.
196  In August 2012, van Boheemen et al reported for a novel 
coronavirus the complete genome sequence, genome 
organization, expression strategy and relationship with known 
viruses. The authors determined that the new virus (ultimately 
responsible for MERS-CoV) was closely related to a bat virus 
but was distant from the causative agent of SARS). Similar 
approaches could help determine the origin and evolutionary 
dynamics of an agent used in a deliberate attack. The authors 
conclude that the results ‘will be vital to rapid advancement of 
both clinical and vital research on this emerging pathogen’.
197  In January 2013, Yap et al reported data on the persistence of 
bacterial genomic DNA following autoclaving. They highlighted 
the potential for fragments of genetic material to be sufficiently 
complete to pose a risk for horizontal gene transfer – for 
bacterial species that come into contact with it to pick it up and 
to develop new properties. The authors highlight the potential 
for virulence genes, environmental persistence, or antibiotic 
resistance characteristics to spread in this manner. The results 
also offer interesting possibilities for downstream sampling 
(either in time or location) of effluent from facilities enabling 
inferences to be made as to what agents are being used, 
what characteristics those agents posses, and what activities 
were being undertaken. Equally, similar techniques might 
offer opportunities to find usable bioforensic data even after 
equipment has been autoclaved.
198  In April 2011, Mak et al reported using real-time reverse–
transcription PCR–based genotyping for rapid and simple 
differentiation of H1N1 influenza reassortants.
199  A July 2012 presentation by Sweden to the BWC Meeting of 
Experts highlighted recent developments in high-throughput 
sequencing and bioinformatics, and their potential benefits 
to the Convention. The author noted the application of these 
technologies for laboratory identification for treatment and 
prophylaxis, including the type of infectious agent, its genus 
and species, antimicrobial resistance, and contagiousness. 
The author also highlighted how these technologies had been 
used during the German E. coli outbreak 2011 and an endemic 
tularaemia outbreak in Sweden, to provide a probable genomic 
history of the outbreak strain.
200 In April 2013, Loman et al reported using culture-independent 
sequence-based metagenomics approaches to investigating 
an outbreak of E. coli. The authors demonstrated that 
metagenomics approaches could be used to identify 
pathogens during an outbreak of diarrheal disease without the 
need to culture the pathogen. They noted ‘challenges include 
improving diagnostic sensitivity, speeding up and simplifying 
workflows, and reducing costs’.
201  In September 2012, Chan et al reported having used whole 
genome sequencing of field isolates of Plasmodium vivax, 
the pathogen responsible for malaria. They demonstrate 
the feasibility of using such approaches to characterise the 
genetic diversity of the parasite and to better understand 
drug resistance, and erythrocyte invasion, all of which has 
been hampered by an inability to culture the pathogen in a 
laboratory. Comprehensive, characterised sequence data could 
potentially enable the synthesis of pathogens impossible or 
difficult to culture from the wild.
202  A January 2013 review of the use of sequencing in the 
management of Staphylococcus aureus infections highlighted 
the importance of whole genome sequencing which ‘could be 
used to predict resistance, assess virulence, and type isolates 
at the highest possible resolution. The results generated could 
be used to guide clinical management and infection control 
practice. Studies using bench-top sequencing machines have 
already demonstrated the feasibility of such approaches’.
203  In August 2013, Albariño et al reported having used whole 
genome sequencing to confirm the causative organisms and 
order of emergence of four viral hemorrhagic fever outbreaks 
in Uganda and the Democratic Republic of the Congo in 2012. 
The authors noted that ‘sequence analyses provided a tool to 
confirm infection and transmission events’.
204  An August 2013 presentation by Poland at the BWC Meeting of 
Experts highlighted the use of pyrosequencing to detect ‘short 
DNA stretches in real-time using biotinylated PCR amplicons’. 
The authors described using this approach to detect virulence 
plasmids associated with Bacillus anthracis ‘in food matrices 
including milk, juice, bottled water, and processed meat’.
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205  A July 2012 presentation by Germany to the BWC Meeting of 
Experts highlighted the use of nucleic acid‐based techniques 
for diagnosis. The authors highlighted DNA Analysis and PCR 
screening of clinical samples, DNA sequencing and synthesis, 
as well as bioinformatics challenges, which the author 
described as ‘the bottleneck of modern approaches’
206  A June 2013 review of data from sequencing highlighted that 
‘DNA sequencing is on the path to becoming an everyday tool 
in life-science research and medicine. Institutions such as the 
Mayo Clinic and the New York Genome Center are beginning 
to sequence patients’ genomes in order to customize care 
according to their genetics’. The authors noted that ‘computing, 
not sequencing, is now the slower and more costly aspect of 
genomics research… Sequencers are improving at a faster 
rate than computers are’. The authors highlighted a number of 
recent efforts to address this challenge, including ‘both better 
algorithms and a renewed focus on such “big data” approaches 
as parallelization, distributed data storage, fault tolerance, and 
economies of scale’. They noted the utility of text compression 
to create algorithms that can better package genomic data and 
cloud computing models for searching through the information’.
207  An August 2013 working paper submitted by the United States 
of America to the BWC Meeting of Experts highlighted ‘High-
throughput DNA sequencing is becoming faster and less 
expensive – and hence more frequently used for identifying 
unknown pathogens, outbreak sources and animal reservoirs. 
Parallel advances in computational biology are accelerating 
the analysis of enormous databases generated by sequencing 
technologies’.
208  In September 2013, Li and Chen reported having used 
sequence information to develop a ‘hypothesis of the 
evolutionary history of Ebola virus’.
209  In June 2014, Naccache et al reported a novel bioinformatics 
platform that overcomes the ‘challenge of analyzing results 
accurately and in a clinically relevant timeframe’ for the use of 
genome sequencing. The authors demonstrated ‘In fast mode, 
SURPI detects viruses and bacteria by scanning data sets of 
7 – 500 million reads in 11 min to 5 h, while in comprehensive 
mode, all known microorganisms are identified, followed by de 
novo assembly and protein homology searches for divergent 
viruses in 50 min to 16 h.’.
210  A November 2013 review of emerging nanotechnology-based 
tools for biology and medicine, highlighted the potential to 
use nanopores to split and sequence DNA. The authors noted 
the challenges of achieving ‘single-base-pair resolution due 
to the stochastic motion of DNA as well as the measurement 
sensitivity at fast translocation speeds’.
211 In August 2011, Deng et al reported having used pyrosequencing 
for the rapid detection and sub-typing of human influenza a 
viruses and reassortants. The authors reported ‘all eight gene 
segments of 57 laboratory isolates and 17 original specimens of 
seasonal H1N1, H3N2 and 2009 H1N1 pandemic viruses were 
correctly matched with their corresponding subtypes. In addition, 
this method was shown to be capable of detecting reassortant 
viruses by correctly identifying the source of all 8 gene segments 
from three vaccine production reassortant viruses and three 
H1N2 viruses’.
212  A July 2012 presentation by Spain to the BWC Meeting of 
Experts highlighted molecular methods to monitor plant 
rhizobacterial communities. The author noted a number of 
relevant technologies including: PCR as being highly specific and 
cost-effective; microarray hybridisation as useful for continuous 
monitoring at a moderate cost; and genome sequencing as 
comprehensive, being capable of taxonomically analysing all 
rhizobacterial components and estimating biodiversity.
213  A July 2012 working paper by China for the BWC Meeting of 
Experts highlighted ‘revelation of pathogenic microbes’ genome 
evolution and its relation with infectivity and pathogenicity and 
greatly enhances the surveillance, diagnosis and therapy of 
related infectious diseases. There is no doubt that such DNA 
sequence information can also be used for the modification of 
antigenicity, infectivity, toxicity and drug resistance of traditional 
pathogens, even for the artificial design and synthesis of totally 
new pathogens, which will lead to the failure of traditional 
prevention and treatment of infectious diseases and make 
efficient prevention and control more difficult’.
214  In April 2013, Relman published an overview of the use of 
sequencing in identifying and investigating disease outbreaks. 
He noted that rapid sequencing of the pathogen’s genome 
‘provides a wealth of information about the functional 
potential of the organism’ and that metagonomic sequencing 
(simultaneously sequencing fragments from the full range of 
organisms captured from a particular environment) ‘provides 
insights into the potential activities of a microbial community, 
possible interactions between microbial community members, 
and the nature of their relationships with their environment (e.g. 
a human host)’.
215  An August 2013 working paper submitted by South Africa to 
the BWC Meeting of Experts highlighted that next generation 
sequencing ‘may be utilised to sequence the 16S ribosomal 
RNA gene (16S rRNA) which would give an indication of the 
identity of the members of a mixed bacterial community in a 
sputum sample’.
216  In January 2012, Calvo et al reported having used next-
generation sequencing to diagnoses cases of Infantile 
Mitochondrial Disease. The authors sequenced ‘42 unrelated 
infants with clinical and biochemical evidence of mitochondrial 
oxidative phosphorylation disease’. They showed that ‘23 of 
42 (55%) patients harboured… recessive genes or pathogenic 
mtDNA variants. Firm diagnoses were enabled in 10 patients 
(24%) who had mutations in genes previously linked to disease. 
Thirteen patients (31%) had mutations in nuclear genes not 
previously linked to disease. The pathogenicity of two such 
genes, NDUFB3 and AGK, was supported by complementation 
studies and evidence from multiple patients, respectively’.
217  In December 2014, Muniraju et al reported the use of whole and 
partial genome sequencing to produce a phylogentypic map 
of all 4 strains of peste des petits ruminants virus. The authors 
use the data to investigate evolutionary and epidemiologic 
dynamics of the virus, identifying common ancestors and the 
physical locations where divergence of strains began.
The Biological and Toxin Weapons Convention   74
218  In December 2014, Ward et al reported a phylogenetic analysis 
of a series of Staphylococcus aureus bacteria responsible 
for infections in the United Kingdom. The authors mapped 
traits onto phylogenies, focusing in particular on a specific 
antibiotic resistance factor. Specific human and animal related 
clades were identified and the relationship between livestock 
and hospital transmission explored. The researchers also 
reported significant differences in the gain and loss, as well as 
dynamics of resistance to methicillin and tetracycline related to 
contrasting historical patterns.
219  In a May 2014 review, Spackman noted ‘[c]ompared to serology 
both RT-PCR and sequencing are preferred sub-typing methods 
because of the number of reference reagents which need to 
be prepared for serological methods and results of molecular 
methods are often easier to interpret’.
220  In September 2014, Bacconi et al reported sensitivity and 
selectivity data for an integrated sample preparation, PCR 
platform able to identify a range of pathogens. The authors 
report that the platform can process whole blood samples and 
makes use of PCR followed by electrospray ionization mass 
spectrometry. Whilst less sensitive than culturing the causative 
organisms, the authors conclude that such platforms do have 
“the potential to provide rapid detection and identification of 
organisms responsible for bloodstream infections”.
221  In January 2014, Nhu et al reported on the use of the GenXpert 
PCR-based platform for the clinical diagnosis of and detection 
of a specific antimicrobial resistance factor in Tuberculous 
meningitis during an outbreak in Vietnam. The GenXpert test 
“is a closed-cartridge-based system that is easy to operate by 
minimally trained staff and gives results in approximately 2h”. 
The authors reported high levels of selectivity and sensitivity 
levels comparable to traditional testing methodologies in non-
specialist laboratories but with increased levels of throughput.
222  In September 2015, Liljander et al reported having developed 
a field-applicable test for an important disease in goats. The 
authors used rapid, specific, and sensitive assay employing 
isothermal DNA amplification using recombinase polymerase 
amplification. The platform was powered by a car battery and 
used clinical samples from goats (with minimal processes or 
DNA extraction) to provide a signal output in 15 – 20 minutes. 
The authors noted that existing diagnostic approaches involved 
“cultivation, serological assays, and PCR, are time-consuming 
and require fully equipped stationary laboratories, which make 
them incompatible with testing in the resource-poor settings 
that are most relevant to this disease”.
223  In June 2012, Kumar et al reported A multiplex PCR assay 
for the simultaneous identification of virulent and avirulent 
Bacillus anthracis. 
224  In March 2013, Wu et al reported a multiplex reverse 
transcription-PCR assay for the detection of influenza A 
virus and differentiation of the H1, H3, H5 and H9 subtypes. 
The successfully used the assay for virus identification and 
differentiation in human and avian clinical samples.
225  A May 2015 review of PCR techniques for vaccine development 
highlighted progress in ‘virus quantification to optimize 
conditions in cell culture or in the associated downstream 
purification steps’. The authors describe how Digital droplet 
PCR separates and isolate single molecules which are then 
amplified. ‘The droplet’s fluorescent intensity depends on 
the presence or absence of the target; as such, positive and 
negative droplets are identified, which allows for absolute 
quantification of the viral genomes’. The authors assert that 
such an approach offers advantages:
•	 Negating need for a standard;
•	 The extracted RNA does not need to be purified from the 
reagents needed to lyse the virus;
•	 Viral associated RNA released by infected cells can be 
measured directly; and
•	 Potential for duplexing with a second assay that measures 
host cell DNA concentration.
226  In September 2012, Chiapponi et al reported developing a 
Multiplex RT-PCR assay for differentiating European swine 
influenza virus subtypes H1N1, H1N2 and H3N2. The authors 
demonstrated 100% specificity for isolated viruses, and 89% 
specificity from samples where no viral isolation had been 
attempted. They used the test to ‘identify mixed viral infections 
and the circulation of a reassortant strain before performing 
genomic studies’.
227  An August 2013 working paper submitted by South Africa to the 
BWC Meeting of Experts highlighted:
•	 ‘An array-based real-time PCR system that combines sample 
preparation, PCR amplification and data analysis onto a 
single instrument with very little user involvement’;
•	 ‘Loop mediated isothermal amplification (LAMP) technology’ 
for DNA extraction and amplification for detection of agents;
•	 An isothermal-based ‘system that does not require electricity 
(socket or battery) to perform Clostridium difficile diagnostics 
in extremely resource limited settings’.
228  An August 2013 working paper submitted by the United 
States of America to the BWC Meeting of Experts highlighted 
‘Recent advances in molecular assays include the application 
of “isothermal amplification” of nucleic acids; these assays 
can be performed without thermal cycling equipment while 
providing essentially the same information as more expensive 
polymerase chain reaction (PCR) testing’.
229  An August 2013 working paper submitted by the United States 
of America to the BWC Meeting of Experts highlighted ‘For 
some infectious diseases, generally inexpensive POC [point-
of-care] devices are available that can increase the speed and 
accuracy of diagnosis…. Recent advances in technology benefit 
diagnosis… at POC… by providing more rapid identification and 
more precise information about known and, in some cases, 
newly emerged pathogens’. The authors identified a ‘trend in 
recent years… to make sophisticated tests, or assays, more 
easily performed with less training, leading to decentralization 
and diagnosis closer to the POC’.
230  A May 2015 review of point-of-care diagnostics noted:
•	 There is worldwide interest in developing point-of-care 
diagnostics, with 110 developing products in every region of 
the world.
•	 The market is highly granular, and different disease classes 
have different, characters and make different contributions. 
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•	 They are particularly useful in combating high-impact 
disease where rapid diagnostics and treatment is critical.
•	 Their primary use is in dealing with infectious disease (70% 
of point-of-care marketplace). 
•	 Applications have been found for anthrax, ricin and bio-
warfare agents and whilst the amount of products available 
is increasing, point-of-care diagnostics associated with these 
diseases still represent only a fraction of the market. 
•	 The use of point-of-care diagnostics for optimization of drugs 
and medication is an emerging theme. 
•	 PCR amplification is increasingly common in point-of-care 
diagnostics. 
•	 A wide range of specific biomakers are ‘an almost 
unexplored space’ and that only a few genetic markers 
with known relevance for diagnostics and therapeutics are 
referenced regularly suggesting that with a few exceptions 
this was ‘still virgin territory, vis-à-vis molecular biomarkers’.
231  In November 2014, Pardee et al reported having developed 
paper-based synthetic gene networks. The authors freeze 
dried commercially available cell-free systems onto paper and 
demonstrated an ability to integrate small-molecule and RNA 
actuation of genetic switches, rapid prototyping of complex gene 
circuits, and programmable in vitro diagnostics. They envisage 
“inexpensive, sterile, and abiotic distribution of synthetic-
biology-based technologies for the clinic, global health, industry, 
research, and education”. The authors described having built 
paper-based genetic circuits with “colorimetric outputs for 
detection by eye” for use in the field and fabricated “a low-cost, 
electronic optical interface”. They constructed glucose sensors 
and strain-specific Ebola virus sensors.
232  Commercial point-of-care devices have begun to be integrated 
with smart phones. For example the ApolloDX, according to 
their own promotional material, uses the such devices for 
processing power and connectivity to “provide laboratory-
quality test results in 10 minutes or less, expediting diagnosis 
and treatment for patients”.
233  In May 2012, Japanese researchers reported having produced 
a rapid, point-of-care test for all strains of H5N1 influenza, 
significantly improving the range of in field detection. In 
June 2013, researchers from the same institution reported 
developing ‘a biochip that can identify 13 different major tropical 
diseases—including dengue fever, chikungunya, hand, foot and 
mouth disease, and malaria—from a single blood sample’.
234  An August 2013 working paper submitted by South Africa to the 
BWC Meeting of Experts highlighted:
•	 ‘Various advances have been made in the fields of 
microfluidics and nanotechnology which may aid the point-
of-care diagnosis of TB and other diseases. A variety of 
mechanical, biochemical and electrical detection methods 
are in development for the detection of this organism’;
•	 ‘Mass/Piezoelectric detectors’ which can detect pathogens 
in real time’;
•	 Field portable versions of classical ELISA (Enzyme Linked 
Immunosorbancy Assay) using lateral flow chromatography;
•	 ‘An array-based real-time PCR system that combines sample 
preparation, PCR amplification and data analysis onto a 
single instrument with very little user involvement’;
•	 ‘Loop mediated isothermal amplification (LAMP) technology’ 
for DNA extraction and amplification for detection of agents;
•	 An isothermal-based ‘system that does not require electricity 
(socket or battery) to perform Clostridium difficile diagnostics 
in extremely resource limited settings’.
235 In August 2015, Cabibbe et al reported efficacy data for the 
use of an integrated lab-on-a-chip platform for the diagnosis 
of a multi-drug resistant pathogen. The authors reported 
high specificity and sensitivity and almost 98% efficacy when 
compared to whole genome sequencing but with significant 
time savings. The authors concluded that lab-on-a-chip 
platforms are “promising tools to fill the diagnostic gap in 
low-income countries: they integrate many of the laboratory 
components on a small chip, thus reducing infrastructure and 
technical requirements but preserving analytical capabilities”. 
The authors also noted benefits in terms of “operating speed, 
ease of modification (addition/removal of probes), the ability to 
perform multiplex tests and to scale-down costs”. (to add to C(v)
Distributed diagnostics.
236  A May 2011 review of the advances in microfluidics to point 
lab-on-a-chip technologies highlighted ‘a large number of 
publications and patents of microfluidic devices functioning as 
pumps, mixers, concentrators, and valves, which are the building 
blocks for creating functional bioreactors and lab-on-a-chip 
systems’. The noted recent progress in: capillary driven and 
paper-based microfluidics; multilayer soft lithography; multiphase 
microfluidics; electrowetting-on-dielectric driven droplet 
microfluidics; electrokinetics; and centrifugal microfluidics.
237  A January 2013 review highlighted the development of bio-
based polymer beads use in point-of-care and lateral flow 
devices. The author reports that these beads are cheaper to 
produce, more environmentally friendly, and multi-functional – 
capable of attaching multiple proteins onto a single bead. The 
company has since expanded its product range to use biobeads 
for antigen and vaccine delivery, biocatalysis, bioseparation, and 
diagnostics. A spin off company is ‘intended to commercialize 
it core bionanoparticle technology for cancer therapeutics and 
autoimune diseases’.
238  A November 2013 review of emerging nanotechnology-based 
tools for biology and medicine, highlighted the potential of 
integrating nanomaterials and microfluidics for application 
in point-of-care diagnostics and implantable monitoring 
devices. The authors noted that ‘microfluidic technologies with 
integrated sensors for processing bodily fluids such as blood or 
saliva can be manufactured very reliably in a high-throughput 
format and also are very robust’.
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239  An August 2013 working paper submitted by the United States 
of America to the BWC Meeting of Experts highlighted ‘more 
advanced (and likely more expensive) diagnostic tests may 
require specialized equipment, resources and laboratories 
(e.g. reference laboratories) but can provide more detailed 
information about pathogens. Recent advances in technology 
benefit diagnosis… by providing more rapid identification 
and more precise information about known and, in some 
cases, newly emerged pathogens’. The authors note a trend 
towards the ‘consolidation of testing in larger labs, driven 
by economies of scale, availability of expertise, and the 
development of newer diagnostic approaches that have 
substantial complexity and costs’.
240  In April 2013, Zhang et al published a review of strengths 
and weaknesses of disease surveillance and notification 
systems in light of the 2009 H1N1 influenza outbreak. Their 
review concludes that ‘investments in global surveillance and 
notification systems made an important difference in the 2009 
H1N1 pandemic. In particular, enhanced laboratory capacity… 
led to earlier detection and characterization of the 2009 H1N1… 
In addition, improved global notification systems contributed 
by helping health officials understand the relevance and 
importance of their own information’.
241  A June 2014 review of the implications of the convergence 
of biology and chemistry highlighted ‘the natural metabolic 
pathways have been published for the production of Saxitoxin, 
ricin and many other toxins. In vitro biosynthesis of Ricin and 
Saxitoxin has been described’. The authors noted ‘at present, 
obtaining ricin, and the small quantities of Saxitoxin required 
for permitted purposes… from their natural sources is simpler 
than employing metabolic engineering strategies. It was 
however noted that as enabling technologies become less 
expensive, more efficient, and more available, this assessment 
may need revising’.
242  In October 2011 Negredo et al described the discovery of a 
new filovirus responsible for bat deaths in Spain. Previously, 
filoviruses, which cause diseases such as Ebola Virus Disease 
and Marburg disease, had been believe to be confined 
sub-Saharan Africa. This paper demonstrates that pathogens 
relevant to the BWC might be found in a wider range of 
environments than previously thought.
243  In August 2012, Snitkin et al reported using Whole Genome 
Sequencing to track a hospital outbreak of multi-drug 
resistant pathogen in real time. Having integrated genomics 
approaches with epidemiological analysis, the authors 
were able to trace the origins of the outbreak, to identify 
unexpected transmission routes and to provide possible 
explanations for these transmissions. The concluded that such 
approaches offer important ‘actionable insights and facilitate 
the control’ of infections.
244  In April 2014, Wagner et al reported have compiled draft 
genomes from individuals to have died from Yersinia pestis 
during the first recorded plague pandemic, the Plague of 
Justinian (6 – 8th centuries). The authors used phylogenic 
analysis to demonstrate that the responsible Y. pestis strain 
represented a novel branch which ‘has no known contemporary 
representatives, and thus is either extinct or unsampled in wild 
rodent reservoirs’. 
245  In January 2013, Holden et al reported having used a variety of 
genomics approaches to track the emergence, evolution and 
global spread of methicillin resistant Staphylococcus aureus. 
The report having identified the molecular basis of 99.8% of 
antimicrobial resistance phenotypes and having documented 
the genetic changes associated with adaptation to the hospital 
environment and with increasing drug resistance over time.
246  In October 2011, Bos et al reported ‘a reconstructed ancient 
genome of Yersinia pestis at 30-fold average coverage from 
Black Death victims securely dated to episodes of pestilence-
associated mortality in London, England, 1348 – 1350’. The 
authors connected the sequence data to other known historical 
and contemporary strains. They demonstrated that ‘no unique 
derived positions in the medieval organism, indicating that the 
perceived increased virulence of the disease during the Black 
Death may not have been due to bacterial phenotype. These 
findings support the notion that factors other than microbial 
genetics, such as environment, vector dynamics and host 
susceptibility, should be at the forefront of epidemiological 
discussions regarding emerging Y. pestis infections’.
247  In August 2012, Coombs et al reported using a raft of 
molecular biology techniques to study the genetic relatedness 
of a strain of Staphylococcus aureus isolated throughout 
different parts of Australia over an extended period. The 
were able to determine that there was very little genetic 
diversity amongst isolates, that core regions of the genome 
are very stable and that the strain independently acquired key 
elements in different physical locations.
248  In August 2015, Carroll et al reported deep sequencing of Ebola 
Virus from 179 patients from the outbreak in West Africa to 
trace the genetic evolution of the virus and the emergence of 
different lineages. The data generated was used for metabolic 
epidemiological analysis. The authors noted such an approach 
“can be used in conjunction with epidemiological information to 
test retrospectively the effectiveness of control measures, and 
provides an unprecedented window into the evolution of an 
ongoing viral haemorrhagic fever outbreak”.
249  In February 2013, Hay et al published a review evaluating 
‘the state of knowledge of the geographical distribution of all 
infectious diseases of clinical significance to humans’. They 
examined both data availability and methods used in mapping 
processes. They determined that mapping about half the 
relevant diseases was possible but that only 4% has been 
comprehensively mapped. They also identified a number of 
factors hindering such efforts and the importance of embracing 
non-conventional data sources to overcome them. Such 
mapping would provide important normal data facilitating the 
identification of both natural and deliberate disease events.
The Biological and Toxin Weapons Convention   77
250  An August 2013 working paper submitted by South Africa to 
the BWC Meeting of Experts highlighted ‘An isothermal-based 
‘system that does not require electricity (socket or battery) to 
perform Clostridium difficile diagnostics in extremely resource 
limited settings’. The author noted ‘the researchers used a 
solid phase extraction manifold to isolate DNA under vacuum, 
which was created using a standard bicycle pump. Target DNA 
amplification was achieved isothermally on a microfluidic chip 
in a simplified instrument that used commercially available 
“toe warmers” to maintain the reaction temperature over the 
required time period. The chemical reaction produced by the 
“toe warmer” was found to be stable and combine with the 
extraction protocol the method was found to be comparable,  
in sensitivity, to laboratory-based methods’.
251  In August 2012, Köser et al reported on the practical 
considerations of the routine use of whole genome sequencing 
in diagnostic and public health microbiology. The authors 
noted that it was already becoming cost effective compared to 
alternative approaches in a number of areas, including ‘molecular 
epidemiology performed for surveillance and outbreak 
investigation and genotypic antimicrobial susceptibility testing for 
microbes that are difficult to grow’.
252  An August 2013 working paper submitted by the United 
States of America to the BWC Meeting of Experts highlighted 
‘advances in technology have led to an increased speed of 
diagnostic test development using nucleic acid sequence 
information and synthetic biology for manufacturing specific 
antigens or antibodies used in those tests’.
253  In February 2013, researchers at Georgia Tech reported having 
developed a Computational Genomics Pipeline capable of 
analysing sequence data from foodbourne pathogens such as 
E.coli, and ‘provides clues as to which genes are involved in 
making people sick. Manually, this process used to take weeks, 
months or a year. Now it takes us about 24 hours’.
254  In April 2013, Munro et al reported the development of a novel 
cheaper, high-throughput friendly assay to test for certain 
influenza subtypes. The new assay uses Luminex microarray 
hybridization. Its efficacy was tested against traditional reverse 
transcription PCR. The authors demonstrated a sensitivity of 
over 89% on all subtypes tested. Their assay had a comparable 
sensitivity when compared to RT-PCR for about half of the sub-
types but was about 10-fold higher for the others.
255  An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted ‘rapid 
advances in a number of enabling technologies including 
the ‘-omics’, bioinformatics, systems biology and immunology 
have assisted the development of new strategies, allowing the 
identification of new targets and reducing the timescale for 
vaccine development’.
256  A January 2013 review of computational drug repositioning 
highlighted progress in ‘computational techniques for 
systematic analysis of transcriptomics (Connectivity Map, CMap), 
side effects, and genetics (genome-wide association study, 
GWAS) data to generate new hypotheses for’ drug targets.
257 A February 2013 review of the impact of scientific 
developments on the Chemical Weapons Convention 
highlighted:
•	 ‘Research on neuropeptides and bioregulators is providing 
an increased understanding of how these molecules work, 
and advances in synthetic biology enable the possibility of 
large-scale production of toxins, bioregulators, and other 
biologically active molecules that could be used for hostile 
purposes ‘; and 
•	 ‘High-Throughput Toxicological Screening… Chemical 
genomics can either be target-based (often using protein 
binding assays or reporter gene assays) or cell-, organism-, 
or tissue- based (phenotype-based screening). Trends in this 
area include the use of techniques based on robotic systems 
and the use of large, validated single-compound libraries. 
This indicates that the science has moved away from the 
use of combinatorial libraries. In addition, there has been 
a marked decrease in the scale of traditional assays (from 
volumes of ~50 to ~4 μL) with faster throughput’. The authors 
noted ‘methodological changes have had implications for the 
outputs of high-throughput screening. Readouts are providing 
information on a bigger scale, i.e., an understanding of the 
effects on the whole organism is being sought, not just on 
specific molecular targets. A crucial area of research is in 
predictive modeling methods to improve the extrapolation of 
data from in vitro to in vivo (systems pharmocology)’.
258 A June 2014 review of the implications of the convergence 
of biology and chemistry highlighted ‘drug companies have 
screened large numbers of metabolically resistant analogues 
[of peptides], mostly with unnatural (chemical) modifications, 
some of which may have substantially increased potency and 
toxicity. However, such modifications may add to the complexity 
and cost of the end product’.
259 In May 2011, Fleishman et al reported having developed ‘a 
general computational method for designing proteins that 
bind a surface patch of interest on a target macromolecule’. 
The authors used their method to design ‘proteins that bind 
a conserved surface patch on the stem of the influenza 
hemagglutinin (HA) from the 1918 H1N1 pandemic virus’. Two of 
the designed proteins bound to the target with low nanomolar 
affinity and crystal structures of one bound to the target were 
‘nearly identical to that in the computational design model’.
260 In June 2014, Procko et al reported induces apoptosis in cells 
infected with the Epstein-Barr virus using a computationally 
designed inhibitor of a viral bcl-2 protein. Computational design 
and experimental optimization were used to generate a novel 
protein called BINDI that binds the gene that the virus uses to 
block apoptosis with picomolar affinity. The authors note that 
‘high-specificity-designed proteins that selectively kill target 
cells may provide an advantage over the toxic compounds 
used in current generation antibody-drug conjugates’.
261 In March 2012, Tatonetti et al reported having developed a 
data-driven prediction of drug effects and interactions. The 
authors used an adaptive data-driven approach to correct for 
unknown or unmeasured variables combined with existing 
methods to improve analyses of drug effects and drug-drug 
interactions. The authors demonstrated ‘the biological use of 
these new resources… to identify drug targets, predict drug 
indications, and discover drug class interactions. We then 
corroborated 47 (P < 0.0001) of the drug class interactions using 
an independent analysis of electronic medical records’.
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262 A July 2012 presentation by Pitt to the BWC Meeting of Experts 
highlighted a range of advances and technologies in the life 
sciences, including effective protein engineering leading 
to designer proteins and protein binding agents, and ‘New 
detection technologies (e.g. peptide aptamers, SOMAmers, etc.)’.
263 A March 2013 review of bioinformatics approaches to identify 
drug-drug interactions (DDIs) highlighted progress in ‘the 
construction of databases for efficient searching of known DDIs 
to the prediction of novel DDIs based on data from electronic 
medical records, adverse event reports, scientific abstracts, and 
other sources’.
264 In March 2013, Huang et al reported having developed a tool 
for the systematic prediction of pharmacodynamic drug-drug 
interactions (PD DDIs) through protein-protein-interaction 
networks. The authors used the tool to predict 9,626 potential 
PD DDIs at the accuracy of 82%.
265 In December 2013, Guimerà and Sales-Pardo reported 
having developed a network inference algorithm to predict 
uncharacterized drug-drug interactions. The algorithm makes 
use of ‘sets of previously reported interactions, and does 
not require any pharmacological or biochemical information 
about the drugs, their targets or their mechanisms of action’. 
The authors assert this approach ‘can deal with adverse 
interactions, synergistic/antagonistic/suppressing interactions, 
or any other type of drug interaction’. They show that this 
method ‘is able to accurately predict interactions, both in 
exhaustive pairwise interaction data between small sets of 
drugs, and in large-scale databases’. The authors demonstrate 
that the algorithm ‘can be used efficiently to discover 
interactions of new drugs as part of the drug discovery 
process’.
266 In October 2014, Cheng and Zhao reported the application of 
machine learning to identify drug-drug interactions (DDIs). The 
authors demonstrated that ‘machine learning-based integration 
of drug phenotypic, therapeutic, structural, and genomic 
similarities, we demonstrated that HNAI [heterogeneous network-
assisted inference] is promising for uncovering DDIs in drug 
development and post-marketing surveillance’.
267 In March 2015, Jiang et al reported applying Semantic 
Web-based approach for mining severe drug-drug 
interaction-induced adverse drug events (ADEs). The authors 
demonstrated their approach could be used to identify 601 
such adverse events involving three frequently prescribed 
cardiovascular drugs. The authors argue that ‘the approach 
developed could be generalized to detect the signals 
of putative severe ADEs induced by DDIs in other drug 
domains and would be useful for supporting translational and 
pharmacovigilance study of severe ADEs’.
268 A November 2013 review of an automated tool to assist in drug 
discovery highlighted ‘software that read tens of thousands of 
research papers and then predicted new discoveries about the 
workings of a protein that’s key to cancer could herald a faster 
approach to developing new drugs’.
269 In February 2014, Wijma et al reported computationally designed 
libraries for rapid enzyme stabilization. The authors constructed 
‘a library with chemically diverse stabilizing mutations [which] 
allows the engineering of drastically stabilized and fully functional 
variants of the mesostable enzyme limonene epoxide hydrolase’. 
The authors experimentally screened the library and revealed 
21 (pairs of) stabilizing mutations. They then combined ‘10 – 12 
of these confirmed mutations resulted in multi-site mutants with 
an increase in apparent melting temperature from 50 to 85°C, 
enhanced catalytic activity, preserved regioselectivity and a 
>250-fold longer half-life’.
270 A September 2014 review of the integration of big data 
approaches into systems biology and systems pharmacology 
stressed the benefits of combining data that report how 
drugs affect the phenotype of human cell lines, how drugs 
induce changes in gene and protein expression in human cell 
lines, knowledge about human disease, side effects induced 
by drugs, and mouse phenotypes. The authors highlighted 
progress in the application of single-node-type networks, 
gene-set libraries, or multipartite graphs. They argue ‘this 
approach can lead us to the identification of more relationships 
between genes, drugs, and phenotypes as well as benchmark 
computational and experimental methods’.
271 An October 2014 review of the convergence of biology and 
chemistry highlighted:
•	 Using directed evolution ‘to take existing, non-optimal 
enzymes and tailor their properties to drive chemical 
reactions with high selectivity and yield’;
•	 Increasing miniaturization and automation, combined with 
the use of standardised biological parts – for example ‘a 
“toolbox” of sequences that have specific effects (gene 
sequence promoters, tags, terminators, etc.) were identified 
and catalogued to allow for easier sequence development’. 
The authors noted such an approach ‘increases quality 
control, aids in records keeping and project tracking, and has 
increased the rate of sequence development significantly. 
This has also reduced the technical skill level required to 
perform the synthesis’. The authors also highlighted the 
potential to combine this approach with directed evolution;
•	 Progress in developing antibody-drug conjugates for the 
specific delivery of cytotoxic payloads. The authors noted 
that such an approach ‘combines selectivity with toxicity, by 
linking antibodies and cytotoxic molecules together’. The 
authors highlighted a Swiss company which ‘has developed 
both the capacity to produce bulk quantities and the 
specialist skills and experience in both the chemical and 
biotech fields necessary to manufacture’ these compounds;
•	 ‘Using one-step synthesis, it is possible to generate 
nanoparticles coated with arrangements of hydrophobic and 
hydrophilic compounds on a length scale similar to biological 
materials’. The authors noted that ‘these nanoparticles have 
been shown to have the ability to penetrate cell membranes. 
Such nanoparticles could either be designed to carry 
small payloads of highly active drugs (for ex- ample certain 
peptides), or the nanoparticle itself could act as a drug by 
interacting with viruses’.
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272 A January 2012 review of biomedical applications of synthetic 
biology highlighted development for:
•	 Drug discovery, including antibiotics, drugs to 
reverse antibiotic resistance, anti-diabetes drugs, and 
immunosuppressants; and
•	 Cancer therapies, including bacterial synthetic devices, viral 
synthetic devices, and a transformation sensor for cancer 
therapy.
273 A 2012 review of technologies for studying cells highlighted 
“describe bioengineering approaches for controlling and 
measuring cell-environmental interactions in vitro, including 
strategies for high-throughput analysis”. The authors reported 
progress in the “reduction of complex multicomponent 
cellular microenvironments into distinct individual signals”. The 
authors conclude that these tools are enabling a wide range 
of applications, including “in fundamental biological studies, in 
vitro modeling of in vivo processes, and cell-based therapies.
274 In August 2012, Prindle et al reported having successfully 
transitioned gene circuits designed for use in E. coli into 
Salmonella typhimurium which they argue is “a therapeutically 
relevant microbe with attenuated strains that have exhibited 
safety in several human clinical trials”. Such a cassis is intended 
to assist applying synthetic biology approaches in a public 
health setting.
275 A November 2013 review of applying synthetic biology 
approaches to chemical engineering identified a range of 
chemicals being produced using bio-based systems, including: 
1, 4 – butanediol, a high-value chemical used as a solvent 
and in the manufacture of plastics and fibers; and n-butanol, 
commonly used in surface coatings like paints. The authors also 
detailed the Gen9 BioFab platfor, developed for the large-scale 
production of genetic material.
276 In January 2011, Fisher et al reported testing a library of de 
novo designed proteins for biological function in E.coli. The 
authors reported having ‘probed the capacity of proteins from 
this library to function in vivo by testing their abilities to rescue 
27 different knockout strains of Escherichia coli, each deleted 
for a conditionally essential gene’. They identified proteins 
capable of rescuing four of the knockout strain.
277 In December 2011, Miller et al reported high-resolution dose–
response screening using droplet-based microfluidics. The 
authors presented an approach that increased the number of 
data points from 7-10 to approximately 10,000 per compound 
enabling highly precise and reproducible assessments of 
drug efficiency and revealing complex dose–response 
relationships. The authors used their approach to identify 
a number of novel inhibitors for a protein associated with 
diabetes, obesity, and cancer.
278 Online laboratories are beginning to offer remote research 
platforms. For example, Emerald Cloud Lab offers 42 functions 
at present from flow cytometry, through protein extraction to 
transfection. Alternatively, Transcriptic offers a whole of life 
cycle process providing experimental design, automated 
research, and results analysis.
279 A March 2011 review highlighted ‘a chip-based method that 
creates uniformly sized vesicles in assembly-line fashion. Sized 
between 20 and 70 micrometers in diameter, the vesicles are 
large enough to be loaded with DNA and the biochemical 
machinery to act as synthetic cells. The synthetic packaging will 
help researchers study the proteins in cell membranes, which 
play important roles as gatekeepers of the cell. Many drugs, 
for example, act on these membrane proteins or otherwise use 
them to get inside cells in order to do their job’.
280 In September 2012, Alsford et al reported using high-
throughput processes to decode the efficacy and resistance 
of drug used to treat African trypanosomiasis. The authors 
reported using ‘genome-scale RNA interference target 
sequencing (RIT-seq) screens in Trypanosoma brucei, revealing 
the transporters, organelles, enzymes and metabolic pathways 
that function to facilitate antitrypanosomal drug action’. They 
noted ‘advances in our understanding of mechanisms of 
antitrypanosomal drug efficacy and resistance will aid the 
rational design of new therapies and help to combat drug 
resistance, and provide unprecedented molecular insight into 
the mode of action of antitrypanosomal drug’.
281 In December 2013, Molinelli et al reported experimental-
computational technology for inferring network models that 
predict the response of cells to perturbations. The model 
focuses on the use of targeted drugs, singly or in combination, 
to affect cancer cell lines. The affect ‘is quantified in terms 
of relative changes in the measured levels of proteins, 
phospho-proteins and cellular phenotypes such as viability’. 
Computational network models explore the ‘large solution 
space of all possible network models’ using a probabilistic 
algorithm. The authors used their model to identify a previously 
unidentified perturbation that would result in the inhibition 
of a key drug target in a melanoma cell line, which was 
subsequently confirmed experimentally.
282 In October 2014, Platt et al reported generated mouse line with 
endogenous expression of the CAS9 proteins enabling CRISPR 
based genome editing using only guide RNAs. The authors 
demonstrated an ability to edit targets in the brain, vasculature, 
immune cells, and lung. They used the mouse model to 
investigate competition between gain- and loss-of-function 
mutations in lung cancer.
283 A September 2014 review of mRNA-based therapeutics 
describes efforts to utilise In vitro transcribed (IVT) mRNA 
to deliver genetic information. The authors note that ‘such 
synthetic mRNA can be engineered to transiently express 
proteins by structurally resembling natural mRNA’. Those 
proteins can be used to combat infectious disease and several 
clinical applications are under development. The authors 
also describe efforts for the ‘in vivo delivery of IVT mRNA to 
replace or supplement proteins, IVT mRNA-based generation 
of pluripotent stem cells and genome engineering using IVT 
mRNA-encoded designer nucleases’.
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284 In August 2011, Saeidi et al reported having engineering 
microbes to sense and eradicate Pseudomonas aeruginosa. The 
authors reported ‘the development of a synthetic genetic system, 
which comprises quorum sensing, killing, and lysing devices, 
that enables Escherichia coli to sense and kill a pathogenic… 
strain through the production and release of pyocin. They 
demonstrated that the introduction of their engineered organism 
led to a 99% decrease in the pathogen and that it ‘inhibited the 
formation of P. aeruginosa biofilm by close to 90%, leading to 
much sparser and thinner biofilm matrices’.
285 A January 2012 review of biomedical applications of synthetic 
biology highlighted development for:
•	 Novel treatments for infection, including ‘breaking bacterial 
resistance by designer phages’, and engineered probiotic 
bacteria to decrease pathogen virulence; and 
•	 Other tools for biomedicine, including RNA controllers of 
cell proliferation, Optogenetic devices in blood glucose 
homeostasis, prosthetic networks, and an artificial 
insemination device.
286 An October 2014 review of the convergence of biology and 
chemistry highlighted:
•	 Research to use CRISPR/CAS9 gene editing technologies 
to treat disease. The authors noted ‘experiments on 
monkeys inactivating the genes for two human diseases, 
which poses the question of potential applications in 
humans’;
•	 ‘Using one-step synthesis, it is possible to generate 
nanoparticles coated with arrangements of hydrophobic 
and hydrophilic compounds on a length scale similar 
to biological materials’. The authors noted that ‘these 
nanoparticles have been shown to have the ability to 
penetrate cell membranes. Such nanoparticles could either 
be designed to carry small payloads of highly active drugs 
(for ex- ample certain peptides), or the nanoparticle itself 
could act as a drug by interacting with viruses’;
•	 ‘Advanced computational methods and directed evolution 
are used to develop enzymes tailored to address a specific 
industrial need… Given recent advances, it is now possible 
to take advantage of the tools of nature and those of 
molecular modelling to take existing, non-optimal enzymes 
and tailor their properties to drive chemical reactions with 
high selectivity and yield’. The authors noted that ‘this work 
may be useful is in treatment or deactivation of harmful 
materials either in vivo or as part of decontamination’.
287 In July 2015, Schumann et al reported a significant step towards 
the clinical application of CRISPR/CAS9 genome editing. The 
authors reported having developed ‘a programmable tool to 
replace specific nucleotide sequences in the genome of mature 
immune cells’. They noted such an approach ‘holds great 
promise for cancer immunotherapies and cell-based therapies 
for HIV, primary immune deficiencies, and autoimmune diseases’.
288 In June 2015, Ramanan et al reported a novel therapeutic 
approach using genome editing tools to directly cleave viral 
DNA, thereby promoting viral clearance. The authors used a 
CRISPR/Cas9 system to specifically target Chronic hepatitis 
B virus, demonstrating “cleavage of cccDNA by Cas9 and a 
dramatic reduction in both cccDNA and other parameters of 
viral gene expression and replication”.
289 In August 2014, Thi et al reported having used a lipid-
encapsulated siRNA to treat non-human primates infected with 
Marburg virus. The authors demonstrated that post infection 
treatment of the drug from 30 minutes to three days after 
infection resulted in 100% survival of the monkeys, whilst all 
those untreated, or treated with a control died between 7 and 9 
days after infection.
290 A February 2015 review of the in vivo challenges of RNAi 
therapeutics highlighted issues around the specific, efficient 
and targeted delivery of siRNAs. The authors noted ‘anatomical 
barriers, drug stability and availability, immunoreactivity 
and existence of various delivery routes, different genetic 
backgrounds are major clinical challenges’.
291 An April 2012 review of therapeutic applications of siRNA 
highlighted progress in addressing such challenges as 
‘stability, potency, off-target effects, and efficient delivery of 
synthetic siRNAs’. The authors noted a number of therapeutics 
currently in development, including a number in Phase I and 
Phase II clinical trials.
292 An August 2011 review of monoclonal antibody therapies against 
Anthrax highlighted progress in developing antibodies ‘to each 
of the virulence components: protective antigen (PA), lethal factor 
(LF) and oedema factor (EF), and the capsule of B. anthracis’.
293 In September 2014, Kammanadiminti et al reported that 
a combined therapy consisting of antibiotics and anthrax 
immune globulin intravenous is potentially more effective than 
antibiotics alone in rabbit model of inhalational anthrax. The 
authors demonstrated that whilst the combination therapy had 
little impact when treatment occurred 60 hours after exposure, 
more animals survived when treatment was delayed.
294 In March 2015, the US Federal Drug Administration ‘approved 
Anthrasil, Anthrax Immune Globulin Intravenous (Human), to 
treat patients with inhalational anthrax in combination with 
appropriate antibacterial drugs’.
295 In August 2013, Pettitt et al reported the successful use of a 
monoclonal antibody cocktail to treat non-human primates 
exposed to Ebola virus. The treatment led to a 43% survival 
rate, rather than a standard 0% for the viral challenge.
296 In March 2014, Krammer et al reported the results of an 
assessment of influenza virus hemagglutinin stalk-based 
immunity in ferrets. The authors demonstrated the efficacy of 
a pan-H1-reactive monoclonal antibody against a pandemic 
H1N1 challenge virus in the ferret model of influenza disease. 
The authors also reported ‘a universal influenza virus vaccine 
strategy based on chimeric hemagglutinin constructs that 
focuses the immune response on the conserved stalk domain 
of the hemagglutinin’. The demonstrated ‘both strategies 
showed efficacy in reducing viral loads after an influenza virus 
challenge in the ferret model’.
297 In December 2012, the US Federal Drug Administration 
approved the monoclonal antibody-based therapy raxibacumab 
for use to treat inhalational anthrax. It was the first use of the 
animal efficiency rule to approve such a drug.
298 A March 2015 review of Anthrax therapeutics development and 
pipeline highlights monotherapy and combination therapies, as 
well as new entrants to the market and the emerging players. 
The authors identified 33 companies currently developing 
anthrax therapeutics. Collectively they are working on 39 
different products.
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299 In December 2011, Koehler et al reported having developed 
a new approach to identify modified Type I interferons that 
demonstrate elevated, broad-spectrum antiviral activity. Type I 
interferons are ‘released from infected cells bind to a receptor… 
on neighbouring cells, triggering signalling cascades that 
limit further infection’. The authors used ‘gene crossbreeding 
method to generate hybrid, type I human IFNs with enhanced 
antiviral activity against four dissimilar, highly pathogenic 
viruses. Approximately 1400 novel IFN genes were expressed 
in plants, and the resultant IFN proteins were screened for 
antiviral activity’.
300 In September 2011, Côté et al reported having identified a new 
drug target to combat Ebola virus. The authors demonstrated 
that the target, Niemann–Pick C1, was essential for Ebola virus 
entry into cells.
301 In April 2014, Nishizawa et al reported having identified ‘a new 
type of antiprion compound, Gly-9,… found to inhibit abnormal 
prion protein formation in prion-infected neuroblastoma 
cells’ following more than 1 day of treatment. The authors 
demonstrated ‘it reduced the intracellular prion protein level 
and significantly modified mRNA expression levels of genes of 
two types… after more than 2 days of treatment. They noted that 
whilst ‘in vivo efficacy of Gly-9 was limited, the findings for Gly-9 
provide insights into the regulation of abnormal prion protein in 
cells and suggest new targets for antiprion compounds’.
302 In April 2013, Perry et al reported having identified a novel 
drug candidate for the treatment of Dengue virus. The authors 
demonstrated the compound ‘reduced mortality, as well as 
viremia and viral RNA in key tissues, and cytokine storm. In 
addition… treatment can be delayed’.
303 In May 2013, Bian et al reported having established invasive, 
inheritable infections of a strain of Wolbachia bacteria in the 
important malaria mosquito vector, Anopheles stephensi. The 
particular strain of Wolbachia bacteria ‘conferred resistance in the 
mosquito to the human malaria parasite Plasmodium falciparum’.
304 An August 2014 presentation to the BWC Meeting of Experts 
highlighted the potential to use CRISPR/CAS9 gene drives 
to influence the inheritance of genes in sexually reproducing 
animals and plants with short reproduction cycles. The author 
noted implications for: eradication of disease, such as removing 
the ability of mosquitoes to act as vectors for malaria or dengue 
fever; suppression of invasive species; reduction of herbicide 
resistance; and the development of immunization drives and 
reversal drives.
305 An August 2013 review of efforts to develop a tularaemia 
vaccine highlighted progress resulting from ‘a substantial 
increase in knowledge of the pathogenic mechanisms of the 
organism and the induced immune responses’.
306 A June 2014 review of vaccine design technologies highlighted 
both successes and failures and an increasing focus on iterative 
approaches. The authors review ‘novel antigens, adjuvants and 
vectors in the preclinical stage with computational analyses 
of clinical data to accelerate vaccine design’. They conclude 
that ‘reverse and structural vaccinology have revealed novel 
antigen candidates and molecular immunology has led to the 
formulation of promising adjuvants. Gene expression profiles 
and immune parameters in patients, vaccinees and healthy 
controls have formed the basis for biosignatures that will 
provide guidelines for future vaccine design’.
307 A July 2014 review of vaccine design highlighted ‘innovative 
technologies currently used in vaccine research and 
development including adjuvants, vectors, nucleic acid 
vaccines, and structure‐based antigen design’.
308 In December 2013, Lua et al reviewed the application of 
engineering principles to the rational design of virus-like 
particles (VLPs). VLPs attempt to ‘harness the optimally tuned 
immunostimulatory properties of natural viruses while omitting 
the infectious trait’. They have been proven to be safe and 
highly effective in humans. The authors note significant 
progress in being able to ‘specifically engineer a desirable 
immune response through modular VLP design, and those 
that seek to improve bioprocess efficiency through inhibition 
of intracellular assembly to allow optimal use of existing 
purification technologies prior to cell-free VLP assembly’. They 
note that a greater understanding of VLP assembly is required 
but predict that economic drivers and cross-discipline research 
will made significant inroad over the coming decade.
309 A July 2014 review of engineering strategies to construct 
immunogenic live vaccines highlighted progress in ‘the 
adaptation of attenuated strains to create multivalent vaccine 
platforms for immunization against multiple unrelated pathogens. 
These carrier vaccines are engineered to deliver sufficient levels 
of protective antigens to appropriate lymphoid inductive sites to 
elicit both carrier-specific and foreign antigen-specific immunity’. 
The authors stressed ‘that the ultimate success of an engineered 
vaccine rests on achieving the proper balance between 
attenuation and immunogenicity. Achieving this balance will 
avoid over-activation of inflammatory responses, which results in 
unacceptable reactogenicity, but will retain sufficient metabolic 
fitness to enable the live vaccine to reach deep tissue inductive 
sites and trigger protective immunity’.
310 In November 2014, Khurana et al reported ‘that N-terminus β 
sheet domain-swap can be used to produce stable functional 
oligomeric forms of better recombinant HA1 vaccines in simple, 
inexpensive bacterial system for rapid response to emerging 
pandemic threat for the global population’. The authors 
demonstrated that influenza vaccine challenge studies revealed 
better protection of ferrets from lethality, weight loss, and 
reduced viral loads and ‘antibody affinity maturation far superior 
to the inactivated H7N7 subunit vaccine’.
311 In a March 2012 review of progress in developing conjugate 
vaccines, Dro noted that significant progress has been made in 
the application of bio-based design and production. He notes 
that recombinant DNA technologies allows for ‘the controlled 
design and production of glycoproteins with customised 
polysaccaride structure, which will target bacterial pathogens 
that cannot be address with existing chemical processes’. 
The author records three potential advantages of a bio-based 
approach: the versatility of expressing specific polysaccarides 
and protein antigens; the ability to express epitopes in an 
almost native form; and benefits for the consistency of products. 
Dro also notes that using a novel design and production 
platform does pose regulatory challenges in demonstrating 
efficacy and safety.
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312 An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted a number 
of developments in vaccine design, including:
•	 ‘Design of self-assembling influenza nanoparticle vaccines 
that elicit broader and more potent immunity than 
traditional influenza vaccines’;
•	 ‘In research on HIV vaccine design, which utilised 
computational prediction and directed evolution to 
engineer an immunogen that would elicit production of 
broadly neutralising antibodies. A self-assembling virus-like 
nanoparticle was designed and coated with multiple copies 
of the optimised immunogen to achieve better stimulation 
of the antibody response’;
•	 ‘Demonstration of the potential of DNA nanostructures 
to serve as general platforms for the rational design and 
construction of a variety of vaccines’;
•	 ‘Development of a synthetic approach that rapidly generated 
influenza vaccine viruses from sequence data’;
•	 ‘Creation of a synthetic vaccine for foot and mouth disease’;
•	 Completion of Phase I clinical testing of a monoclonal 
antibody to ‘a surface polysaccharide common to a diverse 
range of microbial pathogens, including bacterial, fungal and 
protozoan examples, which could provide a promising target 
for the development of a broad spectrum vaccine’.
313 A January 2012 review of biomedical applications of synthetic 
biology highlighted development for:
•	 Improved vaccines, including for chikungunya virus, 
Staphylococcus aureus and antigen-producing 
immunostimulatory liposomes as genetically programmable 
synthetic vaccines; and
•	 Vector control, including for mosquitoes.
314 In October 2014, Shen et al reported using synthetic biology 
techniques to develop a methodology for synthetic attenuated 
virus engineering. The authors demonstrated that changes to 
the preferential usage of certain underrespresented codons 
and codon pairs to encode amino acids and adjacent amino 
acid pairs can attenuate viruses in both cell culture and mouse 
models, in a tunable fashion. They used this approach to 
produce attenuated polioviruses and influenza viruses, HIV 
retroviruses and the bacterium, Streptococcus pneumonia.
315 In April 2014, Warren et al reported having used a novel broad-
spectrum nucleoside analogue to protect against filovirus 
infections. The compound inhibits infection of distinct filoviruses 
in human cells by inhibits viral RNA polymerase function. The 
authors demonstrated:
•	 ‘Post-exposure intramuscular administration… protects 
against Ebola virus and Marburg virus disease in rodent 
models…;
•	 Completely protects cynomolgus macaques from Marburg 
virus infection when administered as late as 48 hours after 
infection…;
•	 Exhibits broad-spectrum antiviral activity against 
numerous viruses, including bunyaviruses, arenaviruses, 
paramyxoviruses, coronaviruses and flaviviruses’.
316 A February 2015 review of RNA-based viral vectors highlighted 
progress in exploiting ‘the basic replication and expression 
strategies of RNA viruses to produce vaccine antigens that 
have been engineered into their genomes’. The authors note 
that there has been ‘significant preclinical testing of many 
RNA virus vectors against a wide range of pathogens as well 
as cancer targets. Multiple RNA virus vectors have advanced 
through preclinical testing to human clinical evaluation’.
317 In March 2013, Porta et al reported having expressed 
recombinant empty viral capsid, rationally redesigned to negate 
the need for a cold-chain, for use as a vaccine against Foot-
and-Mouth Disease. The authors demonstrated that the capsids 
did confer immunity from the disease when challenged in cattle 
as 34 weeks. They asserted that this ‘approach to vaccine 
antigen production has several potential advantages over 
current technologies by reducing production costs, eliminating 
the risk of infectivity and enhancing the temperature stability of 
the product’. They also noted the potential to use the approach 
to produce vaccines for other pathogenic picornaviruses in 
humans and animals.
318 In November 2014, Rincón et al reported identifying 
electrostatic repulsion inside the capsid of Foot-and-Mouth 
Disease viruses as being responsible for its thermolability. They 
rationally redesigned the capsid to increase thermostability. 
This was intended to facilitate the developments of more 
efficient vaccines but could potentially also be used to produce 
a more environmentally resistant virus.
319 In July 2013, Kanekiyo et al reported having designed and 
built self-assembling influenza nanoparticle vaccines against 
influenza. ‘The viral haemagglutinin was genetically fused to 
ferritin, a protein that naturally forms nanoparticles composed 
of 24 identical polypeptides. Haemagglutinin was inserted 
at the interface of adjacent subunits so that it spontaneously 
assembled and generated eight trimeric viral spikes on its 
surface’. The authors demonstrated that these particles 
‘elicited haemagglutination inhibition antibody titres more 
than tenfold higher than those from the licensed inactivated 
vaccine. Furthermore, it elicited neutralizing antibodies to two 
highly conserved vulnerable haemagglutinin structures that are 
targets of universal vaccines: the stem and the receptor-binding 
site on the head’.
320 In September 2013, Smith et al reported developing a virus like 
particle for use as a vaccine against influenza H7N9 and H7N3. 
The authors demonstrated 100% survival of animals in a vaccine 
challenge study compared to 0% with alternate influenza 
vaccines and placebos. They note ‘the data demonstrate that 
recombinant H7N9 vaccine can be rapidly developed that was 
immunogenic and efficacious supporting testing in man as a 
pandemic influenza H7N9 vaccine candidate’.
321 In July 2014, Zhang et al reported the licensing of a Virus-Like 
Particle as a vaccine against Hepatitis E and related diseases. 
They reported a 50-fold increase in particle production in scale 
up from bench to manufacturing.
322 In June 2014, Ruiz et al reported and compared a number of 
different expression systems in Baculovirus Vectors for creating 
empty Foot-and-Mouth Disease virus capsid for use as vaccines.
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323 In May 2015, Deng et al reported a significant step towards 
a universal vaccine against Influenza A viruses. The authors 
reported fusing a conserved influenza surface protein to a 
major coat protein of filamentous bacteriophage f88. They 
demonstrated that the recombinant virus was replication 
competent and displayed the desired protein. Mice 
immunized with the recombinant virus in the presence of an 
adjuvant were protected against challenge with human and 
avian influenza A viruses.
324 A December 2013 review of promising approaches for short 
term improvements in influenza vaccines highlighted:
•	 ‘Technological advances such as mammalian cell culture 
production and synthetic vaccine seeds provide a means to 
increase the speed and accuracy of targeting new influenza 
strains with mass-produced vaccines by dispensing with 
the need for egg isolation, adaptation, and reassortment of 
vaccine viruses. 
•	 New influenza potency assays that no longer require the 
time-consuming step of generating sheep antisera could 
further speed vaccine release. 
•	 Adjuvants that increase the breadth of the elicited immune 
response and allow dose sparing provide an additional 
means to increase the number of available vaccine doses’.
325 A July 2014 review of the use of adjuvants to enhance the 
efficacy of inactivated influenza vaccines noted that ‘Oil-in-
water adjuvants like MF59 and AS03 have been licensed and 
widely used, and shown efficacious in preventing influenza 
infection in the last pandemic. MF59-adjuvanted inactivated 
vaccine was more efficacious than non-adjuvanted vaccine in 
preventing influenza infection in young children and in reducing 
hospitalization due to the influenza infection in the elderly.’ 
These are the groups in which such vaccines have traditionally 
had suboptimal efficacy.
326 In October 2014, Mulligan et al reported the results of a 
Phase I clinical trial that found ‘point-of-use mixing of H5N1 
antigen and MF59 adjuvant achieved target antibody titers 
in a high percentage of subjects and was safe’. The authors 
demonstrated that the target antibody levels were achieved in 
80% of subjects receiving both the vaccine and the adjuvant, 
compared to only 14% of subjects receiving only the vaccine. 
Neutralizing titers were 2- to 3-fold higher with the adjuvant 
than without and the pairing produced cross-reactive antibody 
responses against 4 H5N1 viruses.
327 A February 2015 review of key milestones in the discovery 
and development of self-amplifying mRNA vaccines and their 
potential to be used as a rapid response platform concluded 
that ‘the prospects for non-viral delivery of self-amplifying 
mRNA vaccines are very promising. Like other types of 
nucleic acid vaccines, these vaccines have the potential to 
draw on the positive attributes of live-attenuated vaccines 
while obviating many potential safety limitations’. The authors 
highlight preclinical proof of concept for vaccine candidates 
against influenza, respiratory syncytial virus, rabies, Ebola, 
cytomegalovirus, human immunodeficiency virus and malaria.
328 In May 2013, Blaney et al reported data on antibody quality 
and protection from lethal Ebola virus challenge in nonhuman 
primates immunized with rabies virus based bivalent vaccine.
329 A March 2012 review of developments in vaccine production 
highlighted:
•	 The use of insect cell line to grow virus like particles – 
proteins that mimic viral structure without any genetic 
material;
•	 The use of disposable equipment, both disposable bags 
inside stainless steel incubators to grow the vaccine and 
disposable parts in the purification system;
•	 The use of human cell lines to produce vaccine, allowing 
continuous vaccine production ‘without having to restart cell 
cultures from scratch every 100 generations’;
•	 Directed evolution to remove reliance on animal serum, 
reducing cost, stabilising ingredient chains, and assisting in 
meeting purification standards;
•	 The use of suspended cultures which reduces the physical 
space required for vaccine production and significantly 
reducing cost by enabling batch processing of verification 
steps, and dramatically increasing surge production capacity.
330 In August 2013, Mignaqui et al reported using transient gene 
expression in serum-free suspension-growing mammalian cells 
for the production empty foot-and-mouth disease viral capsids 
as vaccine candidates. The authors report this approach ‘is 
an easy to perform, scalable and cost-effective technology 
for the production of a recombinant subunit vaccine against 
FMDV’. The same month, Gullberg et al reported a second way 
to produce self-assembly viral capsids using a vaccinia-virus-
based transient expression system. The authors characterised 
the physical structure of the capsids and demonstrated an 
immunological response.
331 In January 2013, the US Federal Drug Administration licensed 
the first recombinant, highly purified, egg-free influenza vaccine. 
It was also the first influenza vaccine grown using insect cells to 
get regulatory approval. The process did not involve growing 
any influenza virus, offering biosafety benefits.
332 A February 2013 review of the impact of scientific developments 
on the Chemical Weapons Convention highlighted:
•	 ‘The production of toxic chemicals, including toxins, through 
biological synthesis (an aspect of the convergence of 
chemistry and biology); encapsulation and delivery through 
nanotechnology; and flow microreactors, which enable 
types of chemical reactions under conditions that were not 
previously technically feasible’;
•	 ‘Microreactors have now entered the chemical production 
toolkit for certain kinds of operations. They alter the 
signature of chemical production infrastructure to some 
extent, although they are only one piece of a sequence of 
infrastructure’. The authors noted the ‘major advantages 
of microreactor technology include the safe production of 
hazardous, corrosive chemicals, as well as certain classes of 
biologically active chemicals, which could not be otherwise 
done under batch conditions’. They also highlighted 
they ‘could shorten the time from the discovery of a new 
class of toxic chemicals to production of selected agents. 
There is also the possibility that other toxic chemicals 
(e.g., pharmaceuticals and peptides) could be produced in 
microreactors for prohibited purposes’. 
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333 A December 2014 review by Lin et al of the use of baculovirus/
insect cell expression systems as production platforms 
for recombinant proteins had been extensively used for 
the production of various vaccine candidates, and several 
commercially-available human and veterinary vaccine products. 
The authors also note that as baculovirus is capable of entering 
a broad range of mammalian cells, it is also a promising gene 
delivery vehicle for in vivo antigen expression and display.
334 A January 2015 review of the security implications of synthetic 
biology highlighted the impact of such developments on the 
production of narcotics. The authors noted ‘the potential for 
synthetic biology to enable, and be enabled by, a distributed 
production capacity could also impact upon the existing supply 
chains for illegal narcotics. For example, an engineered yeast 
capable of producing such narcotics would offer a very different 
footprint to agricultural or chemical production approaches. It 
may even lend itself to relocating production closer to the end 
user, diminishing the need for illicit trafficking of bulk material, 
thereby complicating interdiction’.
335 A May 2015 commentary on the recent publication of missing 
steps in the opinoid metabolic pathway noted ‘yeast-based 
production of opiates could provide an alternative system for 
current criminal networks, particularly in North America and 
Europe, where the drugs are in high demand. Because yeast 
is easy to conceal, grow and transport, criminal syndicates and 
law-enforcement agencies would have difficulty controlling 
the distribution of an opiate-producing yeast strain. All told, 
decentralized and localized production would almost certainly 
reduce the cost and increase the availability of illegal opiates — 
substantially worsening a worldwide problem’.
336 In May 2013, Dormitzer et al reported having used sequencing 
and synthesis to deliver a vaccine candidate to the producer 18 
days faster than a second group using traditional recombinant 
DNA techniques. The authors demonstrated increasing 
the yield of the essential vaccine antigen. They noted that 
‘generation of synthetic vaccine seeds, together with more 
efficient vaccine release assays, would accelerate responses 
to influenza pandemics through a system of instantaneous 
electronic data exchange followed by real-time, geographically 
dispersed vaccine production’.
337 In July 2014, Dormitzer described a synthetic approach to 
influenza vaccine virus generation in which ‘viral sequence data 
from many sources are posted on the Internet, are downloaded 
by vaccine manufacturers, and are used to rescue multiple, 
attenuated vaccine viruses directly on high yielding backbones’. 
The author notes that ‘elements of this system were deployed 
in the response to the 2013 H7N9 influenza outbreak in China. 
The result was the production, clinical testing, and stockpiling 
of an H7N9 vaccine before the second wave of the outbreak 
struck at the end of 2013’.
338 An August 2013 presentation by Sanofi to the BWC Meeting 
of Experts highlighted drug production efforts to scale up and 
produce a semi-synthetic artemisinin. The authors noted the 
steps taken to optimise the strain producing the precursor for 
industrial production, optimise fermentation, and optimization 
of the down stream process. Industrial production was then 
outsourced to a multipurpose facility in Bulgaria. The precursor 
produced by a yeast was then transferred to another facility 
and traditional industrial chemistry was used for the final step of 
the synthesis. The author noted that the industrialisation of this 
product from a functional lab scale was around 4 years.
339 A March 2012 review of developments in vaccine production 
highlighted the use of disposable equipment, both disposable 
bags inside stainless steel incubators to grow the vaccine and 
disposable parts in the purification system.
340 An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted a number 
of developments in vaccine production, including:
•	 ‘Design of self-assembling influenza nanoparticle vaccines 
that elicit broader and more potent immunity than traditional 
influenza vaccines’ using synthetic nanoparticles eliminating 
‘the need to grow potentially dangerous viruses in eggs or 
cell culture, a comparatively costly and time-consuming step 
of commercial vaccine production’;
•	 ‘Single-use or disposable bioreactor systems have also 
progressed; these are easily installed, reduce costs, 
streamline validation, increase product consistency and 
reduce overall turnaround times. Simple rocker bags are 
suited to cell-culture for virus vaccine production as an 
alternative to traditional methods of growth in embryonated 
eggs. Single-use or disposable components also feature 
increasingly in downstream processing equipment’; and
•	 ‘The widening diversity of vaccine production methods 
now include: cell cultures and cell suspension bioreactors; 
recombinant DNA; metabolic engineering and synthetic 
biology; chemical peptide synthesis; and transgenic animals 
and plants’.
341 An April 2014 market report on single use bioreactors 
highlighted:
•	 ‘Single-use bioreactors are already being deployed 
for high-density cell culture applications (monoclonal 
antibodies, recombinant proteins, vaccines etc.); newer 
application areas being researched include stem cells and 
personalised medicine.
•	 17 manufacturers offer around 80-90 models of single-use 
bioreactors with working volumes ranging from as low as few 
millilitres to up to 2000L.
•	 Manufacturing collaborations and acquisitions are 
rapidly changing the landscape; amongst the 50 odd 
partnerships we looked at, around 25% were manufacturing 
collaborations and an additional 25% were mergers / 
acquisitions.
•	 Quite recently, many start-ups have sprung up; examples 
include CerCell, PBS Biotech, Cellexus Limited; these start-
ups have launched single-use bioreactors with innovative 
features and are likely to play an increasingly important role 
in the future.
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•	 The overall industry could grow close to USD 1 billion in a few 
years’ time; however, this will be driven to a certain extent by 
the overall growth of the biopharmaceuticals’ market’.
342 An October 2014 review of the impacts of convergence 
of chemistry and biology (Spiez Convergence Report) 
highlighted that:
•	 ‘Using tools that are already available, including direct 
insertion of gene sequences and directed evolution, 
organisms and molecules can be guided to meet a specific 
purpose within a reasonable timeframe and with a degree 
of reliability that was not previously possible. A number 
of examples were presented and discussed for industrial-
scale production of complex molecules with application in 
medicine and elsewhere’;
•	 ‘Genomics, transcriptomics, proteomics and metabolomics 
together provide a set of tools in synthetic biology that 
can be used to design organisms with desired properties. 
These tools have been applied in three different industrial 
projects: The production of lysine – a feed additive – using 
Corynebacterium glutamicum, production of xanthan – a 
thickener for use in food and personal care products – using 
Xanthomonas campestris pv. campestris, and production of 
acarbose – a medication used to treat type II diabetes – by 
Actinoplanes sp. For each of these projects it was critical 
to obtain information about the cellular machinery, from 
genome to metabolome, in order to rationally approach 
modifying the organism’;
•	 Progress in industrial biology is helping ‘to develop effective, 
scalable and robust processes that convert a renewable 
feedstock such as sugar, using a microorganism such 
as genetically engineered yeast, to a desired chemical 
compound at industrial scale’. The authors noted an example 
where ‘To reduce time and costs, the company automated 
and miniaturised as many repetitive R&D processes as 
possible… Though the infrastructure for automation was 
expensive to develop (~$200 M), the cost per sequence to 
develop has dropped exponentially with the implementation 
of this process, and the rate at which new sequences are 
developed has increased by magnitudes;
•	 ‘The response of the organisms to the environment of a 
fermenter is not predictable, and any new organism must be 
carefully tested to prevent failures at the pilot plant scale. 
The timeline for development of a new product has been 
substantially reduced… However, the cost and time required 
to produce a new viable, scalable method are still high’.
343 A January 2012 review of single-use equipment in industry 
highlighted:
•	 Single-use equipment ‘began with straightforward applications 
like media and buffer containers, tubing, and filters. It has 
taken a while to address the more critical process steps, but 
even such complex operations as tangential flow filtration are 
now available in disposable format’;
•	 The use of single-use equipment is growing – one industry 
study ‘estimates that more than 40% of integrated single-
use systems are now used in GMP manufacturing’. The 
authors noted ‘several large biotech companies employ 
fully disposable processing, including chromatography, for 
smaller, mid-titre, clinical trial manufacturing processes’;
•	 Size is not an issue – ‘working volumes for integrated 
single-use bioprocess containers, systems, and support 
equipment have steadily risen from sub-1,000-L levels  
(50 – 500 L) to the 2,000 L range, with prototypes 
exceeding 5,000 L for some applications’;
•	 Scaling is becoming much less of an issue, for two reasons: 
(a) ‘end-users feel comfortable with “scaling out” through the 
use of multiple 500 L or 2,000 L systems rather than scaling 
up to 5,000 L and higher’; and (b) ‘targeted therapeutics 
and higher titres are causing the slow extinction of mega-
processes. Those that remain increasingly turn to multiple 
1,000 L or 2,000 L disposable bioreactors to mitigate risks 
associated with batch loss’;
•	 Recent progress in improving standardization, including 
‘standardized, off-the-shelf assemblies for cell culture harvest 
and tangential flow filtration, disposable, aseptic, genderless, 
universal connectors, and non-proprietary films and materials 
of construction for its bags, connectors, and tubing’;
•	 Recent progress in addressing mixing in single-use equipment 
– maintaining sterility, avoiding sheer stress and rubbing on 
the container pose distinct challenges in disposable systems. 
The authors noted that at least one company has adopted 
air-based systems for stirring and agitating cells, which ‘offers 
scalability from three litres for lab work, and 80 litres for 
preclinical and clinical batches. In targeting full-scale GMP 
production, the company plans to produce a 500 L system 
later this year, and a 2,500 L bioreactor in 2012’.
344 A November 2011 review of virus safety of biopharmaceuticals 
quoted industry professionals and regulators as recognising 
that “that there is no all-encompassing virus detection method 
and no ‘one-(virus cultivation) medium-for-all’ to be able to 
detect all viral contaminants”. The authors noted that the 
risk profile of viral contamination depends upon a variety of 
factors including: “source of the biological, raw materials used, 
production systems, purification reagents and excipients”. 
They highlighted three approaches to mitigate this risk: “(1) 
prevention of access of virus by screening of starting materials 
(cell banks, tissues, or biological fluids) and raw materials/
supplements used in production processes (culture media, 
serum supplements, transferrin, etc); (2) incorporation of robust 
virus clearance steps, into the manufacturing process; and (3) 
monitoring production using a relevant screening assay. The 
authors concluded that “zero risk is a myth, but virus safety can 
be enhanced by incorporation of multiple overlapping virus 
containment and clearance strategies”.
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345 An April 2013 review of technologies for improving 
downstream productivity of bioproduction highlighted 
Multimodal chromatography as ‘a powerful tool for difficult 
separation challenges’. The authors noted ‘a trend over the 
past five years… to apply multimodal media to the difficult 
polishing challenges downstream’. They highlighted such 
technologies as an ‘established workhorse’ in the purification 
of antibody fragments. The authors noted that ion-exchange 
chromatography was an established purification platform for 
monoclonal antibodies but highlighted advances in resin design 
that further optimises the system. The authors highlighted 
developments in cation-exchange resins, such as Eshmuno 
CPX, and high capacity, salt tolerant resins, such as Life 
Technologies’ POROS system. The authors noted that ‘many 
blockbusters already include HPLC [high performance liquid 
chromatography] in their purification process’. The authors 
highlight advances in more user-friendly tools, software and 
services to adapt the process to specific product need. The 
authors noted the importance of optimizing virus filters and 
highlighted the potential to strengthen filtering earlier in the 
production process.
346 A November 2014 review of UV-C Irradiation as a viral 
inactivation method for biopharmaceuticals included an 
evaluation of its effectiveness in inactivating viral pathogens 
from seven different families. Different viruses proved to have 
different levels of susceptibility to UV-C inactivation. The author 
demonstrated that variation in sensitivity was not connected 
to “virus size; presence or lack of a lipid envelope; or genome 
type, size, or strandedness”. The author concluded that this was 
“ a highly versatile viral inactivation step that can be included 
in a purification process in a number of ways. Since it is a flow-
through operation, adding it to a process is relatively simple”.
347 In October 2012, Wigginton et al reported the impact of 
disinfectant on virus function and structural integrity as a viral 
inactivation mechanism. The authors undertook a quantitative 
analysis of the damage to a model virus (bacteriophage MS2) 
from five common virucidal approaches, inclduing heat, UV, 
hypochlorous acid, singlet oxygen, and chlorine dioxide. The 
authors demonstrated that “each treatment targets one or more 
virus functions to achieve inactivation”.
348 A June 2014 review of the implications of the convergence of 
biology and chemistry highlighted:
•	 ‘Biocatalysts (enzymes), usually immobilised, are being 
increasingly applied in the industrial production of bulk 
chemicals and pharmaceuticals. To overcome the limitations 
of naturally occurring enzymes, directed evolution has 
become an important tool for improving activity, selectivity, 
solvent tolerance and general robustness’;
•	 Reprogrammed microorganisms have been created ‘to 
produce biofuels by manipulating metabolic and biosynthetic 
pathways, and the production of drugs that are difficult to 
synthesise or which otherwise would need to be extracted 
from scarce raw materials. Recent examples include the 
production of anthranilic acids such as the anti-allergic 
tranilast in modified yeast strains, 24 and the production of 
terpenoid compounds which form the basis of perfumes and 
many drugs, including novel antimicrobial drugs’;
•	 ‘A survey of synthetic biology products published in 
2012 provides additional insight into applications under 
development.30 The survey identified 68 products across 
seven sectors (including biofuels, chemicals, energy, food, 
materials, and medicine) being developed by companies in 
10 countries’;
•	 ‘Substantial advances in production methods for peptides 
have been made in the last two decades. Although they 
could be produced in genetically modified organisms, 
the pharmaceutical industry currently regards chemical 
synthesis as the most cost-effective method for producing 
many small peptides’. 
349 A January 2012 review of biomedical applications of synthetic 
biology highlighted development for:
•	 Drug production and delivery, including he biosynthesis of 
new secondary metabolites with novel therapeutic activities 
(such as complex polyketides, halogenated alkaloids, and 
the precursors of the anti-malaria drug artemisinin), biohybrid 
materials for drug delivery; and
•	 Other tools for biomedicine, including RNA controllers of 
cell proliferation, Optogenetic devices in blood glucose 
homeostasis, prosthetic networks, and an artificial 
insemination device.
350 An August 2014 presentation by Sweden to the BWC Meeting 
of Experts highlighted the challenges of developing measures 
to ‘surveil development, manufacturing and marketing of a dual 
use agent with a substantial commercial value’. The authors 
noted both existing issues with the commercial production 
of botulinum toxin and those emerging from the adoption of 
synthetic biology techniques.
351 A February 2015 review by Yang et al of engineered biomaterials 
for development of nucleic acid vaccines reported progress in 
enhancing immunogenicity. The authors reviewed advances in 
providing protection during the delivery process and specific 
targeting to immune tissues, developing biomaterials to act as 
co-stimulators for vaccines (for example, taking advantage of 
‘tunable mechanical properties and adjusted multifunction for 
combining with other co-stimulators, such as CpG and cytokines’), 
and providing ‘sustained release of nucleic acid antigens, 
which will establish the immunological memory for prolonged 
surveillance against pathogens or cancer cells’. The authors 
also note ‘a lack of deep and comprehensive understanding 
the in vivo behavior of delivery vectors and immunostimulative 
mechanisms. This impedes progress towards the rational design 
of such delivery systems they argue.
352 In August 2015, Galanie et al reported having designed and 
engineered yeast to produce the selected opioid compounds 
thebaine and hydrocodone starting from sugar. The authors 
used enzyme discovery, enzyme engineering, and pathway 
and strain optimization techniques. The engineered pathway 
required “the expression of 21 (thebaine) and 23 (hydrocodone) 
enzyme activities from plants, mammals, bacteria, and yeast 
itself”. The authors noted that this “is a proof of principle, and 
major hurdles remain before optimization and scale-up could 
be achieved. Open discussions of options for governing this 
technology are also needed in order to responsibly realize 
alternative supplies for these medically relevant compounds”.
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353 In May 2015, Mitchell et al reported having developed a 
qPCR-based high-throughput approach for the detection 
of the specific tags being engineered into the synthetic 
yeast being developed by an international consortium. The 
authors reported a much improved method for being able to 
differentiate between natural and synthetic yeast.
354 In March 2014, Lin et al reported a novel method for the 
efficient in vivo assembly of designed DNA fragments up to 
10 kb long in Saccharomyces cerevisiae. The new method 
“reduces the time-consuming and labour-intensive efforts 
of yeast assembly by improving the screening efficiency for 
correct assemblies”. The method is also relatively simple, 
the paper describes its use by undergraduates. The authors 
conclude that the method “may find routine applications in 
the construction of DNA fragments, especially in hierarchical 
assembly projects”. It is already in use in the SC2.0 synthetic 
yeast project.
355 In July 2015, Mitchell et al reported a novel method for 
compiling genetic pathways for expression in Saccharomyces 
cerevisiae. It makes use of the yeast’s capacity for homologous 
recombination to join sequences together. The authors used 
the new method to compile four, five and six gene pathways to 
produce β-carotene and violacein.
356 In October 2011, Conrado et al reported having used DNA to 
guide assembly of components along a biosynthetic pathway. 
The authors demonstrated that by controlling the special/
temporal space in which these pathways work titres of the 
end product increases. They demonstrated raising titres 
for a number of metabolic products, including resveratrol, 
1,2-propanediol, and mevalonate.
357 An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted the 
‘development of a synthetic approach that rapidly generated 
influenza vaccine viruses from sequence data’. The authors 
noted ‘DNA nanostructures were used as scaffolds to assemble 
antigen-adjuvant complexes that elicited a strong and specific 
antibody response without inducing a reaction to the DNA 
nanostructure itself’.
358 A June 2014 review of the implications of the convergence 
of biology and chemistry highlighted ‘for chemicals produced 
by multi-enzyme processes, the physical spatial organisation 
of enzymes has been demonstrated to increase the efficacy 
and yield. Such approaches have also enabled the tuneable 
adaptation of metabolic flux. Proteinaceous and DNA-based 
scaffolds have been used to spatially locate enzymes important 
for the production of discrete and complex chemicals. These 
scaffolds have been developed for use in bacteria and yeast 
used for industrial production’.
359 A May 2012 review of plant-based production highlighted that 
the first biological drug receiving regulatory approval for use in 
humans. The drug, Protalix’s Elelyso, was manufactured inside 
modified plant cells. The authors noted that at least four other 
drugs, including a H5N1 influenza vaccine, manufactured in 
plant-based systems were in the pipeline.
360 In May 2012, Jul-Larsen et al reported having produced a 
vaccine candidate for H1N1 influenza virus in recombinant 
plants. The authors used ‘a recombinant influenza 
haemagglutinin antigen (HAC1) that was derived from the 
2009 pandemic H1N1 (pdmH1N1) virus and expressed in 
tobacco plants’. They demonstrated that ‘the tobacco derived 
recombinant HAC1 antigen is a promising vaccine candidate 
recognized by both B- and T cells’.
361 In October 2012, Olinger et al reported having produced 
monoclonal antibodies to treat Ebola in plant cells. The authors 
demonstrated that they protected rhesus macaques from lethal 
challenge when administered 1 h post-infection.
362 A November 2014 ECRI Institute review highlighted that a 
trivalent monoclonal antibody therapy for Ebola is ‘humanized 
and recombinantly manufactured in the tobacco plant Nicotiana 
benthamiana’. The authors describe the steps involved:
•	 ‘Planting Nicotiana seeds in flats
•	 Growing for several weeks with careful control of light, 
temperature, and humidity
•	 Treating plants with the antibody vector system
•	 Growing for an additional week allowing the plants to 
manufacture humanized antibody proteins
•	 Harvesting and homogenizing the humanized antibody 
proteins in a large vat followed by separation of the antibody 
proteins using a series of specialized purification techniques
•	 Testing the resultant antibody for purity and potency’.
363 An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted ‘the 
widening diversity of vaccine production methods now 
include… transgenic animals and plants’. The authors noted:
•	 ‘Recombinant proteins have been produced in the milk of 
transgenic animals’; 
•	 ‘Work has recently been revived… on the production of 
malaria antigens as potential vaccine candidates in the milk 
of transgenic goats’
•	 ‘Antigens from several human and veterinary pathogens 
have been expressed in transgenic plants, e.g. rabies, 
hepatitis B, measles, avian influenza and anthrax’;
•	 ‘A vaccine candidate based on transient expression of the 
recombinant protein antigen in the leaves of the tobacco 
plant, which is then extracted and purified to obtain clinical 
grade material, is in clinical trials’;
•	 ‘There have been many reports on studies on the use of 
transgenic plants for the production of veterinary vaccines… 
One recent example is the development of transgenic alfalfa 
plants expressing a recombinant antigen that could induce 
neutralising antibodies to bovine viral diarrhoea virus’.
364 A July 2012 presentation by Pitt to the BWC Meeting of Experts 
highlighted a range of advances and technologies in the life 
sciences, including:
•	 ‘significant advances in the bulk production of biological 
agents’;
The Biological and Toxin Weapons Convention   88
•	 ‘advances in the delivery of biological agents (peptides, 
proteins, DNA) to biological systems (usually based on 
nanotechnology);
•	 Effective protein engineering leading to designer 
proteins and protein binding agents, and ‘New detection 
technologies (e.g. peptide aptamers, SOMAmers, etc.)’;
•	 Nanomaterial and nanoparticle technologies for targeted 
delivery of chemical and biological agents;
•	 Smart delivery including: self assembling (and disassembling) 
systems; “responsive” to environment; transdermal and 
aerosol delivery; and neurological targeting;
•	 Synthetic biology, being used to engineer bacteria, yeast, 
insects and plants; and 
•	 Distributed computing technologies to address 
bioinformatics and big data challenges.
365 In October 2013, Gomila et al reported ‘that the use of chimeric 
HA and NA segments with high-growth backbones is a viable 
strategy that could improve influenza vaccine manufacturing’. 
The authors demonstrated that three optimized backbones 
could be further improved by the inclusion of chimeric 
hemagglutinin (HA) and neuraminidase (NA) genome segments.
366 An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted a number 
of developments in vaccine delivery, including:
•	 ‘Non-parenteral routes of administration, such as intranasal, 
aerosol, oral and transcutaneous are also being exploited’;
•	 ‘A novel vaccination concept that uses gold nanoparticles as 
a delivery vehicle for presentation of viral antigens to induce 
a protective immune response’;
•	 ‘The development of nanotechnology-based skin patches 
has offered a potential alternative for vaccine delivery to 
overcome some of the disadvantages of needles and syringe’;
•	 ‘Another means that has been proposed to address the 
limitations of the refrigeration requirement for distribution 
and storage is the stabilisation of vaccines in silk protein’.
367 In July 2012, Zhang et al reported having used self-standing 
silk protein biomaterial matrices to stabilize labile vaccines and 
antibiotics up to temperature of 60’c for over 6 months. The 
authors note that such an approach negates the need for a cold 
chain for such drugs.
368 In April 2013, Wang et al reported rationally integrating 
biomimetic nucleating peptides onto the capsid of enterovirus 
type 71 by reverse genetics. As a result, ‘calcium phosphate 
mineralization can be biologically induced onto vaccine 
surfaces under physiological conditions, generating a mineral 
exterior’. The authors note that they have improved ‘the 
thermostability and immunogenicity of live vaccines by self-
biomineralization’. The demonstrated ‘t he self-biomineralized 
vaccine can be stored at 26 °C for more than 9 d and at 37 °C 
for approximately 1 wk. Both in vitro and in vivo experiments 
demonstrate that this engineered vaccine can be used 
efficiently after heat treatment or ambient temperature storage’.
369 An October 2014 review of the impacts of convergence of 
chemistry and biology highlighted the potential to use patchy 
particle nanoparticles ‘to better understand the underlying 
causes of the thermal instability of vaccines in order to find ways 
of stabilizing them for transport (for example by adding sucrose 
to increase the viscosity so as to prevent small DNA releases), 
which practically speaking could potentially revolutionize the 
laborious logistical process of vaccine delivery’.
370 In August 2011, Siegwart et al reported having developed tools 
to tune the cores and shells of nanoparticles for intercellular 
delivery. The authors reported having conducted a ‘high-
throughput study of 1,536 structurally distinct nanoparticles with 
cationic cores and variable shells’. This ‘revealed structure-
function relationships and beneficial design guidelines’.
371 In October 2011, Chung et al reported having developed 
biomimetic self-templating supramolecular structures. The 
authors noted that their ‘approach provides insight into the 
complexities of hierarchical assembly in nature and could be 
expanded to other chiral molecules to engineer sophisticated 
functional helical-twisted structures’.
372 A May 2012 review by Couvreur of the use of nanopartices in drug 
delivery highlighted that ‘nanoparticle suspensions which contain 
medicines i.e. ‘nanomedicines’) has made it possible to increase 
the therapeutic index of many components (improvement of the 
activity, reduction of toxicity) by selectively directing them towards 
the diseased tissues and cells (‘drug targeting’)’. The author also 
notes that ‘the shift in size from tens of micrometers to tens or 
hundreds of nanometers has thus been a significant technological 
and medical breakthrough’. They list a limited number of 
nanocarriers that were already on the market or in phase III trials. 
The author highlights progress towards improving drug loading 
and timed release, in particular developments in ‘“squalenoylation 
technology” or the construction of nano metal oxide frameworks’.
373 A December 2013 review by Zhao et al of the use of 
nanoparticles to deliver vaccines noted significant progress. 
The authors reported that the use of nanoparticles in vaccine 
formulations can improve antigen stability and immunogenicity 
and enable targeted delivery and slow release. They note that 
‘a number of nanoparticle vaccines varying in composition, 
size, shape and surface properties have been approved for 
human use and the number of candidates in increasing’. The 
authors also note that there remains a need for additional 
understanding of mechanisms of action, biodistribution and the 
fate of particles is required before full rational design of such 
particles in feasible.
374 A June 2014 review by the OPCW of the implications of the 
convergence of biology and chemistry highlighted:
•	 ‘The shortcomings of peptides as drugs (and by implication 
for uses prohibited by the Convention) can be moderated 
in several ways. Formulations, particularly associated with 
liposomes or nanocarriers, are being explored to enhance 
penetration of the blood brain barrier, overcome host 
defences, and target specific organs’;
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•	 ‘Nanoparticle-based formulations are being widely explored 
for enhanced or ‘smart’ drug delivery. Examples are controlled 
drug release, enhanced penetration of the blood brain barrier 
(e.g. for therapeutic peptides), and targeting specific organs 
or cells (e.g. cancer cells). Nanoparticles most commonly used 
in drug formulations include: imprinted polymers, dendrimers, 
vesicles, nanospheres, nano-capsules, micelles, carbon nano-
tubes, liposomes, and nano-emulsions. Additional bio-based 
nanocarriers are being researched including DNA-based 
systems and viral-based systems’;
•	 ‘Nanocarrier-based delivery systems present several 
advantages over the classic ones: overcoming solubility 
problems, protecting the drug from the external 
environment (temperature, UV radiations, pH), and 
controlling the release profile’;
•	 ‘Nanocarrier-based delivery systems permit a more precise 
and controlled targeting at the site of action, while reducing 
the time of exposure at non-targeted tissues. This can 
increase efficacy, and reduce toxicity and side effects’.
375 In June 2012, Yen-Ting et al reported the structure of a self-
assembling, 12 sub-unit protein cage. The authors note their 
approach ‘of fusing together oligomeric protein domains can 
be generalized to produce other kinds of cages or extended 
materials’.
376 A July 2012 presentation by Pitt to the BWC Meeting of Experts 
highlighted a range of advances and technologies in the life 
sciences, including:
•	 ‘Advances in the delivery of biological agents (peptides, 
proteins, DNA) to biological systems (usually based on 
nanotechnology);
•	 Nanomaterial and nanoparticle technologies for targeted 
delivery of chemical and biological agents;
•	 Smart delivery including: self-assembling (and disassembling) 
systems; “responsive” to environment; transdermal and 
aerosol delivery; and neurological targeting.
377 In October 2012, Zhao et al reported using DNA-based 
nanostructures to form ‘complex assemblies that co-localize 
drugs, targeting ligands and other functionalities in one 
nanostructure’. The authors used these structures to deliver 
the anthracycline drug duxorubcin (Dox) to three different 
human breast cancer cell lines. They demonstrated an 
ability to manipulate the design ‘to (i) tune the encapsulation 
efficiency and the release rate of the drug and (ii) increase the 
cytotoxicity and lower the intracellular elimination rate when 
compared to free Dox’.
378 In July 2015, Benson et al reported ‘a general method of folding 
arbitrary polygonal digital meshes in DNA that readily produces 
structures that would be very difficult to realize using previous 
approaches’. The authors noted their design process was 
highly automated and that the resulting structures ‘have a more 
open conformation… and are therefore stable under the ionic 
conditions usually used in biological assays’.
379 In December 2013, Huert et al reported having developed a 
computational framework for identifying design guidelines to 
increase the penetration of targeted nanoparticles into tumors. 
The models simulates the potency, motion, binding kinetics, 
and cellular internalization of targeted nanoparticles in a section 
of tumor tissue. The authors used the model to demonstrate 
the benefit of delaying nanoparticle binding until after the 
nanoparticles have had time to diffuse deep into the tissue. 
They concluded that following their design rules results in 
nanoparticles which “do not require fine-tuning of their kinetics 
or size and can be administered in lower doses than classical 
targeted nanoparticles for a desired tissue penetration”.
380 In July 2012, Zheng et al reported using Lipid-based liquid 
crystalline nanoparticles as novel drug-delivery systems 
for improving the bioavailability of both hydrophilic and 
hydrophobic drugs. The authors demonstrated that deliver 
using these particles led to a 2.1 times increase of the oral 
bioavailability of a drug.
381 In January 2013, Verma et al reported having used a magnetic 
core-shell nanoparticles for aerosol drug delivery. The authors 
demonstrated the feasibility of filling the nanoparticle with an anti-
cancer drug and evaluated its delivery via aerosol administration.
382 In February 2013, Dian et al reported using a cubic phase 
nanoparticle for sustained release of ibuprofen. The authors 
demonstrated encapsulation efficiency greater than 85%, that 
in vitro release of the drug was greater than 80% at 24 hours, 
showing sustained release, and improved absorption compared 
to that of pure ibuprofen, with evidence of a longer half-life and 
a relative oral bioavailability of 222%.
383 In February 2013, Jin et al reported having used self-
assembled liquid crystalline nanoparticles to overcome the 
low oral absorption and the rapid metabolization of an anti-
cancer drug. The authors demonstrated the key indicators of 
bioavailability of the drug rose by 166% and 248% with the use 
of the nanoparticle.
384 In October 2014, Maddalo et al reported having used a 
viral delivery platform for CRISPR/CAS9 genome editing to 
deliberately create a cancer in a mouse lung. The authors report 
having used this genome editing technique to have improved 
the efficacy of the mouse model for studying human diseases.
385 In July 2015, Zinn et al reported having synthesised ancestral 
viral structures of Adeno-associated virus (AAV) vectors. These 
viruses have been used as delivery devices for gene therapy 
but ‘efforts to engineer AAV vectors have been hampered by a 
limited understanding of the structure-function relationship’. The 
authors characterised the resurrected viruses and identified 
one as ‘a highly potent in vivo gene therapy vector for targeting 
liver, muscle, and retina’.
386 In December 2012, DeMuth et al reported in Nature a novel 
delivery strategy for DNA vaccines, immune-stimulatory RNA, 
and biodegradable polycations. The authors used microneedles 
coated with releasable polyelectrolyte multilayers to deliver 
such agents into the epidermis. Following such application, 
such tattoos ‘promoted local transfection and controlled the 
persistence of DNA and adjuvants in the skin from days to 
weeks, with kinetics determined by the film composition’.
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387 A March 2014 review of skin permeabilization for transdermal 
drug delivery identified a number of successful approaches, 
including: low-frequency sonophoresis, microneedles, 
electroporation and iontophoresis, and combinations of these 
methods. The authors noted that not all permeabilization 
methods are appropriate for all applications but that 
vaccination, protein delivery and analyte sensing are areas 
of impact. They noted the need for focused studies into 
applications utilizing the advantages of each method. 
388 A May 2015 review by Lutton et al of the mechanical tests 
and insertion analytical techniques used by various groups to 
characterise microneedles highlighted ‘the urgent need for 
consistency across the range of microneedle systems in order 
to promote innovation and the successful commercialisation of 
microneedle products’.
389 In May 2015, Vinayakumar et al reported development of a cup-
shaped microneedle. The authors demonstrated ‘reduced drug 
leakage resulting in improvement of efficiency of drug delivery 
and possibility of introducing multiple drugs’.
390 In July 2013, DeMuth et al reported that reproducing the 
kinetics profiles present during acute natural infections can 
improve the efficacy of vaccination with microneedles. The 
authors demonstrated that such an approach, relative to 
traditional parenteral needle-based immunization, led to a 
10-fold increase in antigen-specific T-cell and humoral immune 
responses prompted by a model whole-protein vaccine.
391 A September 2013 review of microneedle patches for vaccine 
delivery noted that studies had demonstrated ‘comparable 
or higher immunogenicity to conventional intramuscular 
routes, overall level of stability, and dose-sparing advantages. 
Furthermore, recent mechanism studies have begun to 
successfully elucidate the biological mechanisms behind 
microneedle vaccination’.
392 In June 2015, Yang et al reported having used a phase-
transition microneedle patch for the trans-dermal delivery 
of insulin. The authors demonstrate only a minor loss of 
functionality in comparison to traditional injector pens with 
advantages for painless administration, freedom of refrigeration, 
and minimal safety concerns. They note the potential to use 
this delivery system for protein/peptide medicines requiring 
frequent dosing.
393 A January 2014 review by Okuda et al of developments to 
address the weak immunogenicity of DNA vaccines in humans 
identified a number of promising approaches, including: 
‘various genetic adjuvants, electroporation, and prime-boost 
methods [which] have been developed preclinically’.
394 In March 2015, van de Wal et al reported having used a tattoo 
delivery patch to administer a tumor vaccine. The authors 
demonstrated that despite a 10-fold lower overall antigen 
expression at the site of administration and draining lymph 
nodes when compared to intramuscular injection, tattoo injection 
resulted in higher or equal levels of immune responses.
395 In March 2015, Edens et al reported having developed and 
used microneedle patches for the delivery of inactivated 
polio vaccine. The authors demonstrated that these patches 
produced equivalent neutralizing antibody titres in monkeys 
when compared to traditional intramuscular injection. The noted 
several advantages including that they are ‘easy to administer, 
have a small package size, generate no sharps waste and are 
inexpensive to manufacture’.
396 A July 2014 review of fabrication techniques for microneedles 
noted ‘recent research has been conducted integrating 
various fabrication techniques for generating sophisticated 
microneedle devices for transdermal delivery including 
progress on their commercialization’.
397 A November 2013 review of the use of nanotechnology 
in biology and medicine surveyed nanotechnology-based 
approaches for precisely measuring and perturbing living 
systems. The authors noted that nanotechnology can be used 
“to characterize single molecules or cells at extraordinarily 
high throughput and deliver therapeutic payloads to specific 
locations as well as exhibit dynamic biomimetic behaviour”. 
They noted particular applications for systems biology as well 
as new therapeutic strategies for personalized medicine.
398 An October 2014 review of the impacts of convergence of 
chemistry and biology (Speiz Convergence) report highlighted:
•	 ‘Antibody-Drug Conjugates (ADCs) have been developed 
and tested for the targeted delivery of cytotoxic payloads 
to cancer cells… an approach has been developed which 
combines selectivity with toxicity, by linking antibodies 
and cytotoxic molecules together in the form of ADCs’. 
The authors note that ‘at this stage of development, ADCs 
are expensive drugs, but the approach is considered 
competitive based on their increased efficacy. Moreover, two 
such approaches have met with FDA approval and some 30 
other ADCs are currently in clinical trials at different phases. 
The Swiss company Lonza, for example, has developed both 
the capacity to produce bulk quantities and the specialist 
skills and experience in both the chemical and biotech fields 
necessary to manufacture ADCs. In terms of capacity, reactor 
sizes can vary from small (6 to 60 litres) to large scale (up to 
600 litres, batch sizes up to 3 kg)’;
•	 ‘Nanoparticles, specifically… gold particles coated with 
hydrophobic and hydrophilic compounds could be used to 
imitate certain biological functions…. these nanoparticles 
have been shown to have the ability to penetrate cell 
membranes. Such nanoparticles could either be designed 
to carry small payloads of highly active drugs (for example 
certain peptides), or the nanoparticle itself could act as a 
drug by interacting with viruses’.
399 An April 2015 review by Cheng et al of targeting disease with 
polymeric nanoparticles notes ‘the route of administration, 
molecular characteristics and temporal control of the 
nanoparticles are potential design variables that must be 
considered simultaneously’ and highlighted the importance of 
such a holistic approach to facilitate the clinical applications of 
the technology.
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400 A July 2012 working paper by the Russian Federation for the 
BWC Meeting of Experts highlighted ‘Human genome mapping, 
studies on how the polymorphism in the human genes is 
linked to some causative agents of human diseases, the 
advancement of molecular and cellular biology, the knowledge 
of genetic features of different races and nationalities allow for 
possibilities in principle to manipulate with human genome and 
to selective impact on certain races’.
401 An August 2012 review of nanotechnologies in therapeutics 
highlighted targeting strategies, including both active and 
passive targeting, and factors impacting drug delivery, 
including the size and shape of nanoparticles and their surface 
characteristics.
402 A February 2013 review of the impact of scientific developments 
on the Chemical Weapons Convention highlighted:
•	 ‘The production of toxic chemicals, including toxins, through 
biological synthesis (an aspect of the convergence of 
chemistry and biology); encapsulation and delivery through 
nanotechnology; and flow microreactors, which enable 
types of chemical reactions under conditions that were not 
previously technically feasible’; 
•	 ‘The application of nanotechnology to improve materials and 
systems relevant for protection against CW and chemical 
decontamination is an area of gradual, but important 
development. Some areas of ongoing research that 
should continue to be monitored include the development 
of nanofibers for protective clothing, nanocatalysts for 
decontamination methods, and nano-based drug delivery 
mechanisms for medical countermeasures’; and 
•	 ‘New polymers, lipids, and other carrier materials for drugs 
or genes is an area of active research. These carriers may 
be used as components of nanomedicines, in which the 
properties of the carrier influence the biodistribution of 
the therapeutic agent that is bound or complexed with it. 
Both the chemical properties of the carrier (e.g., the relative 
hydrophilicity and hydrophobicity or the conjugation of 
“functionalizing” molecules to target particular cellular 
receptors) as well as physical properties (such as size and 
shape) influence the uptake and residence time of a drug in 
the body. These types of nanomedicines have a wide range 
of applications, including improved delivery across biological 
barriers such as the blood–brain barrier, prolonged 
residence time in the blood (reduced clearance in the liver), 
and improved targeting to particular cell types’.
403 A November 2013 review of emerging nanotechnology-based 
tools for biology and medicine, highlighted in developing 
nanocariers to deliver drugs. The authors noted advances to 
‘incorporate advanced functionality such as targeting to specific 
organs and cells, responsiveness to external stimuli, imaging 
capabilities, and drug delivery’. They provided an example of 
a nanoparticle which ‘incorporates a ‘‘stealth’’ polymer brush 
shell that limits immunosurveilance as well as a degradable 
hydrophobic core that could be loaded with drugs. These 
optimized characteristics promoted circulation times while 
reducing liver accumulation’.
404 In May 2011, von Maltzahn et al reported the in vivo use of 
‘communicating’ nanoparticles to increase tumor targeting. 
The authors used nanotechnology and synthetic biology 
approaches to construct systems with ‘signalling’ modules 
that “target tumours and then locally activate the coagulation 
cascade to broadcast tumour location to clot-targeted 
‘receiving’ nanoparticles in circulation that carry a diagnostic 
or therapeutic cargo, thereby amplifying their delivery”. The 
authors demonstrated the use of different types of signalling 
and receiving modules, transmitting information through several 
molecular pathways to increase targeting by over 40 times.
405 An August 2012 review of nanotechnologies in therapeutics 
highlighted:
•	 The use of nanocarriers and their application. The authors 
noted: nanocrystaline drugs including immunosuppressives, 
anti-emetics, hypercholesterolemia, and anti-anorexia; 
liposomes, including to treat fungal infections, ovarian and 
breast cancer, lymphomatous meningitis, and Kaposi’s 
sarcoma; polymer-drug conjugates, including to treat 
enzyme deficiencies, leukaemia, and Hepatitis C; polymeric 
micelles for cancer chemotherapy; protein nanoparticles, 
to treat breast cancer; and lipid colloidal dispersion to treat 
fungal infections; 
•	 Targeting strategies, including both active and passive 
targeting;
•	 Factors impacting drug delivery, including the size and shape 
of nanoparticles and their surface characteristics.
406 An October 2012 review by Zhang et al of advanced materials 
and processing for drug delivery highlighted ‘innovation in 
material chemistry allows the generation of biodegradable, 
biocompatible, environment-responsive, and targeted delivery 
systems. Nanotechnology enables control over size, shape and 
multi-functionality of particulate drug delivery systems’.
407 A July 2011 review by Yoo et al of synthetic carriers, such 
as polymer and lipid particles, noted that they often fail to 
meet clinical expectations. The authors highlight progress in 
re-engineering the various natural carriers which are ‘highly 
optimized for their specific functions in vivo and possess 
features that are often desired in drug delivery carriers’.
408 An April 2014 review of advanced drug delivery systems 
highlighted that ‘intelligent drug delivery systems are 
continuously improved with the purpose to maximize 
therapeutic activity and to minimize undesirable side-effects’. 
The authors noted ‘advanced drug delivery systems based on 
micelles, polymeric nanoparticles, and dendrimers’ and that 
‘polymeric carbon nanotubes and many others demonstrate a 
broad variety of useful properties’.
409 In March 2012, Tong et al reported having developed a 
new type of nanoparticle drug delivery system. The authors 
demonstrate that the particle reversibly changes shape and 
size when stimulated by UV light allowing spatiotemporal 
control of drug release and allowing for ‘repetitive dosing from 
a single administration’. The authors also demonstrate that the 
nanoparticle facilitates tissue penetration.
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410 In July 2012, Zheng et al reported having developed a 
nanocarrier capable of crossing the epidermal barrier to deliver 
siRNA. The carrier ‘can be delivered in a commercial moisturizer 
or phosphate-buffered saline, and do not require barrier 
disruption or transfection agents’. The authors note that the 
delivery devices ‘are virtually undetectable in internal organs’.
411 A July 2012 presentation by Japan to the BWC Meeting 
of Experts highlighted the dual use potential of recent 
developments, including in:
•	 Nanobiology providing capabilities to engineer an ‘artificial 
membrane to cover disease-causing agents as well as 
toxins’; and 
•	 Nanotechnology drug delivery devices which enhance 
the ‘infectious ability of microorganism’ and delivers drugs 
across the blood brain barrier.
412 In April 2013 Impel NeuroPharma announced ‘the first ever 
successful neuroimaging study demonstrating peptide delivery 
direct to the brain’. The study made use of the company’s 
precision olfactory delivery devices that increase drug deposition 
to the upper nasal cavity from around 5% to greater than 50%.
413 A December 2013 review by Zhao et al of the use of 
nanoparticles to deliver vaccines noted significant progress. 
The authors reported that the use of nanoparticles in vaccine 
formulations can improve antigen stability and immunogenicity 
and enable targeted delivery and slow release. They note that 
‘a number of nanoparticle vaccines varying in composition, 
size, shape and surface properties have been approved for 
human use and the number of candidates in increasing’. The 
authors also note that there remains a need for additional 
understanding of mechanisms of action, biodistribution and the 
fate of particles is required before full rational design of such 
particles in feasible.
414 In March 2012, Schroeder et al reported having developed 
a remotely activated protein-producing nanoparticle. The 
authors housed components of cellular machinery necessary 
for transcription and translation of Green Fluorescent Protein 
and enzymically active luciferase inside of a lipid vesicle. 
The authors demonstrated spatiotemporal control of protein 
production in vitro and in vivo by ‘irradiating micrometer-scale 
regions on the time scale of milliseconds’.
415 In October 2011, Singh et al reported having developed 
bioresponsive nanoparticles for drug release. The authors 
designed and built mesoporous silica nanoparticles with 
therapeutics loaded into core and shell domains. The authors 
demonstrated in vitro that in response to proteases found at 
tumor sites, the nanoparticles released their payload and were 
capable of inducing cellular apoptosis.
416 In September 2013, Dapat et al reported on sensitivity in 
Japan to the antiviral Neuraminidase inhibitors used to treat 
influenza. The authors noted that there had been a rise in 
resistant viruses but that prevalence remained low. During the 
2010-2011 influenza season, viruses were circulating with a 
200-300-fold increase in resistance to two of the four licensed 
Neuraminidase inhibitors – one of which had only been 
licensed the same year. A similar paper from January 2014 
reviewed the susceptibility of influenza viruses circulating in 
the United States from 2011 to 2013 to all four Neuraminidase 
inhibitors. The authors noted that resistance was only identified 
in a single sample, which included rare mutations reducing 
inhibition by oseltamivir (31-fold) and zanamivir (66-fold). A 
March 2014 paper examining resistance to the two most 
recently licensed Neuraminidase inhibitors in samples collected 
from Asia, Africa and Oceania revealed no resistance to one 
and 3.2% resistance in Influenza A viruses.
417 In July 2014, Ashley et al reported that P. falciparum resistant 
to artemisinin was prevalent across mainland Southeast Asia. 
The authors noted that the drug resistance is associated 
with mutations in kelch13. The authors demonstrated that 
‘prolonged courses of artemisinin-based combination 
therapies [comprised of artesunate followed by a standard 
course of artemisinin] are currently efficacious in areas where 
standard 3-day treatments are failing’.
418 In May 2013, Miotto et al reported the identification of 
subspecies of P.falciparum exhibiting resistance to artemisinin 
in Cambodia. The authors cataloged SNPs connected to 
resistance, including coding variants in transporter proteins and 
DNA mismatch repair proteins.
419 A May 2012 review of Carbapenem resistance in 
Enterobacteriaceae highlighted worldwide emergence 
of resistance not only in hospital settings but also in the 
community. The authors noted the ‘corresponding genes are 
mostly plasmid-located and associated with various mobile 
genetic structures (insertion sequences, interons, transposons), 
further enhancing their spread’. They noted progress in 
understanding related activity, distribution, clinical impact, and 
possible novel antibiotic pathways.
420 In March 2014, Fowler and Hanson reported the specific 
mutation in Pseudomonas aeruginosa that confers carbapenem 
resistance. The authors demonstrated that in each of the 
isolates they sequenced the location of the insertion was 
different.
421 In May 2014, Adler reported the mechanisms and dynamics of 
carbapenem resistance in Escherichia coli.
422 In February 2015, Witchuda et al reported Molecular 
Epidemiology and Mechanisms of Carbapenem Resistance of 
Acinetobacter spp. . The authors reported the specific gene 
insertions necessary to confer resistance.
423 A January 2013 review of mechanisms of resistance to the four 
licensed neuraminidase inhibitors used to treat and prevent 
influenza highlighted that ‘because of differences in their 
chemistry and subtle differences in NA structures, resistance 
can be both NAI- and subtype specific’. The author identifies a 
number of specific mutations that confer anti-viral resistance or 
reduced sensitivity.
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424 In May 2012, Kos et al reported the mutation responsible for 
vancomycin resistance in Staphylococcus aureus. The authors 
demonstrated that in all of the cases in the US to date, the 
bacteria had all spontaneously evolved a mutation residing on a 
fusion of plasmids from S. aureus and an enterococcal bacteria. 
By July 2013, VRSA had spread to Europe.
425 In April 2014, Rossi et al reported a case of transferable 
Vancomycin Resistance in Stapholococcus aureus.
426 In July 2014, Gardete and Tomasz reported having developed a 
model that describes the mechanisms of vancomycin resistance 
in Staphylococcus aureus.
427 In January 2014, Renzette et al reported how the genome 
of Influenza A viruses evolve during the development of 
oseltamivir resistance in vitro. The authors demonstrate that 
‘only selection of H274Y is required for oseltamivir resistance 
and that H274Y is not deleterious in the absence of the drug’.
428 An October 2012 review of biofilm infections highlighted 
that major regulators of biofilm formation are associated with 
antibiotic tolerance and that different components of these 
signalling networks might be appropriate targets for antibiofilm 
therapy in combination with antibiotic treatment strategies’. The 
authors noted that given the ‘almost universal presence’ of 
microbial-associated molecular patterns, conserved structures 
‘are also potential immunotherapeutic agents to treat antibiotic-
resistant bacterial infections’.
429 In January 2013, Wang et al reported the structural mechanism 
through which a mutation confers resistance to influenza drugs 
that target the M2 ion channel (amantadine and rimantadine). 
The authors identified small molecule drugs that work in a 
similar manner to amantadine and rimantadine, are not affected 
by the drug resistance mutation and show greater potency. 
Additional details of these potential new drugs were published 
in April 2013.
430 In April 2014, Polishchuk et al reported the thermodynamic and 
functional characterization of the mutation that makes influenza 
A viruses resistant to drugs targeting their M2 ion channel.
431 In December 2014, Plug et al reported the structure of Influenza 
A polymerase bound to the viral RNA promoter. The authors 
asserted that ‘this structure lays the basis for an atomic-level 
mechanistic understanding of the many functions of influenza 
polymerase, and opens new opportunities for anti-influenza 
drug design’.
432 In January 2015, Mok et al reported having used population 
transcriptomics of human malaria parasites to reveal the 
mechanism of artemisinin resistance.
433 A February 2013 review of bacterial populations responses 
to non-lethal concentrations of antibiotics acknowledged that 
‘bacteria may sense antibiotics as extracellular chemicals to 
trigger different cellular responses, which may include an altered 
antibiotic resistance/tolerance profile’. The authors discussed 
‘the different types of interactions mediated by antibiotics and 
non-antibiotic metabolites as a function of their concentrations 
and speculate on how these may amplify the overall antibiotic 
resistance/tolerance and the spread of antibiotic resistance 
determinants in a context of polymicrobial community’.
434 In July 2012, Grant et al reported the role of persister cells in 
infections with Mycobacteria. The authors demonstrated that 
‘that the small persister subpopulation within a larger antibiotic-
susceptible population also shows differential susceptibility 
to antibiotic-induced hydroxyl radicals. Furthermore, we show 
that stimulating ROS production can eradicate persisters, thus 
providing a potential strategy to managing persistent infections’.
435 In July 2013, Orman and Brynildsen reported that dormancy is 
not necessary or sufficient for bacterial persistence and that 
a range of additional characteristics is needed to define the 
persister phenotype.
436 In March 2014, Amato and Brynildsen reported that nutrient 
transitions are a source of persisters in Escherichia coli biofilms.
437 In March 2012, Vega et al reported that bacterial populations 
use Indol-activated genes that respond to stress to signal 
a sub-set the population to enter into a dormant state. That 
dormant state reduces the impact of antibiotics, allowing them 
to tolerate higher levels. The identification of the importance 
of these persister cells and the signalling molecules that 
prompt their formation offers a novel target for efforts to reduce 
antibiotic resistance.
438 In February 2014, Butt et al described part of the mechanism 
controlling persistors in Burkholderia pseudomallei populations.
439 In February 2014, Ghorbal et al reported having used the 
CRISPR/CAS9 genome editing system in P. falciparum the 
causative agent of malaria. The authors demonstrated 
‘disrupting chromosomal loci and generating marker-free, 
single-nucleotide substitutions with high efficiency’. They 
used CRISPR/CAS9 to add polymorphisms known to confer 
resistance to artemisinin.
440 A July 2012 working paper by the Russian Federation for the 
BWC Meeting of Experts highlighted ‘active studies in the 
field of Enterobacteriaceae (Salmonella, Escherichia coli), 
the most widespread group of microorganisms which inhabit 
the intestines of humans and animals and can contaminate 
the environment, food and ready meals and cause anthrax 
and cholera. In 2011-2012 a number of scientists published 
their findings on Enterobacteriaceae, Salmonella and anthrax 
(USA), anthrax (Japan), Escherichia coli (People’s Republic of 
China) and cholera (Iran)… Study areas include both the genetic 
multidrug resistance mechanisms and the possibility of an 
artificial simulation of new strains resistant to certain groups of 
antibacterial agents’.
441 A July 2015 review of antibiotics currently in clinical 
development found that “an estimated 36 new antibiotics1 that 
have the potential to treat serious bacterial infections are in 
clinical development for the U.S. market. The success rate for 
drug development is low; at best, only 1 in 5 candidates that 
enter human testing will be approved for patients”. The review, 
which had been updated periodically since February 2014 
provided details of drugs in the pipeline, including the name, 
development phase, company, the type of drug, expected 
activity against resistant strains, expected activity against 
priority pathogens, and potential indication(s).
442 A December 2014 review of antibiotics currently under 
development estimated that 37 candidates were in clinical 
development. This number had fallen from 45 candidates in 
February 2014. The authors noted:
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•	 ‘Of the 37 antibiotics in development, 10 were in Phase 1 
clinical trials, 18 in Phase 2, eight in Phase 3, and one has 
a new drug application submitted. Historically, about 60 
percent of drugs that enter Phase 3 will be approved’; 
•	 ‘At least two antibiotics in early development attack bacteria 
in an entirely new way by sidestepping the resistance of 
some bacteria to available antibiotics. Other drugs in the 
pipeline attack the same targets in bacteria as available 
drugs but seek to thwart resistance by using new chemical 
compounds’; and 
•	 A shift in who was developing antibiotics – ‘Nearly 80 
percent of the products currently in development are 
being studied by small companies rather than the large 
pharmaceutical firms that once dominated this field.3 
Additionally, just under half of the companies are considered 
pre-revenue, meaning that they have no products currently 
on the market’.
443 An April 2015 review of novel influenza therapies highlighted 
‘several new classes of antiviral candidates targeting viral 
replication through individual domains of the polymerase and 
the nucleoprotein have been developed through structure-
based design’. The authors noted ‘Antiviral candidates targeting 
the NP and polymerase domains are in the pipeline but their 
pharmacokinetics needs further studies. The recently published 
structures of the polymerase expand the possibilities for 
development of new antivirals’.
444 In July 2011, Rider et al reported having used a new approach 
to kill cells containing viral genetic material. The mechanism, 
‘dubbed Double-stranded RNA (dsRNA) Activated Caspase 
Oligomerizer (DRACO) that selectively induces apoptosis in 
cells containing viral dsRNA’. The authors ‘created DRACOs and 
shown that they are nontoxic in 11 mammalian cell types and 
effective against 15 different viruses’. In March 2015, Guo et al 
reported using this system to inhibit Porcine Reproductive and 
Respiratory Syndrome virus replication in vitro.
445 In April 2014, Alhadeff et al reported computational and 
experimental analysis of drug binding to the Influenza M2 
channel. The authors used a cell-based assay to identify two 
new Influenza M2 channel blockers, demonstrates that these 
were more effective than Rimantadine against otherwise 
resistant flu strains, and used computational analyses to provide 
insights into the increased efficacy of the new compounds.
446 In December 2014, Wu et al reported having identified a 
compound capable of blocking the M2 ion channel in Influenza 
A viruses in both its mutated and wild type. The authors 
modelled how the compound fits and binds to the ion channel 
in both cases, opening the door ‘for the next round of rational 
design of broad-spectrum antiviral drugs’.
447 In January 2015, Zhao et al reported having identified a 
camphor derivative as novel M2 ion channel inhibitors of 
influenza A virus. The authors demonstrate that the new 
compound takes up more space in, thereby blocking more 
completely, the ion channel.
448 In April 2013, Vigant et al reported developing a non-cytotoxic, 
membrane-targeted, broad-spectrum antiviral which inhibits 
the entry of many lipid-enveloped viruses. The authors 
delineated the molecular mechanism which underlies antiviral 
activity and improved its photochemical, photophysical, and 
pharmacokinetic properties. The reported ‘encouraging in vivo 
efficacy against a lethal emerging pathogen’.
449 In October 2013, Kessler et al reported the discovery and 
synthesis of novel benzofurazan derivatives which act as 
inhibitors of influenza A virus.
450 In November 2013, Furuta et al reported on a novel viral RNA 
polymerase inhibitor, Favipiravir. The drug had competed Phase 
II clinical trials for use against influenza viruses in USA and Japan. 
The authors noted that ‘favipiravir blocks the replication of many 
other RNA viruses, including arenaviruses…; phleboviruses…; 
hantaviruses …; flaviviruses…; enteroviruses…; an alphavirus…; a 
paramyxovirus…; and noroviruses’. Favipiravir has subsequently 
been used in clinical trials against Ebola Virus Disease.
451 In May 2014, Lepri et al reported having optimized small-
molecule inhibitors of Influenza Virus Polymerase. These 
drugs target a new part of these viruses, potentially offering 
entirely new therapeutic options not currently impacted by drug 
resistance.
452 In May 2015, Massari et al reported having developed a 
hybrid small molecule disrupting the function of Influenza A 
polymerases. The authors demonstrated ‘the identification of 
compounds endowed with both the ability to disrupt PA–PB1 
subunits interaction and anti-Flu activity with no cytotoxicity’.
453 In December 2011, Okandeji et al reported having identified 
an enhanced compound capable of blocking efflux pumps in 
certain multidrug resistance bacteria making them susceptible 
again to antibiotics. Similar compounds have been used to 
this end in Gram-negative bacteria. The authors identified a 
related compound that worked in Gram-positive bacteria and 
used it to ‘inhibit two chloramphenicol-specific efflux pumps in 
Streptomyces coelicolor, a Gram-positive bacterium that is a 
relative of the human pathogen Mycobacterium tuberculosis’. 
The authors synthesised a library of related compounds, one of 
which demonstrated three-fold efficiency improvements when 
compared to the wild type.
454 A May 2015 review of therapeutic options and emerging 
alternatives for multidrug resistant staphylococcal infections is 
a tour de force of recent developments to deal with bacterial 
infections. The authors highlighted:
•	 ‘A range of approved antibiotics from the glycopeptide, 
lipopeptide, pleuromutilin, macrolide, oxazolidinone, 
lincosamide, aminoglycoside, tetracycline, steptogramin, 
and cephalosporin classes has been employed to treat 
MRSA infections. 
•	 The upcoming pipeline of drugs for MRSA includes 
some new compounds from the above classes, together 
with fluoroquinolones, antibacterial peptide mimetics, 
aminomethylciclines, porphyrins, peptide deformylase 
inhibitors, oxadiazoles, and diaminopyrimidines. 
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•	 A range of non-drug alternative approaches has emerged for 
MRSA treatment. Bacteriophage-therapy including purified 
lysins has made a comeback after being discovered in the 
1930s. Quorum-sensing inhibitors are under investigation. 
Small molecule inhibitors of multi-drug efflux pumps may 
potentiate existing antibiotics. 
•	 The relative failure of staphylococcal vaccines is being 
revisited by efforts with multi-valent vaccines and improved 
adjuvants. 
•	 Photodynamic therapy uses non-toxic photosensitizers and 
harmless visible light to produce reactive oxygen species 
that can nonspecifically destroy bacteria while preserving 
host cells. 
•	 Preparation of nanoparticles can kill bacteria themselves, as 
well as improve the delivery of anti-bacterial drugs’. 
455 In October 2012, Lin et al reported that a new class of 
antibiotics then under development, LpxC inhibitors, were 
able to disarm but not kill certain types of antibiotics resistant 
pathogens. The authors demonstrated that the new antibiotics 
‘blocked the ability of bacteria to activate the sepsis cascade, 
enhanced opsonophagocytic killing of the bacteria, and 
protected mice from lethal infection’.
456 In June 2013, Morones-Ramirez et al reported having identified 
the antibacterial properties of silver. The authors demonstrate 
that ‘silver disrupts multiple bacterial cellular processes, 
including disulfide bond formation, metabolism, and iron 
homeostasis. These changes lead to increased production of 
reactive oxygen species and increased membrane permeability 
of Gram-negative bacteria that can potentiate the activity of 
a broad range of antibiotics against Gram-negative bacteria 
in different metabolic states, as well as restore antibiotic 
susceptibility to a resistant bacterial strain’. They demonstrated 
in vitro using silver: to increase the potency of antibiotics; to 
expand the antibacterial spectrum of antibiotics (sensitizing 
Gram-negative bacteria to the Gram-positive–specific antibiotic 
vancomycin); and in combination with antibiotics, to eradicate 
bacterial persister cells.
457 In July 2013, Jang et al reported having identified a novel 
antibiotic from a marine-derived Actinomycete. The authors 
demonstrated that ‘chlorination of anthracimycin gives a 
dichloro derivative that retains activity against Gram-positive 
bacteria, such as anthrax, but also shows activity against 
selected Gram-negative bacteria’.
458 In May 2015, Kwan et al reported the FDA-approved anti-
cancer drug mitomycin C eradicates persister cells. The 
authors demonstrated that the drug: eradicates cells grown in 
numerous different growth states and in both rich and minimal 
media; worked against persisters from multiples species of 
bacteria, including Escherichia coli K-12 as well as pathogenic 
species of E. coli, Staphylococcus aureus and Pseudomonas 
aeruginosa; and its efficacy in ‘an animal model and a wound 
model, substantiating the clinical applicability of MMC against 
bacterial infections’.
459 A November 2011 review of best practice in improving 
community buy-in noted the importance of behavioural and 
social scientists in: helping communities to adopt proven 
interventions; and to scale up such measures to increase the 
impact of interventions. The author noted the importance of 
addressing cultural barriers from within communities.
460 In September 2014, the World Health Organization published 
details as to how anthropologists were helping medics fight 
Ebola Virus Disease in Guinea. In particular they noted: many 
villagers are wary of the medical teams battling the epidemic; 
anthropologists from the sub-region helped to mediate with 
local people; and that traditional beliefs and the high illiteracy 
rate make the task harder.
461 In January 2015, the World Health Organization published 
information on best practice learned from the Ebola Virus 
Control Teams deployed in West Africa. They noted the 
important role that anthropologists played in listening to 
affected communities, providing psychosocial assistance to 
families and people who have come into contact with the 
disease, and help to calm the fears of people. Such integration 
into the communities has helped identify additional cases of the 
disease and determine additional chains of infection, assisting 
in epidemiological and control efforts.
462 A December 2012 review of best practice in preventing 
pandemics via international development found that ‘that the 
most prominent driver is the breakdown or lack of public health 
infrastructure and argue that there is a mismatch between the 
drivers of public health events and current trends in public 
health spending and pandemic prevention’.
463 An April 2013 review of prevention and control strategies for 
emerging infectious diseases highlighted that ‘the response 
to pandemic influenza outbreaks has improved markedly 
in terms of control strategies, stockpiles of antivirals, and 
vaccine development. These improvements also suggest 
advances in disease surveillance, transparency in reporting, 
and regional collaboration and cooperation’. The authors noted 
shortcomings in focusing ‘on high-risk groups, quantitative and 
measurable results… and quantitative assessment’.
464 In April 2013, Milne et al reported having modelled the cost 
effectiveness of pandemic influenza interventions. The authors 
demonstrated that ‘the most cost effective strategies for 
mitigating an influenza pandemic involve combining sustained 
social distancing with the use of antiviral agents’. The authors 
also differentiated between low intensity and high intensity 
pandemics. The noted ‘during low severity pandemics costs 
are dominated by productivity losses due to illness and social 
distancing interventions, while for high severity pandemics 
costs are dominated by hospitalisation costs and productivity 
losses due to death’.
465 In May 2014, Halder et al reported having modelled the cost 
effectiveness of pre-pandemic influenza vaccination. The authors 
demonstrate that ‘compared to reactive vaccination, pre-emptive 
strategies would be more effective and more cost effective, 
conditional on the pre-pandemic vaccine being able to achieve 
a certain level of coverage and efficacy. Reactive vaccination 
strategies exist which are as effective at mortality reduction as 
pre-emptive strategies, though they are less cost effective’.
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466 In March 2012, Hong et al reported an integrated model 
of environmental transport and human health exposure to 
biological pathogens. The authors used the model ‘to develop 
quantitative guidelines for how environmental pathogen 
concentrations may be related to human health risk in an indoor 
environment’. The authors espouse the model to ‘provide a 
framework for developing the many different environmental 
standards that are needed for making risk-informed response 
decisions, such as when prophylactic antibiotics should be 
distributed, and whether or not a contaminated area should 
be cleaned up’. This model was updated in May 2015 to 
take advantage of actual data from the sites of one of the 
anthrax letter attacks to reduce the uncertainties of inputs with 
uniformed prior estimates.
467 A January 2015 review of engineering control of respiratory 
infection and low-energy design of healthcare facilities 
highlighted ‘active research and development on reducing 
hospital energy use while improving infection control and 
discusses the potential for conducting “clinical trials” to 
gain the necessary evidence to support changes in hospital 
ventilation design’.
468 In May 2015, Cooney et al reported on possibilities for 
community-based early detection for Ebola response. The 
authors use models to show that 50% engagement with such 
strategies could lead to a rapid decline of new cases. The also 
use the model to show ‘travel restriction policies to be effective 
at reducing the risks associated with compliance substantially 
below the 40% level, shortening the outbreak and enabling 
efforts to be focused on affected areas’.
469 In May 2015, Hamilton et al reported ‘an analysis of post-
attack response strategies to mitigate the risks of reoccupying 
contaminated areas following a release of Bacillus anthracis 
spores… in an urban setting’. The authors determine that: for 
high-risk scenarios, evacuation and building decontamination 
is desirable; for medium-risk scenarios, ‘the preferred option is 
to evacuate for a short period, vaccinate, and then reoccupy 
once the vaccine has taken effect’; for low-risk scenarios, only 
vaccination is necessary; and for minimal risk scenarios, no 
mitigation strategy offers any degree of cost effectiveness.
470 In March 2013, Milton et al reported that ‘surgical masks worn 
by patients reduce aerosols shedding of virus. The abundance 
of viral copies in fine particle aerosols and evidence for their 
infectiousness suggests an important role in seasonal influenza 
transmission’.
471 A number of health agencies published advice on infection 
prevention and control measures for Ebola Virus Disease, 
following the largest ever outbreak of the disease in West 
Africa. For example, the Public Health Agency of Canada 
provided guidance on the minimum level of infection control 
measures, based on a review of available scientific evidence. 
The guidance covered: risk and transmission; preventing 
exposure and transmission; engineering controls, administrative 
controls and personal protective equipment; organizational risk 
assessment routine practices; point-of-care risk assessment; 
triage and screening; source control; hand hygiene; duration 
of precautions; notifications; handling of sharps; laboratory 
precautions; dedicated equipment; cleaning, disinfection and 
sterilization of medical equipment; environmental cleaning; 
handling bodies of deceased patients; handling dishes and 
cutlery; waste and linen management; education of patients 
and visitors; and visitor management.
472 A February 2013 review of the historical use of quarantine and 
other measures for controlling epidemic diseases highlighted 
controversies due to political, ethical, and socioeconomic 
issues and stressed the importance of finding a careful balance 
between public interest and individual rights.
473 A June 2014 review of the implications of the convergence of 
biology and chemistry highlighted ‘new research approaches 
to physical protective equipment’. The authors noted ‘Current 
research is directed primarily at systems which enhance 
protection but with reduced physiological burden for the 
wearer, and which are less cumbersome. There are also 
research efforts to develop self-decontaminating protective 
clothing, e.g. with the incorporation of enzymes and/or 
catalysts’. They highlighted research ‘to develop nanomaterials 
as effective gas mask canister adsorbents and for protective 
clothing which may have a lower burden for the wearer than 
current systems’.
474 A February 2013 review of the impact of scientific 
developments on the Chemical Weapons Convention 
highlighted the application of nanotechnology to improve 
materials and systems relevant for protection against CW 
and chemical decontamination is an area of gradual, but 
important development. Some areas of ongoing research that 
should continue to be monitored include the development 
of nanofibers for protective clothing, nanocatalysts for 
decontamination methods, and nano-based drug delivery 
mechanisms for medical countermeasures’.
475 An October 2014 review of the impacts of convergence of 
chemistry and biology highlighted that international reviews of 
scientific and technological developments had shown that:
•	 ‘the great benefits that convergence and, more generally 
speaking, the advances in the life sciences are expected 
to bring about. They reach from more effective medical 
countermeasures (for example… new diagnostic tools 
such as biosensors embedded in smart phones) to new 
decontamination methods or detectors for toxic chemicals as 
well as biological agents’;
•	 ‘advanced computational methods and directed evolution 
are used to develop enzymes tailored to address a specific 
industrial need… Given recent advances, it is now possible to 
take advantage of the tools of nature and those of molecular 
modelling to take existing, non-optimal enzymes and 
tailor their properties to drive chemical reactions with high 
selectivity and yield’. The authors noted that ‘this work may 
be useful is in treatment or deactivation of harmful materials 
either in vivo or as part of decontamination’.
476 In July 2011, Calfee et al reported testing the efficacy of 
six sporicides in remediating contamination with Bacillus 
anthracis ames on a variety of outdoor surfaces. The 
authors demonstrated that non-porous surfaces were easily 
decontaminated but that porous surfaces presented more of a 
challenge. Only one sporicide decontaminated all surfaces.
477 In March 2012, Calfree et al reported testing the efficacy of 
three decontaminates in remediating contamination with 
Brucella suis on a variety of outdoor surfaces. The authors 
demonstrates that ‘passive decontamination (through 
attenuation) may not be feasible, as this organism can persist 
for months. In addition, the results suggest that some sporicidal 
decontaminants may be ineffective on materials such as wood, 
even for vegetative biological agents such as Br. suis’.
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478 In May 2012, Calfee et al reported evaluating the effectiveness 
of two spray-based decontamination methods for surface 
contamination reduction and to determine the potential 
for contamination spread by these methods. The authors 
demonstrated ‘consideration of material surface type is 
important when selecting a decontaminant. Also, achieving 
conditions that effectively inactivate surface biological 
contamination are critical to preventing the spread of 
contamination’.
479 In January 2014, Kembel et al reported that architectural design 
drives the biogeography of indoor bacterial communities. The 
authors demonstrate ‘that humans have a guiding impact on the 
microbial biodiversity in buildings, both indirectly through the 
effects of architectural design on microbial community structure, 
and more directly through the effects of human occupancy 
and use patterns on the microbes found in different spaces 
and space types. The impact of design decisions in structuring 
the indoor microbiome offers the possibility to use ecological 
knowledge to shape our buildings in a way that will select for 
an indoor microbiome that promotes our health and well-
being’. Presumably, architectural decisions will also impact on 
how contaminated they might become following a deliberate 
release and how easily they can be decontaminated.
480 In January 2013, Yap et al reported data on the persistence of 
bacterial genomic DNA following autoclaving. They highlighted 
the potential for fragments of genetic material to be sufficiently 
complete to pose a risk for horizontal gene transfer – for 
bacterial species that come into contact with it to pick it up and 
to develop new properties. The authors highlight the potential 
for virulence genes, environmental persistence, or antibiotic 
resistance characteristics to spread in this manner. The results 
also offer interesting possibilities for downstream sampling 
(either in time or location) of effluent from facilities enabling 
inferences to be made as to what agents are being used, 
what characteristics those agents posses, and what activities 
were being undertaken. Equally, similar techniques might 
offer opportunities to find usable bioforensic data even after 
equipment has been autoclaved.
481 A 2015 review of the industrialisation of biology conducted 
by the US National Academies of sciences determined that 
“the past decade has seen an explosion in the technologies 
to com- pose, read, write, and debug DNA. This has rapidly 
increased the scale and sophistication of genetic engineering 
projects, and in the near term this will lead to more complex 
chemical structures and composite nano- materials, which 
require precise control over dozens of genes”. The authors 
concluded that “lowered costs, increases in production speed, 
flexibility of manufacturing plants, and increased production 
capacity are among the many potential benefits that the 
increased industrialization of biology may bring to producers 
and consumers of chemical products that have not been 
previously available at scale”. Furthermore “the growth of this 
field will enable the use of biology to produce high-valued 
chemical products that cannot be produced at high purity and 
high yield through traditional chemical synthesis. The future 
may also include a large number of high- volume chemicals, 
where biology represents a better synthetic pathway (cheaper 
and greener) than the conventional chemical synthesis”.
482 An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted a number 
of developments in vaccine production, including: 
•	 The ‘design of self-assembling influenza nanoparticle 
vaccines that elicit broader and more potent immunity than 
traditional influenza vaccines’ using synthetic nanoparticles 
eliminating ‘the need to grow potentially dangerous viruses 
in eggs or cell culture, a comparatively costly and time-
consuming step of commercial vaccine production’;
•	 ‘Many developments in vaccine design result in elimination 
of the need for production in high containment facilities and 
reduction of manufacturing times’;
483 An October 2014 review of the impacts of convergence of 
biology and chemistry highlighted that international reviews 
of scientific and technological developments had shown that 
genome editing techniques ‘including zinc finger nucleases, 
CRISPR/Cas, TALEN, and meganuclease’ are already in use. 
The authors noted ‘one project of particular interest… is that 
of the use of gene editing to remove Ricin from the castor 
plant. Removal of the toxin would also have obvious positive 
implications for the control of Ricin’.
484 In August 2013, Langlois et al reported a molecular 
biocontainment approach that did not prevent influenza 
replication and transmissibility in ferrets, but did attenuate 
influenza pathogenicity in mice, and (based upon the presence 
of species-specific endogenous small RNAs) humans. Such an 
approach should address biosafety concerns around gain-of-
function experiments and, according to the authors, ‘should 
be applicable beyond influenza A virus to minimize the risk of 
experiments involving other pathogenic viruses’.
485 In December 2014, McNamara et al reported the ‘rigorous 
screening program’ developed by the International Genetically 
Engineered Machines Competition to screen projects for 
potential risks. The authors noted the procedures were 
designed ‘to expand, not contract, the universe of acceptable 
projects’. They highlighted ‘policy process evolution thus far, 
screening findings from the 2013 competition, and expectations 
for future policy evolution’
486 In April 2015, a desktop gene printer was released. The printer 
was capable of assembling up to 32 genes of between 400 
and 1.8kb and included high fidelity production and dedicated 
error correction technologies.
487 A May 2014 review of emerging technology reported that 
two software engineers had compiled and rebooted a living 
virus from genetic material. The author noted that the two 
researchers working in an academic laboratory (to ensure 
the necessary safety and responsible conduct oversight) 
synthesised a bacteriophage in just over two weeks for about 
$1000. The genetic material was bought from commercial gene 
synthesis companies and then joined the fragments together 
and actived the virus – demonstrating that tacit knowledge is 
not a barrier to synthesing viruses.
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488 A May 2014 review of large-scale de novo DNA synthesis 
highlighted that since the creation of infectious poliovirus 
in 2001, ‘dozens of RNA viruses have been chemically 
reconstructed—including the 1918 Spanish influenza, the likely 
coronavirus progenitors to severe acute respiratory syndrome 
and many others for purposes of viral attenuation, historical 
reconstructions, vaccine development and viral genomic 
studies. Several DNA-based bacteriophages have been 
synthesized de novo as well. Beyond viral genomes, over a 
series of studies, the Venter Institute designed, built, assembled 
and transplanted a fully synthetic bacterial genome to encode a 
viable organism. Such efforts are only increasing. For example, 
the design, synthesis and viability of synthetically designed 
yeast chromosomal arms was shown… and work on a fully 
synthetic yeast genome is ongoing’.
489 A July 2012 working paper by the UK to the BWC Meeting of 
Experts highlighted ‘small peptides, including toxins, can be 
chemically synthesised – a service that is now readily available 
commercially. As one recent study has noted, peptides are of 
interest in the incapacitating chemical agent context because 
peptide based bioregulators are responsible for the control of a 
number of vital physiological functions in the human body’.
490 An October 2014 review of the impacts of convergence 
of chemistry and biology highlighted that ‘the technical 
capability for chemical synthesis of toxins exists, and synthetic 
biology approaches could also be used for toxin production 
and modification. Specifically, there is current research in 
synthesizing Saxitoxin by exploiting the function of sxt genes, 
expressing the Ricin A and B side chains through modifying 
E. coli, and chemically modifying conotoxins to develop new 
drug candidates’.
491 In December 2014, Jeon et al reported identifying genomic 
components that influence the toxicity of B. anthracis toxin 
through TNF-α production.
492 A May 2014 review of large-scale de novo DNA synthesis 
highlighted significant progress the understanding and 
engineering of regulatory elements. The authors noted:
•	 ‘Recent efforts focused on understanding the structural 
and functional characteristics of thousands of cis-regulatory 
sequences governing transcriptional, translational and other 
regulatory processes in mammalian, yeast and bacterial 
systems. Over the coming years, NGS-based methodologies 
that are developed to measure transcription, translation, 
epigenetics, splicing and other gene regulatory phenomena 
will also be used to analyze synthetic libraries. The goal is 
to understand which sequences are responsible for causal 
changes to these processes and how we can use them to 
engineer new functionalities’;
•	 To better understand and engineer particular genetic 
systems, agents have been refactored – their regulatory 
elements removed and well-characterized replacements 
added. Examples of refactoring in bacteria and 
bacteriophages were provided. ‘The refactored system 
reconstituted functionality, albeit at reduced production 
levels. Improvements in the design and automated assembly 
of these refactored segments allowed reconstitution to wild-
type production levels’; 
•	 Increasingly sophisticated methodologies for identifying and 
obtaining parts – for example, the application of ‘synthetic 
metagenomics for part mining to find libraries of orthogonal 
repressors (73 synthetic genes) and transcription factors 
(62 synthetic genes). Thus, as the genetic networks and 
pathways of engineered systems in synthetic biology get 
larger and studies move to new organisms, there will be 
increasing reliance on de novo DNA synthesis to generate 
requisite system components.
493 An August 2013 statement by Iran on behalf of the Group of 
NAM and other States Parties to the BWC Meeting of Experts, 
reiterated in December 2014, highlighted ‘due to the dual use 
nature of some of the new technologies, there is a potential 
for uses contrary to the provisions of the Convention including 
by programming cells to produce toxins, viruses or other 
cells which could cause harm, designing and building new or 
altered pathogenic viruses, the ability to confer mammalian 
transmissibility to viruses or drug resistance to pathogens, 
the decreasing genetic diversity and the development of 
incapacitating weapons and the increasing capacity to deliver 
biological weapons via the alimentary route’.
494 In May 2013, Amato et al reported the metabolic control 
mechanisms for persister formation in E. coli. Persister cells 
are one way that bacterial populations become resistant 
to antibiotics by responding to stress by signaling a small 
percentage of their population to enter into a dormant mode.
495  An April 2014 review of molecular mechanisms underlying 
bacterial persisters highlighted how recent technological 
advances in microfluidics and reporter genes have improved 
our understanding. The authors note that ‘ubiquitous bacterial 
stress alarmone’ is an emerging central regulator of multidrug 
tolerance and persistence and that ‘in several different 
organisms, toxin-antitoxin modules function as effectors of… 
persistence’.
496 A July 2012 working paper by the Russian Federation for the 
BWC Meeting of Experts highlighted ‘research papers devoted 
to creation of bacterial formulations were published in 2011-
12 by scientists from Finland (lactic acid bacilli) and the USA 
(tularaemia, salmonellosis)’.
497 A July 2012 statement by Switzerland to the BWC Meeting 
of Experts noted that ‘biological systems and even, to 
some extent, living organisms can be built from scratch 
and manipulated in ways that are unprecedented. Such 
sophisticated developments and the associated technology 
have enormous potential for public health, biomedical science, 
and agriculture. However, they may also pose risks to our 
societies as the same knowledge and the products and 
technologies involved can be misused to cause harm’.
498 In September 2011, Dymond et al reported completed the 
redesign and synthesis of a chromosome arm of yeast. This 
is the first step in an attempt to engineer an entire eukaryote 
genome to conform to three design principles: ‘first, it should 
result in a (near) wild-type phenotype and fitness; second, it 
should lack destabilizing elements such as tRNA genes or 
transposons; and third, it should have genetic flexibility to 
facilitate future studies’.
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499 In April 2014, Annaluru et al reported the successful redesign 
of the first full chromosome in the SC2.0 project. The authors 
demonstrated that the chromosome was full functional in 
Saccharomyces cerevisiae.
500 An October 2014 review of the convergence of biology and 
chemistry highlighted:
•	 The use of TALENs gene editing to ‘add a function to a 
crop (herbicide-resistant cotton plant), remove functionality 
in a crop (non-pollinating corn to facilitate controlled 
hybridisation), and modify functionality (change pigment 
expression in flowers)’;
•	 Using genomics, transcriptomics, proteomics and 
metabolomics approaches together ‘to design organisms 
with desired properties. These tools have been applied in 
three different industrial projects: The production of lysine 
– a feed additive – using Corynebacterium glutamicum, 
production of xanthan – a thickener for use in food and 
personal care products – using Xanthomonas campestris pv. 
campestris, and production of acarbose – a medication used 
to treat type II diabetes – by Actinoplanes sp. For each of 
these projects it was critical to obtain information about the 
cellular machinery, from genome to metabolome, in order to 
rationally approach modifying the organism’;
•	 Research to use CRISPR/CAS9 gene editing technologies to 
treat disease. The authors noted ‘experiments on monkeys 
inactivating the genes for two human diseases, which poses 
the question of potential applications in humans’;
•	 ‘Using one-step synthesis, it is possible to generate 
nanoparticles coated with arrangements of hydrophobic and 
hydrophilic compounds on a length scale similar to biological 
materials’. The authors noted that ‘these nanoparticles have 
been shown to have the ability to penetrate cell membranes. 
Such nanoparticles could either be designed to carry 
small payloads of highly active drugs (for example certain 
peptides), or the nanoparticle itself could act as a drug by 
interacting with viruses’;
•	 ‘A number of computational methods, software tools and 
programming languages have recently emerged in the 
life science community which have served to compress 
the laboratory time required for converting design of a 
recombinant vector to its delivery’.
501 A July 2012 working paper by China for the BWC Meeting of 
Experts highlighted ‘an alternative cryptic approach to attack 
human population specifically through population specific 
microbes’. The authors also noted ‘revelation of pathogenic 
microbes’ genome evolution and its relation with infectivity 
and pathogenicity and greatly enhance the surveillance, 
diagnosis and therapy of related infectious diseases. There 
is no doubt that such DNA sequence information can also be 
used for the modification of antigenicity, infectivity, toxicity and 
drug resistance of traditional pathogens, even for the artificial 
design and synthesis of totally new pathogens, which will 
lead to the failure of traditional prevention and treatment of 
infectious diseases and make efficient prevention and control 
more difficult’. They also highlighted ‘primary results of human 
microbiome researches… indicate that our normal physiological 
functions are closely related to our second genome, whose 
disorder might affect normal physiological metabolism of 
humans and even cause illness’.
502 In January 2011, Kim et al reported having developed 
preassembled zinc-finger arrays for rapid construction of Zinc 
Finger Nucleases, which are an important genome editing 
tool. The authors demonstrated using the array and having 
‘assembled and tested ZFNs to target a human gene and 
a mouse gene’. They noted that this technology enabled 
‘rapid construction of ZFNs in a few days using conventional 
recombinant DNA technology, and fewer ZFNs need to be 
synthesized to obtain a functional enzyme’.
503 A February 2011 review of optimized transcription activator-like 
effectors highlighted their potential for ‘efficient genome editing 
and transcriptome modulation’.
504 In July 2011, Isaacs et al reported a mechanism for genome-
wide codon replacement enabling the precise manipulation 
of chromosomes in vivo. The authors reported using two 
tools multiplex automated genome engineering (MAGE) and 
conjugative assembly genome engineering (CAGE) ‘capable of 
fundamentally reengineering genomes from the nucleotide to 
the megabase scale’. They demonstrated having merged ‘sets 
of codon modifications into genomes with 80 precise changes’.
505 In November 2012, Bedell et al reported using designed 
transcription activator-like effector nucleases (TALENs) for 
‘targeted zebrafish genome editing and functional genomic 
applications’. The authors demonstrated having ‘used single-
stranded DNA oligonucleotides to precisely modify sequences 
at predefined locations in the zebrafish genome through 
homology-directed repair’. They also showed successful 
germline transmission of engineered chromosomes.
506 An August 2014 statement by Switzerland to the BWC Meeting 
of Experts highlighted the use of CRISPR/CAS9 systems and 
that ‘recent advances have now demonstrated that this feature 
of the bacterial immune system can be exploited to edit, silence 
and activate genes at any given site in virtually any kind of 
genome, including human cells. It promises to become a very 
powerful genomic engineering tool that may be very useful in 
terms of e.g. gene therapy or research’.
507 In July 2015, Schumann et al reported a significant step towards 
the clinical application of CRISPR/CAS9 genome editing. The 
authors reported having developed ‘a programmable tool 
to replace specific nucleotide sequences in the genome 
of mature immune cells’. They noted their approach could 
‘efficiently “knock out” genes and “knock in” targeted genome 
modifications to modulate T-cell function’.
508 An August 2014 commentary on reports of CRISPR/CAS9 gene 
drives highlighted that inheritable selfish genes ‘could also 
be used to alter populations of agricultural plants or livestock 
by actors intent on doing harm’. The authors noted ‘gene 
drives and most other advanced applications of genomic 
engineering do not use proscribed agents or create regulated 
toxins and hence fall beyond the scope of operational 
regulations and agreements’.
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509 An August 2014 presentation to the BWC Meeting of Experts 
highlighted the potential to use CRISPR/CAS9 gene drives 
to influence the inheritance of genes in sexually reproducing 
animals and plants with short reproduction cycles. The author 
noted implications for: ‘gain-of-function enabling ability to host 
diseases; suppression of crops and livestock in traditional 
agriculture; suppression of pollinators and other keystone 
species Immunization drives may protect self and allies from 
effects; and the reversal drives may be withheld for economic 
or political gain.
510 A September 2015 review of the history of optogenetics, 
examines technical developments in the field over the last 10 
years. The authors describe an exponential growth in papers 
being published with keywords associated with optogenetics 
since the Seventh Review Conference.
511 A November 2014 article in Nature highlighted the application 
of novel microscopy “technique that makes mouse brains 
transparent shows how the entire brain responds to cocaine 
addiction and fear”. The authors note that such research “could 
uncover new brain circuits involved in drug response”.
512 A July 2012 statement by Poland to the BWC Meeting of Experts 
highlighted ‘the potential military, terrorist uses of molecules 
such as biological regulators and their dual use implications. In 
particular important features and military advantages of the new 
bioregulators are novel sides of toxic action, rapid and specific 
effect, penetration of protective filters and equipment and 
military effective incapacitation’.
513 A July 2012 working paper by the UK for the BWC Meeting of 
Experts highlighted ‘potential military and law enforcement 
applications arising from… key advances in neuroscience, 
including neuropharmacology, functional neuroimaging and 
neural interface systems’.
514 A June 2014 review of the implications of the convergence of 
biology and chemistry highlighted:
•	 ‘Drug companies have screened large numbers of 
metabolically resistant analogues [of peptides], mostly with 
unnatural (chemical) modifications, some of which may have 
substantially increased potency and toxicity. However, such 
modifications may add to the complexity and cost of the end 
product’
•	 ‘Some peptides that cause bronchoconstriction, e.g. 
substance P, have been reported to have moderate to high 
inhalation toxicity in small rodent species. Such peptides 
interact with receptors on the surface of the lung which does 
not require penetration of membranes’;
•	 ‘Other types of bioregulators should also be noted. For 
example, some of those derived from lipid pathways, such 
as eicosanoids (prostaglandins, thromboxanes, leukotrienes) 
and platelet activating factor, have high physiological activity, 
and in some cases high toxicity (particularly metabolically 
less labile analogues). These have mostly been synthesised 
through multistage chemical processes, although biologically 
mediated stages are known’.
515 A July 2012 presentation by the Netherlands to the BWC 
Meeting of Experts highlighted that synthetic biology would 
facilitate using genes to programme cells to become ‘microbial 
factories’ to make a high value product, like pharmaceuticals, 
bioplastics, or biofuels, alternatively it could be used to make 
‘dedicated cells or viruses for misuse’.
516 An August 2012 review of synthetic biology highlighted progress 
in: DNA synthesis and assembly; design and production 
of biological parts; protein engineering; understanding, 
manipulating and building networks and pathways; synthetic life; 
software and modeling; and instruments.
517 A January 2014 review of synthetic biology in mammalian 
cells highlighted that ‘a new generation of synthetic biology 
research tools’ and ‘programmable DNA-binding domains 
and RNA regulators are leading to unprecedented control of 
gene expression and elucidation of gene function. Rebuilding 
complex biological circuits such as T cell receptor signaling 
in isolation from their natural context has deepened our 
understanding of network motifs and signaling pathways’.
518 An August 2014 presentation by the OPCW to the BWC Meeting 
of Experts highlighted enabling technologies having resulted in 
‘an expanded capability to redesign or manipulate organisms’ 
and ‘to design and engineer improved enzymes’. The authors 
noted ‘peptides are the largest group of bioregulators and 
have been the class for which commentators on the CWC 
have expressed most concern for misuse… Peptides could 
be produced using metabolic engineering and synthetic 
biology but the pharmaceutical industry currently regards 
multi-step chemical synthesis, using specialized equipment, 
as the most cost- effective method for producing many small 
peptides’. The authors noted that ‘there are shortcomings of 
peptides as drugs’. An October 2014 review of the impacts of 
convergence of chemistry and biology highlighted that ‘using 
tools that are already available, including direct insertion 
of gene sequences and directed evolution, organisms and 
molecules can be guided to meet a specific purpose within a 
reasonable timeframe and with a degree of reliability that was 
not previously possible. A number of examples were presented 
and discussed for industrial-scale production of complex 
molecules with application in medicine and elsewhere’.
519 A May 2013 review highlighted progress in combining 
computational design of enzymes with directed evolution, 
molecular dynamics simulations, and crowd-sourced structure-
prediction approaches to result in significant improvements in 
binding, turnover, and thermal stability.
520 In November 2013, Cherny et al reported engineering enzymes 
to detoxify V-type nerve agents using computationally focused 
libraries. The authors used ‘an integrated computational and 
experimental approach to increase Brevundimonas diminuta 
phosphotriesterase’s (PTE) detoxification rate of V-agents by 
5000-fold’. They experimental tested the results and fed them 
back to improve the computational models. After five rounds, 
the authors had variants that ‘hydrolyze the toxic SP isomers 
of all three V-agents with kcat/KM values of up to 5 × 10(6) M(-1) 
min(-1) and also efficiently detoxify G-agents’.
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521 A January 2015 review of tools for creating custom organisms 
in yeast highlighted ‘computational tools for the prediction of 
biochemical pathways, molecular biology methods for assembly 
of DNA parts into pathways, and for introducing the pathways 
into the host, and finally approaches for optimizing performance 
of the introduced pathways’.
522 In September 2013, Procko et al reported the computational 
design of a protein-based enzyme inhibitor. The authors used 
computational design techniques to design a protein that 
binds to the acidic active site of hen egg lysozyme and inhibits 
the enzyme. The authors demonstrated experimentally that 
the designed protein ‘bound lysozyme with low nanomolar 
affinity, and a combination of NMR studies, crystallography, and 
knockout mutagenesis confirmed the designed binding surface 
and orientation’.
523 An October 2014 review of the convergence of biology and 
chemistry highlighted:
•	 ’The technical capability for chemical synthesis of toxins 
exists, and synthetic biology approaches could also be used 
for toxin production and modification’. The authors noted 
recent research with Saxitoxins;
•	 The use of genome editing technologies to remove Ricin 
from the castor plant. The authors noted ‘there were 
questions about whether it would be possible to use these 
techniques to increase (rather than remove) the number of 
copies of the gene sequence for one of the isoforms in the 
castor plant, to increase the concentration of Ricin toxin. 
Though this was deemed technically feasible, it remains 
questionable whether and why someone wishing to acquire 
large quantities of Ricin would not simply follow the low-cost 
and low-tech avenue of planting more castor plants’.
524 A May 2014 review of large-scale de novo DNA synthesis 
highlighted significant progress in efforts ‘to engineer new 
protein functions by taking advantage of computational 
design and metagenomic information’. The authors noted 
‘the development of deep mutational scanning techniques to 
measure structure-function relationships in multiplex will enable 
rapid characterization of large designed synthetic gene libraries 
as synthesis methods improve’.
525 A March 2012 review of developments in vaccine production 
highlighted the use of suspended cultures which reduces the 
physical space required for vaccine production and significantly 
reducing cost by enabling batch processing of verification 
steps, and dramatically increasing surge production capacity. 
The authors noted that the ‘actual facility and the equipment is 
much smaller for getting the same amount of doses’.
526 A February 2013 review of the impact of scientific 
developments on the Chemical Weapons Convention 
highlighted microreactors ‘alter the signature of chemical 
production infrastructure to some extent, although they are 
only one piece of a sequence of infrastructure’. The authors 
noted they ‘could shorten the time from the discovery of 
a new class of toxic chemicals to production of selected 
agents. There is also the possibility that other toxic chemicals 
(e.g., pharmaceuticals and peptides) could be produced in 
microreactors for prohibited purposes’.
527 An October 2014 review of the convergence of biology and 
chemistry highlighted:
•	 ‘The potential of 3D printing for building customised reaction 
vessels, such as micro-reactors and the related processing 
equipment, which although limited in volume sizes… offers a 
means to subvert traditional controls on process equipment 
made of high performance and corrosion resistant materials’. 
The authors also noted ‘3D-printed tissue culture systems… 
potentially offered actors the possibility of lower production 
costs and materials used and, significantly, a smaller footprint 
for production’;
•	 ‘A number of computational methods, software tools and 
programming languages have recently emerged in the 
life science community which have served to compress 
the laboratory time required for converting design of a 
recombinant vector to its delivery’. 
528 In February 2015, Kelwick et al reported having used a forward 
design approache to engineer E. coli to produce increasing 
amounts of a plastic. Having compiled a device for the 
production of the plastic the authors then developed a series 
of different devices using different promoters and ribosome 
binding sites. They reported a combination that resulted in 
a six-fold increase in plastic production. The authors also 
demonstrated thefeasibility of using non-recyclable waste as a 
low-cost carbon source for this biodegradable plastic.
529 An October 2014 review of the impacts of convergence of 
chemistry and biology highlighted that:
•	 ‘Using tools that are already available, including direct 
insertion of gene sequences and directed evolution, 
organisms and molecules can be guided to meet a specific 
purpose within a reasonable timeframe and with a degree 
of reliability that was not previously possible. A number 
of examples were presented and discussed for industrial-
scale production of complex molecules with application in 
medicine and elsewhere’;
•	 Progress in industrial biology is helping ‘to develop effective, 
scalable and robust processes that convert a renewable 
feedstock such as sugar, using a microorganism such 
as genetically engineered yeast, to a desired chemical 
compound at industrial scale’. The authors noted an example 
where ‘to reduce time and costs, the company automated 
and miniaturised as many repetitive R&D processes as 
possible… Though the infrastructure for automation was 
expensive to develop (~$200 M), the cost per sequence to 
develop has dropped exponentially with the implementation 
of this process, and the rate at which new sequences are 
developed has increased by magnitudes;
•	 ‘The response of the organisms to the environment of a 
fermenter is not predictable, and any new organism must be 
carefully tested to prevent failures at the pilot plant scale. 
The timeline for development of a new product has been 
substantially reduced… However, the cost and time required 
to produce a new viable, scalable method are still high’.
530 A March 2012 review of developments in vaccine production 
highlighted directed evolution to remove reliance on animal 
serum, reducing cost, stabilising ingredient chains, and assisting 
in meeting purification standards.
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531 A November 2013 review of emerging nanotechnology-based 
tools for biology and medicine, highlighted the potential to use 
nanoparticles ’to partition bulk solutions into smaller volumes 
that contain discrete numbers of molecules or cells’. The 
authors noted ‘libraries of droplets encoding different analytes 
such as drug compounds, viruses, antibodies, or enzymes 
could be screened against cells or other reactants’. They 
provide one example where this ‘technology was applied to 
the directed evolution of the enzyme horseradish peroxidase, 
which generated mutants with catalytic rates >10 times faster 
than the parent, with a 1000-fold increase in speed and a 1 
million-fold reduction in cost’.
532 A February 2013 review of the impact of scientific developments 
on the Chemical Weapons Convention highlighted:
•	 ‘The production of toxic chemicals, including toxins, through 
biological synthesis (an aspect of the convergence of 
chemistry and biology); encapsulation and delivery through 
nanotechnology; and flow microreactors, which enable 
types of chemical reactions under conditions that were not 
previously technically feasible’;
•	 ‘Microreactors have now entered the chemical production 
toolkit for certain kinds of operations. They alter the 
signature of chemical production infrastructure to some 
extent, although they are only one piece of a sequence of 
infrastructure’. The authors noted the ‘major advantages 
of microreactor technology include the safe production of 
hazardous, corrosive chemicals, as well as certain classes of 
biologically active chemicals, which could not be otherwise 
done under batch conditions’. They also highlighted 
they ‘could shorten the time from the discovery of a new 
class of toxic chemicals to production of selected agents. 
There is also the possibility that other toxic chemicals 
(e.g., pharmaceuticals and peptides) could be produced in 
microreactors for prohibited purposes’. 
533 A June 2014 review of the implications of the convergence of 
biology and chemistry highlighted:
•	 ‘A variety of microbes have been modified for commercial 
production. Metabolic engineering methods and techniques 
are becoming more mature and diverse chemicals can be 
produced on a commercial scale by engineered organisms’; 
•	 ‘Engineered yeasts and bacteria are being used in process 
development plants and large scale production facilities 
around the world to produce ethanol as well as other 
products’;
•	 ‘Biocatalysts (enzymes), usually immobilised, are being 
increasingly applied in the industrial production of bulk 
chemicals and pharmaceuticals. To overcome the limitations 
of naturally occurring enzymes, directed evolution has 
become an important tool for improving activity, selectivity, 
solvent tolerance and general robustness’;
•	 Reprogrammed microorganisms have been created ‘to 
produce biofuels by manipulating metabolic and biosynthetic 
pathways, and the production of drugs that are difficult to 
synthesise or which otherwise would need to be extracted 
from scarce raw materials. Recent examples include the 
production of anthranilic acids such as the anti-allergic 
tranilast in modified yeast strains, and the production of 
terpenoid compounds which form the basis of perfumes and 
many drugs, including novel antimicrobial drugs’;
•	 ‘A survey of synthetic biology products published in 
2012 provides additional insight into applications under 
development. The survey identified 68 products across seven 
sectors (including biofuels, chemicals, energy, food, materials, 
and medicine) being developed by companies in 10 countries’;
•	 ‘Substantial advances in production methods for peptides 
have been made in the last two decades. Although they 
could be produced in genetically modified organisms, 
the pharmaceutical industry currently regards chemical 
synthesis as the most cost-effective method for producing 
many small peptides’.
534 An October 2014 review of the convergence of biology and 
chemistry highlighted:
•	 Using directed evolution ‘to take existing, non-optimal 
enzymes and tailor their properties to drive chemical 
reactions with high selectivity and yield’. The authors noted 
that ‘from an industrial perspective, this technology has the 
potential to increase efficiency and reduce waste in existing 
or new processes… This has already been demonstrated 
as possible by Merck Company, which, in collaboration 
with Codexis, revised a process to incorporate an artificial 
enzyme instead of a man-made catalyst after only 11 rounds 
of directed evolution’;
•	 ‘Growing research interest in toxins for applications in medical 
treatment, life sciences research, pharmaceuticals, and 
agriculture shows that technological advances are changing 
the way in which toxins are being produced and used’;
•	 The use of TALENs gene editing to ‘add a function to a 
crop (herbicide-resistant cotton plant), remove functionality 
in a crop (non-pollinating corn to facilitate controlled 
hybridisation), and modify functionality (change pigment 
expression in flowers)’;
•	 Using genomics, transcriptomics, proteomics and 
metabolomics approaches together ‘to design organisms 
with desired properties. These tools have been applied in 
three different industrial projects: The production of lysine 
– a feed additive – using Corynebacterium glutamicum, 
production of xanthan – a thickener for use in food and 
personal care products – using Xanthomonas campestris pv. 
campestris, and production of acarbose – a medication used 
to treat type II diabetes – by Actinoplanes sp.’;
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•	 Increasing miniaturization and automation, combined with 
the use of standardised biological parts – for example ‘a 
“toolbox” of sequences that have specific effects (gene 
sequence promoters, tags, terminators, etc.) were identified 
and catalogued to allow for easier sequence development’. 
The authors noted such an approach ‘increases quality 
control, aids in records keeping and project tracking, and has 
increased the rate of sequence development significantly. 
This has also reduced the technical skill level required to 
perform the synthesis’. The authors also highlighted the 
potential to combine this approach with directed evolution.
535 A May 2015 review buy Liu and Stewart of plant synthetic 
biology examined enabling tools including those for designing 
components and their assembly and deployment. The authors 
provided examples of engineering synthetic sensors, metabolic 
pathways, and plastids. 
536 A July 2012 statement by Poland to the BWC Meeting of 
Experts highlighted that ‘advances in science and technology 
alter possible methods of production for molecules like toxins 
and regulators. Therefore, this biologically active compound 
increasingly can be produced in large amounts through 
chemical synthesis or biological process’.
537 A July announcement reported ‘the launch of the first 
commercial surfactant derived from microalgae oil’. The 
authors noted the use of ‘a highly controlled fermentation 
process to convert sugarcane into oils of the highest purity 
and performance’.
538 A June 2014 review of biopharming highlighted progress in 
‘flexible and rapid engineering methods, combined with benefits 
of high volume expression for protein isolation, or seed-based 
long-term storage’. The author noted that a number of products 
are already under development and that the FDA had already 
approved a ‘recombinant plant drug to treat a disease’.
539 An October 2014 review of the convergence of biology and 
chemistry highlighted the use of TALENs gene editing to 
‘add a function to a crop (herbicide-resistant cotton plant), 
remove functionality in a crop (non-pollinating corn to facilitate 
controlled hybridisation), and modify functionality (change 
pigment expression in flowers)’.
540 A June 2014 review of novel start-ups highlighted the 
emergence of virtual biotechnology companies. The authors 
describe a small number of new companies founded by 
a number of individuals with an idea. In some cases, the 
companies have no employees or laboratory space but 
outsource all the work to consultants.
541 An April 2013 review of single use bioreactors highlighted 
that ‘A number of bioprocess analysts estimate that the entire 
single-use market has been growing at about 15–20% per year. 
Single-use bioreactors (SUB), in particular, are rapidly increasing 
in popularity and seem destined to stay’.
542 An August 2012 industry survey of 300 biomanufacturers 
‘indicated a clear preference’ for single-use bioreactors. At 
the clinical scale two-thirds of respondents indicated that they 
expected to implement batch-fed single use bioreactors (as 
opposed to just under a third who expected to use stainless 
steel batch–fed bioreactors). At the commercial scale, over half 
of respondents expected to still be using stainless steel (which 
is a significant reduction from the current market share).
543 An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted ‘single-use 
or disposable bioreactor systems have also progressed; these 
are easily installed, reduce costs, streamline validation, increase 
product consistency and reduce overall turnaround times. 
Simple rocker bags are suited to cell-culture for virus vaccine 
production as an alternative to traditional methods of growth in 
embryonated eggs. Single-use or disposable components also 
feature increasingly in downstream processing equipment’.
544 An October 2014 review of the impacts of convergence of 
chemistry and biology highlighted ‘the potential of 3D printing 
for building customised reaction vessels, such as micro-reactors 
and the related processing equipment, which although limited in 
volume sizes (at the moment: 10 ml or less) could nevertheless 
eventually allow someone outside a chemistry laboratory or 
plant to print production equipment configured specifically for a 
particular end product. The technology thus offers a means to 
subvert traditional controls on process equipment made of high 
performance and corrosion resistant materials’.
545 In 2011, the US National Academies of Sciences published 
a report reviewing the threat posed by fungal diseases 
to human, animal and plant health. The report addresses 
fungi as pathogens, noting their ability to ‘cause disease in 
healthy humans and animals’ as well as to ‘endure adverse 
environmental conditions and thrive outside their host’. The 
impact on plants was also stressed, noting that fungal plant 
pathogens had been responsible for the Irish Potato Famine, 
the Southern Corn Leaf Blight epidemic of the 1970s as well as 
Dutch Elm disease. Comparatively little attention has been paid 
to the potential use of fungal pathogens as a weapon, despite 
their comparative environmental stability.
546 In March 2013, Wessman et al reported four different formulae 
and approaches for freeze drying bacteria. The authors 
compared cell survivability in competing approaches and 
identified key properties whose control can significantly 
influence survival rates.
547 An August 2013 working paper submitted by the United 
Kingdom to the BWC Meeting of Experts highlighted:
•	 ‘The ‘creation of a synthetic vaccine for foot and mouth 
disease’. The authors noted ‘steps to engineer enhanced 
stability characteristics into the construct mean that it would 
not require cold storage and that it would be cheaper to 
produce and distribute’;
•	 ‘Encapsulation of vaccines in silk matrices has been 
evaluated with the MMR vaccine, demonstrating that the 
matrices were capable of stabilising labile vaccines for more 
than six months over a range of tropical temperatures’.
548 An October 2012 review of advanced materials and processing 
for drug delivery highlighted ‘innovation in material chemistry 
allows the generation of biodegradable, biocompatible, 
environment-responsive, and targeted delivery systems. 
Nanotechnology enables control over size, shape and multi-
functionality of particulate drug delivery systems’.
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549 A June 2014 review of the implications of the convergence of 
biology and chemistry highlighted:
•	 ‘The shortcomings of peptides as drugs (and by implication 
for uses prohibited by the Convention) can be moderated 
in several ways. Formulations, particularly associated with 
liposomes or nanocarriers, are being explored to enhance 
penetration of the blood brain barrier, overcome host 
defences, and target specific organs’;
•	 ‘Nanoparticle-based formulations are being widely explored 
for enhanced or ‘smart’ drug delivery. Examples are 
controlled drug release, enhanced penetration of the blood 
brain barrier (e.g. for therapeutic peptides), and targeting 
specific organs or cells (e.g. cancer cells). Nanoparticles 
most commonly used in drug formulations include: imprinted 
polymers, dendrimers, vesicles, nanospheres, nano-capsules, 
micelles, carbon nano-tubes, liposomes, and nano-emulsions. 
Additional bio-based nanocarriers are being researched 
including DNA-based systems and viral-based systems’;
•	 ‘Nanocarrier-based delivery systems present several 
advantages over the classic ones: overcoming solubility 
problems, protecting the drug from the external 
environment (temperature, UV radiations, pH), and 
controlling the release profile’;
•	 ‘Nanocarrier-based delivery systems permit a more precise 
and controlled targeting at the site of action, while reducing 
the time of exposure at non-targeted tissues. This can 
increase efficacy, and reduce toxicity and side effects’.
550 An October 2014 review of the convergence of biology and 
chemistry highlighted ‘using one-step synthesis, it is possible 
to generate nanoparticles coated with arrangements of 
hydrophobic and hydrophilic compounds on a length scale 
similar to biological materials’. The authors noted that ‘these 
nanoparticles have been shown to have the ability to penetrate 
cell membranes. Such nanoparticles could either be designed 
to carry small payloads of highly active drugs (for ex- ample 
certain peptides), or the nanoparticle itself could act as a drug 
by interacting with viruses’.
551 A February 2013 review of the impact of scientific developments 
on the Chemical Weapons Convention highlighted:
•	 ‘The production of toxic chemicals, including toxins, through 
biological synthesis (an aspect of the convergence of 
chemistry and biology); encapsulation and delivery through 
nanotechnology; and flow microreactors, which enable 
types of chemical reactions under conditions that were not 
previously technically feasible’; 
•	 ‘The application of nanotechnology to improve materials and 
systems relevant for protection against CW and chemical 
decontamination is an area of gradual, but important 
development. Some areas of ongoing research that 
should continue to be monitored include the development 
of nanofibers for protective clothing, nanocatalysts for 
decontamination methods, and nano-based drug delivery 
mechanisms for medical countermeasures’; and 
•	 ‘New polymers, lipids, and other carrier materials for drugs 
or genes is an area of active research. These carriers may 
be used as components of nanomedicines, in which the 
properties of the carrier influence the biodistribution of 
the therapeutic agent that is bound or complexed with it. 
Both the chemical properties of the carrier (e.g., the relative 
hydrophilicity and hydrophobicity or the conjugation of 
“functionalizing” molecules to target particular cellular 
receptors) as well as physical properties (such as size and 
shape) influence the uptake and residence time of a drug in 
the body. These types of nanomedicines have a wide range 
of applications, including improved delivery across biological 
barriers such as the blood–brain barrier, prolonged 
residence time in the blood (reduced clearance in the liver), 
and improved targeting to particular cell types’.
552 In January 2014, Kembel et al reported that architectural design 
drives the biogeography of indoor bacterial communities. Their 
analysis might be of use in modeling how an attack might be 
optimized in a closed space.
553 In September 2012, Emaneul et al reported a novel mechanism 
for tagging agents to study their environmental spread. The 
authors noted that ‘the use of genetically tagged spores 
overcomes the ambiguity of discerning the test material from 
pre-existing environmental microflora or from previously 
released background material’. They demonstrated under field 
conditions that it was possible to detect the released agent 
and differentiate it from other tagged agents and wild-type 
spores. As a proof of principle, in September 2012, Buckley et 
al reported using this barcoding system to track a release of a 
B. anthracis simulant.
554 A May 2012 review of the use of nanopartices in drug delivery 
highlighted that ‘nanoparticle suspensions which contain 
medicines i.e. ‘nanomedicines’) has made it possible to increase 
the therapeutic index of many components (improvement of 
the activity, reduction of toxicity) by selectively directing them 
towards the diseased tissues and cells (‘drug targeting’)’.
555 A June 2014 review of the implications of the convergence of 
biology and chemistry highlighted:
•	 ‘The shortcomings of peptides as drugs (and by implication 
for uses prohibited by the Convention) can be moderated 
in several ways. Formulations, particularly associated with 
liposomes or nanocarriers, are being explored to enhance 
penetration of the blood brain barrier, overcome host 
defences, and target specific organs’;
•	 ‘Nanocarrier-based delivery systems permit a more precise 
and controlled targeting at the site of action, while reducing 
the time of exposure at non-targeted tissues. This can 
increase efficacy, and reduce toxicity and side effects’.
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556 An October 2014 review of the impacts of convergence of 
chemistry and biology highlighted:
•	 ‘Antibody-Drug Conjugates (ADCs) have been developed 
and tested for the targeted delivery of cytotoxic payloads 
to cancer cells… an approach has been developed which 
combines selectivity with toxicity, by linking antibodies 
and cytotoxic molecules together in the form of ADCs’. 
The authors note that ‘at this stage of development, ADCs 
are expensive drugs, but the approach is considered 
competitive based on their increased efficacy. Moreover, two 
such approaches have met with FDA approval and some 30 
other ADCs are currently in clinical trials at different phases. 
The Swiss company Lonza, for example, has developed both 
the capacity to produce bulk quantities and the specialist 
skills and experience in both the chemical and biotech fields 
necessary to manufacture ADCs. In terms of capacity, reactor 
sizes can vary from small (6 to 60 litres) to large scale (up to 
600 litres, batch sizes up to 3 kg)’;
•	 ‘nanoparticles, specifically… gold particles coated with 
hydrophobic and hydrophilic compounds could be used to 
imitate certain biological functions…. these nanoparticles 
have been shown to have the ability to penetrate cell 
membranes. Such nanoparticles could either be designed 
to carry small payloads of highly active drugs (for example 
certain peptides), or the nanoparticle itself could act as a 
drug by interacting with viruses’.
557 In February 2012, Ellis et al reported having identified a more 
efficient way to deliver protein-based drugs into cells. The 
authors demonstrated using boronic acid to boost the uptake of 
a protein by over four times.
558 There have been a number of recent cases of individuals 
using the internet, dark web and other information technology 
platforms to acquire toxins. For example, in November 2014, the 
UK used its Biological Weapons Act for the first time to convict 
a woman of attempting to acquire Abrin to kill her mother. A 
second conviction followed in April 2015, when a 16 year old boy 
attempted to acquire Abrin as part of a suicide attempt. A third 
conviction followed in July 2015 when a man was convicted of 
attempting to acquire Ricin for unspecified purposes.
559 In March 2015, Zilinksis and Mauger reported having surveyed 
materials provided by online venders of technologies controlled 
under the Australia Group. The authors reported “that a 
significant proportion of them were particularly vulnerable to 
proliferator exploitation. These typically were small firms with 
limited resources, facing significant competition, and offering 
transactions of single units”. The authors also noted that 
“online vendors routinely offered payment options that could 
be utilized by unscrupulous buyers to hide their identities 
and to launder funds”. The also concluded “that a host of new 
biotechnology innovations had emerged in the last ten or more 
years that potentially have BW-related applications and are 
being offered for sale by vendors on the Internet”.
560 A July 2012 working paper by the Russian Federation for 
the BWC Meeting of Experts highlighted ‘Current methods in 
molecular biology [which] provide means to modify pathogens 
the way that will make it difficult to identify them by existing 
means of identification’. The author noted ‘this hampers 
significantly the effectiveness of diagnosis and preventive 
vaccination’.
561 An October 2014 review of the convergence of biology and 
chemistry highlighted ‘the potential of 3D printing for building 
customised reaction vessels, such as micro-reactors and the 
related processing equipment, which although limited in volume 
sizes… offers a means to subvert traditional controls on process 
equipment made of high performance and corrosion resistant 
materials’. The authors also noted ‘3D-printed tissue culture 
systems… potentially offered actors the possibility of lower 
production costs and materials used and, significantly, a smaller 
footprint for production’.
